<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>CELEBREX- <span class='product-label-link' type='medication' conceptid='1118084' conceptname='celecoxib'>celecoxib</span> capsule </strong> G.D. Searle LLC Division of Pfizer Inc </p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use CELEBREX safely and effectively.  See full prescribing information for CELEBREX.   CELEBREX <span class="Sup">®</span> (<span class='product-label-link' type='medication' conceptid='1118084' conceptname='celecoxib'>celecoxib</span>) capsules Initial U.S. Approval: 1998</div>
<div class="Warning">
<div>
<h1 class="Warning"><span class="Bold">WARNING: CARDIOVASCULAR AND GASTROINTESTINAL RISKS</span></h1>
<h1 class="Warning"><span class="Italics">See full prescribing information for complete boxed warning</span></h1>
<p class="Highlighta"><span class="Bold Underline">Cardiovascular Risk</span> </p>
<ul>
<li><span class="Bold">CELEBREX may cause an increased risk of serious cardiovascular thrombotic events, <span class='product-label-link' type='condition' conceptid='4329847' conceptname='Myocardial infarction'>myocardial infarction</span>, and stroke, which can be fatal.  All NSAIDs may have a similar risk. This risk may increase with duration of use.  Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk. <span class="Italics"> (<a href="#S5.1">5.1</a>,<a href="#S14.6">14.6</a>)</span></span></li>
<li><span class="Bold">CELEBREX is contraindicated for the treatment of peri-operative <span class='product-label-link' type='condition' conceptid='4329041' conceptname='Pain'>pain</span> in the setting of coronary artery bypass graft (CABG) surgery. <span class="Italics">(<a href="#S4">4</a>, <a href="#S5.1">5.1</a>)</span></span></li>
</ul>
<p class="Highlighta"><span class="Bold Underline">Gastrointestinal Risk</span> </p>
<ul><li><span class="Bold">NSAIDs, including CELEBREX, cause an increased risk of serious gastrointestinal adverse events including <span class='product-label-link' type='condition' conceptid='437312' conceptname='Bleeding'>bleeding</span>, <span class='product-label-link' type='condition' conceptid='4177703' conceptname='Ulcer'>ulcer</span>ation, and perforation of the stomach or intestines, which can be fatal.  These events can occur at any time during use and without warning symptoms.  Elderly patients are at greater risk for serious gastrointestinal (GI) events.  <span class="Italics">(<a href="#S5.4">5.4</a>)</span></span></li></ul>
</div>
<div></div>
<div></div>
</div>
<div></div>
<div class="Warning">
<div>
<h1 class="Warning"><span class="Bold">WARNING: CARDIOVASCULAR AND GASTROINTESTINAL RISKS</span></h1>
<h1 class="Warning"><span class="Italics">See full prescribing information for complete boxed warning</span></h1>
<p class="Highlighta"><span class="Bold Underline">Cardiovascular Risk</span> </p>
<ul>
<li><span class="Bold">CELEBREX may cause an increased risk of serious cardiovascular thrombotic events, <span class='product-label-link' type='condition' conceptid='4329847' conceptname='Myocardial infarction'>myocardial infarction</span>, and stroke, which can be fatal.  All NSAIDs may have a similar risk. This risk may increase with duration of use.  Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk. <span class="Italics"> (<a href="#S5.1">5.1</a>,<a href="#S14.6">14.6</a>)</span></span></li>
<li><span class="Bold">CELEBREX is contraindicated for the treatment of peri-operative <span class='product-label-link' type='condition' conceptid='4329041' conceptname='Pain'>pain</span> in the setting of coronary artery bypass graft (CABG) surgery. <span class="Italics">(<a href="#S4">4</a>, <a href="#S5.1">5.1</a>)</span></span></li>
</ul>
<p class="Highlighta"><span class="Bold Underline">Gastrointestinal Risk</span> </p>
<ul><li><span class="Bold">NSAIDs, including CELEBREX, cause an increased risk of serious gastrointestinal adverse events including <span class='product-label-link' type='condition' conceptid='437312' conceptname='Bleeding'>bleeding</span>, <span class='product-label-link' type='condition' conceptid='4177703' conceptname='Ulcer'>ulcer</span>ation, and perforation of the stomach or intestines, which can be fatal.  These events can occur at any time during use and without warning symptoms.  Elderly patients are at greater risk for serious gastrointestinal (GI) events.  <span class="Italics">(<a href="#S5.4">5.4</a>)</span></span></li></ul>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">									CELEBREX is a nonsteroidal anti-inflammatory drug indicated for: </p>
<ul>
<li><span class='product-label-link' type='condition' conceptid='80180' conceptname='Osteoarthritis'>Osteoarthritis</span> (OA) (<a href="#S1.1">1.1</a>)</li>
<li>Rheumatoid <span class='product-label-link' type='condition' conceptid='4291025' conceptname='Arthritis'>Arthritis</span> (RA) (<a href="#S1.2">1.2</a>)</li>
<li>Juvenile Rheumatoid <span class='product-label-link' type='condition' conceptid='4291025' conceptname='Arthritis'>Arthritis</span> (JRA) in patients 2 years and older (<a href="#S1.3">1.3</a>)</li>
<li><span class='product-label-link' type='condition' conceptid='437082' conceptname='Ankylosing spondylitis'>Ankylosing <span class='product-label-link' type='condition' conceptid='4223530' conceptname='Spondylitis'>Spondylitis</span></span> (AS) (<a href="#S1.4">1.4</a>)</li>
<li>Acute <span class='product-label-link' type='condition' conceptid='4329041' conceptname='Pain'>Pain</span> (AP) (<a href="#S1.5">1.5</a>)</li>
<li>Primary <span class='product-label-link' type='condition' conceptid='194696' conceptname='Dysmenorrhea'>Dysmenorrhea</span> (PD) (<a href="#S1.6">1.6</a>)</li>
</ul>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<p class="Highlighta"><span class="Bold">Use lowest effective dose for the shortest duration consistent with treatment goals for the individual patient. (<a href="#S1">1</a>, <a href="#S5.1">5.1</a>, <a href="#S5.4">5.4</a>)</span> </p>
<ul>
<li>OA: 200 mg once daily or 100 mg twice daily (<a href="#S2.1">2.1</a>, <a href="#S14.1">14.1</a>)</li>
<li>RA: 100 to 200 mg twice daily (<a href="#S2.2">2.2</a>, <a href="#S14.2">14.2</a>)</li>
<li>JRA: 50 mg twice daily in patients 10–25 kg. 100 mg twice daily in patients more than 25 kg (<a href="#S2.3">2.3</a>, <a href="#S14.3">14.3</a>)</li>
<li>AS: 200 mg once daily single dose or 100 mg twice daily. If no effect is observed after 6 weeks, a trial of 400 mg (single or divided doses) may be of benefit (<a href="#S2.4">2.4</a>, <a href="#S14.4">14.4</a>)</li>
<li>AP and PD: 400 mg initially, followed by 200 mg dose if needed on first day. On subsequent days, 200 mg twice daily as needed (<a href="#S2.5">2.5</a>, <a href="#S14.5">14.5</a>)</li>
</ul>
<p class="Highlighta">Reduce daily dose by 50% in patients with moderate hepatic impairment (Child-Pugh Class B).  </p>
<p class="Highlighta">Consider a dose reduction by 50% (or alternative management for JRA) in patients who are known or suspected to be CYP2C9 poor metabolizers, (<a href="#S2.6">2.6</a>, <a href="#S8.4">8.4</a>, <a href="#S8.8">8.8</a>, <a href="#S12.3">12.3</a>). </p>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Capsules: 50 mg, 100 mg, 200 mg and 400 mg (<a href="#S3">3</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul>
<li>Known hypersensitivity to <span class='product-label-link' type='medication' conceptid='1118084' conceptname='celecoxib'>celecoxib</span> or sulfonamides (<a href="#S4">4</a>)</li>
<li>History of <span class='product-label-link' type='condition' conceptid='317009' conceptname='Asthma'>asthma</span>, <span class='product-label-link' type='condition' conceptid='139900' conceptname='Urticaria'>urticaria</span>, or other allergic-type reactions after taking aspirin or other NSAIDs (<a href="#S4">4</a>, <a href="#S5.7">5.7</a>, <a href="#S5.8">5.8</a>, <a href="#S5.13">5.13</a>) </li>
<li>History of asthma, urticaria, or other allergic-type reactions after taking <span class='product-label-link' type='medication' conceptid='1112807' conceptname='Aspirin'>aspirin</span> or other NSAIDs (<a href="#S4">4</a>, <a href="#S5.7">5.7</a>, <a href="#S5.8">5.8</a>, <a href="#S5.13">5.13</a>) </li>
<li>Use during the perioperative period in the setting of coronary artery bypass graft (CABG) surgery (<a href="#S4">4</a>, <a href="#S5.1">5.1</a>)</li>
<li>Active gastrointestinal <span class='product-label-link' type='condition' conceptid='437312' conceptname='Bleeding'>bleeding</span> (<a href="#s4">4</a>, <a href="#s5.4">5.4</a>)</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li>Serious and potentially fatal cardiovascular (CV) thrombotic events, <span class='product-label-link' type='condition' conceptid='4329847' conceptname='Myocardial infarction'>myocardial infarction</span>, and stroke.  Patients with known CV disease/risk factors may be at greater risk (<a href="#S5.1">5.1</a>, <a href="#S14.6">14.6</a>, <a href="#S17.2">17.2</a>).  </li>
<li>Serious gastrointestinal (GI) adverse events, which can be fatal.  The risk is greater in patients with a prior history of <span class='product-label-link' type='condition' conceptid='4177703' conceptname='Ulcer'>ulcer</span> disease or GI <span class='product-label-link' type='condition' conceptid='437312' conceptname='Bleeding'>bleeding</span>, and in patients at high risk for GI events, especially the elderly.   CELEBREX should be used with caution in these patients (<a href="#S5.4">5.4</a>, <a href="#S8.5">8.5</a>, <a href="#S14.6">14.6</a>, <a href="#S17.3">17.3</a>).</li>
<li>Elevated liver enzymes and, rarely, severe hepatic reactions.  Discontinue use of CELEBREX immediately if abnormal liver enzymes persist or worsen (<a href="#S5.5">5.5</a>, <a href="#S17.4">17.4</a>).</li>
<li>New onset or worsening of hypertension.  Blood pressure should be monitored closely during treatment with CELEBREX (<a href="#S5.2">5.2</a>, <a href="#S7.4">7.4</a>, <a href="#S17.2">17.2</a>).</li>
<li>Fluid retention and <span class='product-label-link' type='condition' conceptid='433595' conceptname='Edema'>edema</span>.  CELEBREX should be used with caution in patients with fluid retention or <span class='product-label-link' type='condition' conceptid='316139' conceptname='Heart failure'>heart failure</span> (<a href="#S5.3">5.3</a>, <a href="#S17.6">17.6</a>).</li>
<li>Renal <span class='product-label-link' type='condition' conceptid='444409' conceptname='Papillary necrosis'>papillary necrosis</span> and other renal injury with long term use.  Use CELEBREX with caution in the elderly, those with impaired renal function, <span class='product-label-link' type='condition' conceptid='316139' conceptname='Heart failure'>heart failure</span>, liver dysfunction, and those taking diuretics, ACE-inhibitors, or angiotensin II antagonists (<a href="#S5.6">5.6</a>, <a href="#S7.4">7.4</a>, <a href="#S8.7">8.7</a>, <a href="#S17.6">17.6</a>).</li>
<li>Anaphylactoid reactions.  Do not use CELEBREX in patients with the <span class='product-label-link' type='medication' conceptid='1112807' conceptname='Aspirin'>aspirin</span> triad (<a href="#S5.7">5.7</a>, <a href="#S10">10</a>, <a href="#S17.7">17.7</a>).</li>
<li>Serious skin adverse events such as exfoliative dermatitis, <span class='product-label-link' type='condition' conceptid='141651' conceptname='Stevens-Johnson syndrome'>Stevens-Johnson syndrome</span> (SJS), and toxic epidermal necrolysis (TEN), which can be fatal and can occur without warning even without known prior sulfa allergy.  Discontinue CELEBREX at first appearance of rash or skin reactions (<a href="#S5.8">5.8</a>, <a href="#S17.5">17.5</a>).</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Most common adverse reactions in <span class='product-label-link' type='condition' conceptid='4291025' conceptname='Arthritis'>arthritis</span> trials (&gt;2% and &gt;placebo): <span class='product-label-link' type='condition' conceptid='200219' conceptname='Abdominal pain'>abdominal <span class='product-label-link' type='condition' conceptid='4329041' conceptname='Pain'>pain</span></span>, <span class='product-label-link' type='condition' conceptid='196523' conceptname='Diarrhea'>diarrhea</span>, dyspepsia, flatulence, peripheral <span class='product-label-link' type='condition' conceptid='433595' conceptname='Edema'>edema</span>, accidental injury, dizziness, <span class='product-label-link' type='condition' conceptid='4226263' conceptname='Pharyngitis'>pharyngitis</span>, <span class='product-label-link' type='condition' conceptid='4320791' conceptname='Rhinitis'>rhinitis</span>, <span class='product-label-link' type='condition' conceptid='4283893' conceptname='Sinusitis'>sinusitis</span>, upper <span class='product-label-link' type='condition' conceptid='4170143' conceptname='Respiratory tract infection'>respiratory tract infection</span>, rash  (<a href="#S6.1">6.1</a>).  </p>
<p class="Highlighta">  </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Pfizer at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch</span> </p>
</div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul>
<li>Concomitant use of CELEBREX and <span class='product-label-link' type='medication' conceptid='1310149' conceptname='Warfarin'>warfarin</span> may result in increased risk of bleeding complications.  (<a href="#S7.1">7.1</a>)</li>
<li>Concomitant use of CELEBREX and warfarin may result in increased risk of <span class='product-label-link' type='condition' conceptid='437312' conceptname='Bleeding'>bleeding</span> <span class='product-label-link' type='condition' conceptid='433128' conceptname='Complication'>complication</span>s.  (<a href="#S7.1">7.1</a>)</li>
<li>Concomitant use of CELEBREX increases lithium plasma levels. (<a href="#S7.2">7.2</a>)</li>
<li>Concomitant use of CELEBREX may reduce the antihypertensive effect of ACE Inhibitors and angiotensin II antagonists. Concomitant use of CELEBREX with ACE-Inhibitors in elderly or volume depleted or renally compromised patients may result in deterioration of renal function, including acute renal failure. (<a href="#S7.4">7.4</a>)</li>
<li>Use caution with drugs known to inhibit P450 2C9 or metabolized by 2D6  due to the potential for increased plasma levels (<a href="#S2.6">2.6</a>, <a href="#S8.4">8.4</a>, <a href="#S8.8">8.8</a>, <a href="#S12.3">12.3</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul><li>Pregnancy Category C prior to 30 weeks gestation; Category D starting at 30 weeks gestation (<a href="#S5.9">5.9</a>, <a href="#S8.1">8.1</a>, <a href="#S17.8">17.8</a>)</li></ul></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
</div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.</p>
<p class="HighlightsRevision">Revised: 12/2012</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc"><span class="Emphasis">WARNING: CARDIOVASCULAR AND GASTROINTESTINAL RISKS</span></a></h1>
<h2><a href="#section-1.1" class="toc">Cardiovascular Risk</a></h2>
<h2><a href="#section-1.2" class="toc">Gastrointestinal Risk</a></h2>
<h1><a href="#section-1" class="toc">1.	INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1	<span class='product-label-link' type='condition' conceptid='80180' conceptname='Osteoarthritis'>Osteoarthritis</span> (OA)</a></h2>
<h2><a href="#section-1.2" class="toc">1.2	Rheumatoid <span class='product-label-link' type='condition' conceptid='4291025' conceptname='Arthritis'>Arthritis</span> (RA)</a></h2>
<h2><a href="#section-1.3" class="toc">1.3 	Juvenile Rheumatoid <span class='product-label-link' type='condition' conceptid='4291025' conceptname='Arthritis'>Arthritis</span> (JRA)</a></h2>
<h2><a href="#section-1.4" class="toc">1.4	<span class='product-label-link' type='condition' conceptid='437082' conceptname='Ankylosing spondylitis'>Ankylosing <span class='product-label-link' type='condition' conceptid='4223530' conceptname='Spondylitis'>Spondylitis</span></span> (AS)</a></h2>
<h2><a href="#section-1.5" class="toc">1.5	Acute <span class='product-label-link' type='condition' conceptid='4329041' conceptname='Pain'>Pain</span> (AP)</a></h2>
<h2><a href="#section-1.6" class="toc">1.6	Primary <span class='product-label-link' type='condition' conceptid='194696' conceptname='Dysmenorrhea'>Dysmenorrhea</span> (PD)</a></h2>
<h1><a href="#section-2" class="toc">2.	DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1	<span class='product-label-link' type='condition' conceptid='80180' conceptname='Osteoarthritis'>Osteoarthritis</span></a></h2>
<h2><a href="#section-2.2" class="toc">2.2	Rheumatoid <span class='product-label-link' type='condition' conceptid='4291025' conceptname='Arthritis'>Arthritis</span></a></h2>
<h2><a href="#section-2.3" class="toc">2.3	Juvenile Rheumatoid <span class='product-label-link' type='condition' conceptid='4291025' conceptname='Arthritis'>Arthritis</span></a></h2>
<h2><a href="#section-2.4" class="toc">2.4	<span class='product-label-link' type='condition' conceptid='437082' conceptname='Ankylosing spondylitis'>Ankylosing <span class='product-label-link' type='condition' conceptid='4223530' conceptname='Spondylitis'>Spondylitis</span></span></a></h2>
<h2><a href="#section-2.5" class="toc">2.5	Management of Acute <span class='product-label-link' type='condition' conceptid='4329041' conceptname='Pain'>Pain</span> and Treatment of Primary <span class='product-label-link' type='condition' conceptid='194696' conceptname='Dysmenorrhea'>Dysmenorrhea</span></a></h2>
<h2><a href="#section-2.6" class="toc">2.6	Special Populations</a></h2>
<h1><a href="#section-3" class="toc">3.	DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4.	CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5.	WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1	Cardiovascular Thrombotic Events</a></h2>
<h2><a href="#section-5.2" class="toc">5.2	Hypertension</a></h2>
<h2><a href="#section-5.3" class="toc">5.3	Congestive <span class='product-label-link' type='condition' conceptid='316139' conceptname='Heart failure'>Heart Failure</span> and <span class='product-label-link' type='condition' conceptid='433595' conceptname='Edema'>Edema</span></a></h2>
<h2><a href="#section-5.4" class="toc">5.4	Gastrointestinal (GI) Effects</a></h2>
<h2><a href="#section-5.5" class="toc">5.5	Hepatic Effects</a></h2>
<h2><a href="#section-5.6" class="toc">5.6	Renal Effects</a></h2>
<h2><a href="#section-5.7" class="toc">5.7	Anaphylactoid Reactions</a></h2>
<h2><a href="#section-5.8" class="toc">5.8	Skin Reactions</a></h2>
<h2><a href="#section-5.9" class="toc">5.9	Pregnancy</a></h2>
<h2><a href="#section-5.10" class="toc">5.10 Corticosteroid Treatment</a></h2>
<h2><a href="#section-5.11" class="toc">5.11 Hematological Effects</a></h2>
<h2><a href="#section-5.12" class="toc">5.12 <span class='product-label-link' type='condition' conceptid='436093' conceptname='Disseminated intravascular coagulation'>Disseminated Intravascular Coagulation</span> (DIC) </a></h2>
<h2><a href="#section-5.13" class="toc">5.13 Preexisting <span class='product-label-link' type='condition' conceptid='317009' conceptname='Asthma'>Asthma</span></a></h2>
<h2><a href="#section-5.14" class="toc">5.14 Laboratory Tests</a></h2>
<h2><a href="#section-5.15" class="toc">5.15 Inflammation </a></h2>
<h2><a href="#section-5.16" class="toc">5.16 Concomitant NSAID Use </a></h2>
<h1><a href="#section-6" class="toc">6.	ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Pre-marketing Controlled <span class='product-label-link' type='condition' conceptid='4291025' conceptname='Arthritis'>Arthritis</span> Trials</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 The <span class='product-label-link' type='medication' conceptid='1118084' conceptname='celecoxib'>Celecoxib</span> Long-Term Arthritis Safety Study  </a></h2>
<h2><a href="#section-6.2" class="toc">6.2 The Celecoxib Long-Term <span class='product-label-link' type='condition' conceptid='4291025' conceptname='Arthritis'>Arthritis</span> Safety Study  </a></h2>
<h2><a href="#section-6.3" class="toc">6.3 Juvenile Rheumatoid <span class='product-label-link' type='condition' conceptid='4291025' conceptname='Arthritis'>Arthritis</span> Study</a></h2>
<h2><a href="#section-6.4" class="toc">6.4 Other Pre-Approval Studies</a></h2>
<h2><a href="#section-6.5" class="toc">6.5 The APC and PreSAP Trials</a></h2>
<h1><a href="#section-7" class="toc">7.	DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1	<span class='product-label-link' type='medication' conceptid='1310149' conceptname='Warfarin'>Warfarin</span></a></h2>
<h2><a href="#section-7.2" class="toc">7.2	Lithium</a></h2>
<h2><a href="#section-7.3" class="toc">7.3	<span class='product-label-link' type='medication' conceptid='1112807' conceptname='Aspirin'>Aspirin</span></a></h2>
<h2><a href="#section-7.4" class="toc">7.4	ACE-inhibitors and Angiotensin II Antagonists</a></h2>
<h2><a href="#section-7.5" class="toc">7.5	<span class='product-label-link' type='medication' conceptid='1754994' conceptname='Fluconazole'>Fluconazole</span></a></h2>
<h2><a href="#section-7.6" class="toc">7.6	<span class='product-label-link' type='medication' conceptid='956874' conceptname='Furosemide'>Furosemide</span></a></h2>
<h2><a href="#section-7.7" class="toc">7.7 <span class='product-label-link' type='medication' conceptid='1305058' conceptname='Methotrexate'>Methotrexate</span></a></h2>
<h2><a href="#section-7.8" class="toc">7.8 Concomitant NSAID Use </a></h2>
<h1><a href="#section-8" class="toc">8.	USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1	Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.2	Labor and Delivery</a></h2>
<h2><a href="#section-8.3" class="toc">8.3	Nursing Mothers</a></h2>
<h2><a href="#section-8.4" class="toc">8.4	Pediatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.5	Geriatric Use</a></h2>
<h2><a href="#section-8.6" class="toc">8.6 Hepatic Insufficiency</a></h2>
<h2><a href="#section-8.7" class="toc">8.7 Renal Insufficiency</a></h2>
<h2><a href="#section-8.8" class="toc">8.8 Poor Metabolizers of CYP2C9 Substrates</a></h2>
<h1><a href="#section-9" class="toc">10.	OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11.	DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12.	CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1	Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2	Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3	Pharmacokinetics</a></h2>
<h2><a href="#section-11.4" class="toc">12.5 Pharmacogenomics</a></h2>
<h1><a href="#section-12" class="toc">13. NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h2><a href="#section-12.2" class="toc">13.2 Animal Toxicology</a></h2>
<h1><a href="#section-13" class="toc">14.	CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1	<span class='product-label-link' type='condition' conceptid='80180' conceptname='Osteoarthritis'>Osteoarthritis</span></a></h2>
<h2><a href="#section-13.2" class="toc">14.2	Rheumatoid <span class='product-label-link' type='condition' conceptid='4291025' conceptname='Arthritis'>Arthritis</span></a></h2>
<h2><a href="#section-13.3" class="toc">14.3	Juvenile Rheumatoid <span class='product-label-link' type='condition' conceptid='4291025' conceptname='Arthritis'>Arthritis</span></a></h2>
<h2><a href="#section-13.4" class="toc">14.4	<span class='product-label-link' type='condition' conceptid='437082' conceptname='Ankylosing spondylitis'>Ankylosing <span class='product-label-link' type='condition' conceptid='4223530' conceptname='Spondylitis'>Spondylitis</span></span></a></h2>
<h2><a href="#section-13.5" class="toc">14.5	Analgesia, including Primary <span class='product-label-link' type='condition' conceptid='194696' conceptname='Dysmenorrhea'>Dysmenorrhea</span></a></h2>
<h2><a href="#section-13.6" class="toc">14.6	Special Studies</a></h2>
<h1><a href="#section-14" class="toc">16.	HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17. PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-15.1" class="toc">17.1	Medication Guide</a></h2>
<h2><a href="#section-15.2" class="toc">17.2	Cardiovascular Effects</a></h2>
<h2><a href="#section-15.3" class="toc">17.3	Gastrointestinal Effects</a></h2>
<h2><a href="#section-15.4" class="toc">17.4	Hepatic Effects</a></h2>
<h2><a href="#section-15.5" class="toc">17.5	Adverse Skin Reactions</a></h2>
<h2><a href="#section-15.6" class="toc">17.6	Weight Gain and <span class='product-label-link' type='condition' conceptid='433595' conceptname='Edema'>Edema</span></a></h2>
<h2><a href="#section-15.7" class="toc">17.7	Anaphylactoid Reactions</a></h2>
<h2><a href="#section-15.8" class="toc">17.8	Effects During Pregnancy</a></h2>
<h2><a href="#section-15.9" class="toc">17.9	Preexisting <span class='product-label-link' type='condition' conceptid='317009' conceptname='Asthma'>Asthma</span></a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="Box"></a><a name="section-1"></a><p></p>
<h1><span class="Emphasis">WARNING: CARDIOVASCULAR AND GASTROINTESTINAL RISKS</span></h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1.1"></a><p></p>
<h2>Cardiovascular Risk</h2>
<ul>
<li><span class="Bold">CELEBREX may cause an increased risk of serious cardiovascular thrombotic events, <span class='product-label-link' type='condition' conceptid='4329847' conceptname='Myocardial infarction'>myocardial infarction</span>, and stroke, which can be fatal.  All nonsteroidal anti-inflammatory drugs (NSAIDs) may have a similar risk. This risk may increase with duration of use.  Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk. <span class="Italics"> (<a href="#S5.1">5.1</a>,<a href="#S14.6">14.6</a>)</span></span></li>
<li><span class="Bold">CELEBREX is contraindicated for the treatment of peri-operative <span class='product-label-link' type='condition' conceptid='4329041' conceptname='Pain'>pain</span> in the setting of coronary artery bypass graft (CABG) surgery. <span class="Italics">(<a href="#S4">4</a>, <a href="#S5.1">5.1</a>)</span></span></li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1.2"></a><p></p>
<h2>Gastrointestinal Risk</h2>
<ul><li><span class="Bold">NSAIDs, including CELEBREX, cause an increased risk of serious gastrointestinal adverse events including <span class='product-label-link' type='condition' conceptid='437312' conceptname='Bleeding'>bleeding</span>, <span class='product-label-link' type='condition' conceptid='4177703' conceptname='Ulcer'>ulcer</span>ation, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients are at greater risk for serious gastrointestinal events. <span class="Italics">(<a href="#S5.4">5.4</a>)</span></span></li></ul>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="S1"></a><a name="section-1"></a><p></p>
<h1>1.	INDICATIONS AND USAGE</h1>
<p class="First">Carefully consider the potential benefits and risks of CELEBREX and other treatment options before deciding to use CELEBREX. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals [<span class="Italics">see <a href="#S5">Warnings and Precautions (5)</a></span>]</p>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.1"></a><a name="section-1.1"></a><p></p>
<h2>1.1	<span class='product-label-link' type='condition' conceptid='80180' conceptname='Osteoarthritis'>Osteoarthritis</span> (OA)</h2>
<p class="First">CELEBREX is indicated for relief of the signs and symptoms of OA [<span class="Italics">see <a href="#S14.1">Clinical Studies (14.1)</a></span>]</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.2"></a><a name="section-1.2"></a><p></p>
<h2>1.2	Rheumatoid <span class='product-label-link' type='condition' conceptid='4291025' conceptname='Arthritis'>Arthritis</span> (RA)</h2>
<p class="First">CELEBREX is indicated for relief of the signs and symptoms of RA [<span class="Italics">see <a href="#S14.2">Clinical Studies (14.2)</a></span>]</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.3"></a><a name="section-1.3"></a><p></p>
<h2>1.3 	Juvenile Rheumatoid <span class='product-label-link' type='condition' conceptid='4291025' conceptname='Arthritis'>Arthritis</span> (JRA)</h2>
<p class="First">CELEBREX is indicated for relief of the signs and symptoms of JRA in patients 2 years and older [<span class="Italics">see <a href="#S14.3">Clinical Studies (14.3)</a></span>]</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.4"></a><a name="section-1.4"></a><p></p>
<h2>1.4	<span class='product-label-link' type='condition' conceptid='437082' conceptname='Ankylosing spondylitis'>Ankylosing <span class='product-label-link' type='condition' conceptid='4223530' conceptname='Spondylitis'>Spondylitis</span></span> (AS)</h2>
<p class="First">CELEBREX is indicated for the relief of signs and symptoms of AS [<span class="Italics">see <a href="#S14.4">Clinical Studies (14.4)</a></span>]</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.5"></a><a name="section-1.5"></a><p></p>
<h2>1.5	Acute <span class='product-label-link' type='condition' conceptid='4329041' conceptname='Pain'>Pain</span> (AP)</h2>
<p class="First">CELEBREX is indicated for the management of AP in adults [<span class="Italics">see <a href="#S14.5">Clinical Studies (14.5)</a></span>]</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.6"></a><a name="section-1.6"></a><p></p>
<h2>1.6	Primary <span class='product-label-link' type='condition' conceptid='194696' conceptname='Dysmenorrhea'>Dysmenorrhea</span> (PD)</h2>
<p class="First">CELEBREX is indicated for the treatment of PD [<span class="Italics">see <a href="#S14.5">Clinical Studies (14.5)</a></span>]</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="S2"></a><a name="section-2"></a><p></p>
<h1>2.	DOSAGE AND ADMINISTRATION</h1>
<p class="First">Use lowest effective dose for the shortest duration consistent with treatment goals for the individual patient. </p>
<p>These doses can be given without regard to timing of meals.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.1"></a><a name="section-2.1"></a><p></p>
<h2>2.1	<span class='product-label-link' type='condition' conceptid='80180' conceptname='Osteoarthritis'>Osteoarthritis</span></h2>
<p class="First">For relief of the signs and symptoms of OA the recommended oral dose is 200 mg per day administered as a single dose or as 100 mg twice daily.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.2"></a><a name="section-2.2"></a><p></p>
<h2>2.2	Rheumatoid <span class='product-label-link' type='condition' conceptid='4291025' conceptname='Arthritis'>Arthritis</span></h2>
<p class="First">For relief of the signs and symptoms of RA the recommended oral dose is 100 to 200 mg twice daily.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.3"></a><a name="section-2.3"></a><p></p>
<h2>2.3	Juvenile Rheumatoid <span class='product-label-link' type='condition' conceptid='4291025' conceptname='Arthritis'>Arthritis</span></h2>
<p class="First">For the relief of the signs and symptoms of JRA the recommended oral dose for pediatric patients (age 2 years and older) is based on weight.  For patients ≥10 kg to ≤25 kg the recommended dose is 50 mg twice daily. For patients &gt;25 kg the recommended dose is 100 mg twice daily.</p>
<p>For patients who have difficulty swallowing capsules, the contents of a CELEBREX capsule can be added to applesauce. The entire capsule contents are carefully emptied onto a level teaspoon of cool or room temperature applesauce and ingested immediately with water. The sprinkled capsule contents on applesauce are stable for up to 6 hours under refrigerated conditions (2–8° C/ 35–45° F).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.4"></a><a name="section-2.4"></a><p></p>
<h2>2.4	<span class='product-label-link' type='condition' conceptid='437082' conceptname='Ankylosing spondylitis'>Ankylosing <span class='product-label-link' type='condition' conceptid='4223530' conceptname='Spondylitis'>Spondylitis</span></span></h2>
<p class="First">For the management of the signs and symptoms of AS, the recommended dose of CELEBREX is 200 mg daily in single (once per day) or divided (twice per day) doses. If no effect is observed after 6 weeks, a trial of 400 mg daily may be worthwhile. If no effect is observed after 6 weeks on 400 mg daily, a response is not likely and consideration should be given to alternate treatment options.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.5"></a><a name="section-2.5"></a><p></p>
<h2>2.5	Management of Acute <span class='product-label-link' type='condition' conceptid='4329041' conceptname='Pain'>Pain</span> and Treatment of Primary <span class='product-label-link' type='condition' conceptid='194696' conceptname='Dysmenorrhea'>Dysmenorrhea</span></h2>
<p class="First">The recommended dose of CELEBREX is 400 mg initially, followed by an additional 200 mg dose if needed on the first day. On subsequent days, the recommended dose is 200 mg twice daily as needed.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.6"></a><a name="section-2.6"></a><p></p>
<h2>2.6	Special Populations</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.6.1"></a><p></p>
<p class="First"><span class="Bold Italics">Hepatic insufficiency</span><span class="Italics">:  </span>The daily recommended dose of CELEBREX capsules in patients with moderate hepatic impairment (Child-Pugh Class B) should be reduced by 50%. The use of CELEBREX in patients with severe hepatic impairment is not recommended [<span class="Italics">see <a href="#S5.5">Warnings and Precautions (5.5)</a>, <a href="#S8.6">Use in Specific Populations (8.6)</a> and <a href="#S12.3">Clinical Pharmacology (12.3)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.6.2"></a><p></p>
<p class="First"><span class="Bold Italics">Poor Metabolizers of CYP2C9 Substrates:  </span>Patients who are known or suspected to be poor CYP2C9 metabolizers based on genotype or previous history/experience with other CYP2C9 substrates (such as <span class='product-label-link' type='medication' conceptid='1310149' conceptname='Warfarin'>warfarin</span>, <span class='product-label-link' type='medication' conceptid='740910' conceptname='Phenytoin'>phenytoin</span>) should be administered <span class='product-label-link' type='medication' conceptid='1118084' conceptname='celecoxib'>celecoxib</span> with caution.  Consider starting treatment at half the lowest recommended dose in poor metabolizers (i.e. CYP2C9*3/*3).  Consider using alternative management in JRA patients who are poor metabolizers.   [<span class="Italics">see <a href="#S8.8">Use in Specific populations (8.8)</a>, and <a href="#S12.5">Clinical Pharmacology (12.5)</a>]</span>.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="S3"></a><a name="section-3"></a><p></p>
<h1>3.	DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">Capsules: 50 mg, 100 mg, 200 mg and 400 mg</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="S4"></a><a name="section-4"></a><p></p>
<h1>4.	CONTRAINDICATIONS</h1>
<p class="First">CELEBREX is contraindicated:</p>
<ul>
<li>In patients with known hypersensitivity to <span class='product-label-link' type='medication' conceptid='1118084' conceptname='celecoxib'>celecoxib</span>, <span class='product-label-link' type='medication' conceptid='1112807' conceptname='Aspirin'>aspirin</span>, or other NSAIDs. </li>
<li>In patients who have demonstrated allergic-type reactions to sulfonamides.</li>
<li>In patients who have experienced <span class='product-label-link' type='condition' conceptid='317009' conceptname='Asthma'>asthma</span>, <span class='product-label-link' type='condition' conceptid='139900' conceptname='Urticaria'>urticaria</span>, or allergic-type reactions after taking aspirin or other NSAIDs.  Severe anaphylactoid reactions to NSAIDs, some of them fatal, have been reported in such patients [<span class="Italics">see <a href="#S5.7">Warnings and Precautions (5.7</a>, <a href="#S5.13">5.13)</a></span>].</li>
<li>In patients who have experienced asthma, urticaria, or allergic-type reactions after taking <span class='product-label-link' type='medication' conceptid='1112807' conceptname='Aspirin'>aspirin</span> or other NSAIDs.  Severe anaphylactoid reactions to NSAIDs, some of them fatal, have been reported in such patients [<span class="Italics">see <a href="#S5.7">Warnings and Precautions (5.7</a>, <a href="#S5.13">5.13)</a></span>].</li>
<li>For the treatment of peri-operative <span class='product-label-link' type='condition' conceptid='4329041' conceptname='Pain'>pain</span> in the setting of coronary artery bypass graft (CABG) surgery [<span class="Italics">see <a href="#S5.1">Warnings and Precautions (5.1)</a></span>].</li>
<li>In patients with active gastrointestinal <span class='product-label-link' type='condition' conceptid='437312' conceptname='Bleeding'>bleeding</span>. [<span class="Italics">see <a href="#s5.4">Warnings and Precautions (5.4)</a></span>].</li>
</ul>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="S5"></a><a name="section-5"></a><p></p>
<h1>5.	WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.1"></a><a name="section-5.1"></a><p></p>
<h2>5.1	Cardiovascular Thrombotic Events</h2>
<p class="First">											Chronic use of CELEBREX may cause an increased risk of serious adverse cardiovascular thrombotic events, <span class='product-label-link' type='condition' conceptid='4329847' conceptname='Myocardial infarction'>myocardial infarction</span>, and stroke, which can be fatal. In the APC (Adenoma Prevention with Celecoxib) trial, the hazard ratio for the composite endpoint of cardiovascular death, MI, or stroke was 3.4 (95% CI 1.4 – 8.5) for CELEBREX 400 mg twice daily and 2.8 (95% CI 1.1 – 7.2) with CELEBREX 200 mg twice daily compared to placebo. Cumulative rates for this composite endpoint over 3 years were 3.0% (20/671 subjects) and 2.5% (17/685 subjects), respectively, compared to 0.9% (6/679 subjects) with placebo treatment. The increases in both celecoxib dose groups versus placebo-treated patients were mainly due to an increased incidence of <span class='product-label-link' type='condition' conceptid='4329847' conceptname='Myocardial infarction'>myocardial infarction</span> [<span class="Italics">see <a href="#S14.6">Clinical Studies (14.6)</a></span>].</p>
<p class="First">											Chronic use of CELEBREX may cause an increased risk of serious adverse cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. In the APC (Adenoma Prevention with <span class='product-label-link' type='medication' conceptid='1118084' conceptname='celecoxib'>Celecoxib</span>) trial, the hazard ratio for the composite endpoint of cardiovascular death, MI, or stroke was 3.4 (95% CI 1.4 – 8.5) for CELEBREX 400 mg twice daily and 2.8 (95% CI 1.1 – 7.2) with CELEBREX 200 mg twice daily compared to placebo. Cumulative rates for this composite endpoint over 3 years were 3.0% (20/671 subjects) and 2.5% (17/685 subjects), respectively, compared to 0.9% (6/679 subjects) with placebo treatment. The increases in both <span class='product-label-link' type='medication' conceptid='1118084' conceptname='celecoxib'>Celecoxib</span> dose groups versus placebo-treated patients were mainly due to an increased incidence of myocardial infarction [<span class="Italics">see <a href="#S14.6">Clinical Studies (14.6)</a></span>].</p>
<p>All NSAIDs, both COX-2 selective and non-selective, may have a similar risk. Patients with known CV disease or risk factors for CV disease may be at greater risk. To minimize the potential risk for an adverse CV event in patients treated with CELEBREX, the lowest effective dose should be used for the shortest duration consistent with individual patient treatment goals. Physicians and patients should remain alert for the development of such events, even in the absence of previous CV symptoms. Patients should be informed about the signs and/or symptoms of serious CV toxicity and the steps to take if they occur.</p>
<p>There is no consistent evidence that concurrent use of <span class='product-label-link' type='medication' conceptid='1112807' conceptname='Aspirin'>aspirin</span> mitigates the increased risk of serious CV thrombotic events associated with NSAID use. The concurrent use of <span class='product-label-link' type='medication' conceptid='1112807' conceptname='Aspirin'>aspirin</span> and CELEBREX does increase the risk of serious GI events [<span class="Italics">see <a href="#S5.4">Warnings and Precautions (5.4)</a></span>]. </p>
<p>Two large, controlled, clinical trials of a different COX-2 selective NSAID for the treatment of <span class='product-label-link' type='condition' conceptid='4329041' conceptname='Pain'>pain</span> in the first 10–14 days following CABG surgery found an increased incidence of <span class='product-label-link' type='condition' conceptid='4329847' conceptname='Myocardial infarction'>myocardial infarction</span> and stroke [<span class="Italics">see <a href="#S4">Contraindications (4)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.2"></a><a name="section-5.2"></a><p></p>
<h2>5.2	Hypertension</h2>
<p class="First">As with all NSAIDs, CELEBREX can lead to the onset of new hypertension or worsening of preexisting hypertension, either of which may contribute to the increased incidence of CV events. Patients taking thiazides or loop diuretics may have impaired response to these therapies when taking NSAIDs. NSAIDs, including CELEBREX, should be used with caution in patients with hypertension. Blood pressure should be monitored closely during the initiation of therapy with CELEBREX and throughout the course of therapy. The rates of hypertension from the CLASS trial in the CELEBREX, <span class='product-label-link' type='medication' conceptid='1177480' conceptname='Ibuprofen'>ibuprofen</span> and <span class='product-label-link' type='medication' conceptid='1124300' conceptname='Diclofenac'>diclofenac</span>-treated patients were 2.4%, 4.2% and 2.5%, respectively [<span class="Italics">see <a href="#S14.6">Clinical Studies (14.6)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.3"></a><a name="section-5.3"></a><p></p>
<h2>5.3	Congestive <span class='product-label-link' type='condition' conceptid='316139' conceptname='Heart failure'>Heart Failure</span> and <span class='product-label-link' type='condition' conceptid='433595' conceptname='Edema'>Edema</span></h2>
<p class="First">Fluid retention and <span class='product-label-link' type='condition' conceptid='433595' conceptname='Edema'>edema</span> have been observed in some patients taking NSAIDs, including CELEBREX [<span class="Italics">see <a href="#S6.1">Adverse Reactions (6.1)</a></span>]. In the CLASS study [<span class="Italics">see <a href="#S14.6">Clinical Studies (14.6)</a></span>], the Kaplan-Meier cumulative rates at 9 months of peripheral <span class='product-label-link' type='condition' conceptid='433595' conceptname='Edema'>edema</span> in patients on CELEBREX 400 mg twice daily (4-fold and 2-fold the recommended OA and RA doses, respectively), ibuprofen 800 mg three times daily and diclofenac 75 mg twice daily were 4.5%, 6.9% and 4.7%, respectively.  CELEBREX should be used with caution in patients with fluid retention or <span class='product-label-link' type='condition' conceptid='316139' conceptname='Heart failure'>heart failure</span>.</p>
<p class="First">Fluid retention and edema have been observed in some patients taking NSAIDs, including CELEBREX [<span class="Italics">see <a href="#S6.1">Adverse Reactions (6.1)</a></span>]. In the CLASS study [<span class="Italics">see <a href="#S14.6">Clinical Studies (14.6)</a></span>], the Kaplan-Meier cumulative rates at 9 months of peripheral edema in patients on CELEBREX 400 mg twice daily (4-fold and 2-fold the recommended OA and RA doses, respectively), <span class='product-label-link' type='medication' conceptid='1177480' conceptname='Ibuprofen'>ibuprofen</span> 800 mg three times daily and <span class='product-label-link' type='medication' conceptid='1124300' conceptname='Diclofenac'>diclofenac</span> 75 mg twice daily were 4.5%, 6.9% and 4.7%, respectively.  CELEBREX should be used with caution in patients with fluid retention or heart failure.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.4"></a><a name="section-5.4"></a><p></p>
<h2>5.4	Gastrointestinal (GI) Effects</h2>
<p class="First"><span class="Bold">Risk of GI <span class='product-label-link' type='condition' conceptid='4177703' conceptname='Ulcer'>Ulcer</span>ation, <span class='product-label-link' type='condition' conceptid='437312' conceptname='Bleeding'>Bleeding</span>, and Perforation  </span></p>
<p>NSAIDs, including CELEBREX, can cause serious gastrointestinal events including <span class='product-label-link' type='condition' conceptid='437312' conceptname='Bleeding'>bleeding</span>, <span class='product-label-link' type='condition' conceptid='4177703' conceptname='Ulcer'>ulcer</span>ation, and perforation of the stomach, small intestine or large intestine, which can be fatal. These serious adverse events can occur at any time, with or without warning symptoms, in patients treated with NSAIDs. Only one in five patients who develop a serious upper GI adverse event on NSAID therapy is symptomatic. Complicated and symptomatic <span class='product-label-link' type='condition' conceptid='4177703' conceptname='Ulcer'>ulcer</span> rates were 0.78% at nine months for all patients in the CLASS trial, and 2.19% for the subgroup on low-dose ASA. Patients 65 years of age and older had an incidence of 1.40% at nine months, 3.06% when also taking ASA [<span class="Italics">see <a href="#S14.6">Clinical Studies (14.6)</a></span>]. With longer duration of use of NSAIDs, there is a trend for increasing the likelihood of developing a serious GI event at some time during the course of therapy. However, even short-term therapy is not without risk.</p>
<p>NSAIDs should be prescribed with extreme caution in patients with a prior history of <span class='product-label-link' type='condition' conceptid='4177703' conceptname='Ulcer'>ulcer</span> disease or gastrointestinal <span class='product-label-link' type='condition' conceptid='437312' conceptname='Bleeding'>bleeding</span>. Patients with a prior history of <span class='product-label-link' type='condition' conceptid='4027663' conceptname='Peptic ulcer'>peptic <span class='product-label-link' type='condition' conceptid='4177703' conceptname='Ulcer'>ulcer</span></span> disease and/or gastrointestinal <span class='product-label-link' type='condition' conceptid='437312' conceptname='Bleeding'>bleeding</span> who use NSAIDs have a greater than 10-fold increased risk for developing a GI bleed compared to patients with neither of these risk factors. Other factors that increase the risk of GI <span class='product-label-link' type='condition' conceptid='437312' conceptname='Bleeding'>bleeding</span> in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. Most spontaneous reports of fatal GI events are in elderly or debilitated patients and therefore special care should be taken in treating this population.</p>
<p>To minimize the potential risk for an adverse GI event, the lowest effective dose should be used for the shortest duration consistent with individual patient treatment goals. Physicians and patients should remain alert for signs and symptoms of GI <span class='product-label-link' type='condition' conceptid='4177703' conceptname='Ulcer'>ulcer</span>ation and <span class='product-label-link' type='condition' conceptid='437312' conceptname='Bleeding'>bleeding</span> during CELEBREX therapy and promptly initiate additional evaluation and treatment if a serious GI adverse event is suspected. For high-risk patients, alternate therapies that do not involve NSAIDs should be considered.</p>
<p>Celebrex is contraindicated in patients with active GI <span class='product-label-link' type='condition' conceptid='437312' conceptname='Bleeding'>bleeding</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.5"></a><a name="section-5.5"></a><p></p>
<h2>5.5	Hepatic Effects</h2>
<p class="First">Borderline elevations of one or more liver-associated enzymes may occur in up to 15% of patients taking NSAIDs, and notable elevations of ALT or AST (approximately 3 or more times the upper limit of normal) have been reported in approximately 1% of patients in clinical trials with NSAIDs.  These laboratory abnormalities may progress, may remain unchanged, or may be transient with continuing therapy.  Rare cases of severe hepatic reactions, including <span class='product-label-link' type='condition' conceptid='137977' conceptname='Jaundice'>jaundice</span> and fatal fulminant hepatitis, liver necrosis and <span class='product-label-link' type='condition' conceptid='4245975' conceptname='Hepatic failure'>hepatic failure</span> (some with fatal outcome) have been reported with NSAIDs, including CELEBREX [<span class="Italics">see <a href="#S6.1">Adverse Reactions (6.1)</a></span>]. In controlled clinical trials of CELEBREX, the incidence of borderline elevations (greater than or equal to 1.2 times and less than 3 times the upper limit of normal) of liver associated enzymes was 6% for CELEBREX and 5% for placebo, and approximately 0.2% of patients taking CELEBREX and 0.3% of patients taking placebo had notable elevations of ALT and AST.</p>
<p>A patient with symptoms and/or signs suggesting liver dysfunction, or in whom an abnormal liver test has occurred, should be monitored carefully for evidence of the development of a more severe hepatic reaction while on therapy with CELEBREX.  If clinical signs and symptoms consistent with liver disease develop, or if systemic manifestations occur (e.g., eosinophilia, rash, etc.), CELEBREX should be discontinued.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.6"></a><a name="section-5.6"></a><p></p>
<h2>5.6	Renal Effects</h2>
<p class="First">Long-term administration of NSAIDs has resulted in renal <span class='product-label-link' type='condition' conceptid='444409' conceptname='Papillary necrosis'>papillary necrosis</span> and other renal injury. Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. In these patients, administration of an NSAID may cause a dose-dependent reduction in prostaglandin formation and, secondarily, in renal blood flow, which may precipitate overt renal decompensation. Patients at greatest risk of this reaction are those with impaired renal function, <span class='product-label-link' type='condition' conceptid='316139' conceptname='Heart failure'>heart failure</span>, liver dysfunction, those taking diuretics, ACE-inhibitors, angiotensin II receptor antagonists, and the elderly. Discontinuation of NSAID therapy is usually followed by recovery to the pretreatment state. Clinical trials with CELEBREX have shown renal effects similar to those observed with comparator NSAIDs. </p>
<p>No information is available from controlled clinical studies regarding the use of CELEBREX in patients with advanced renal disease.  Therefore, treatment with CELEBREX is not recommended in these patients with advanced renal disease.  If CELEBREX therapy must be initiated, close monitoring of the patient's renal function is advisable.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.7"></a><a name="section-5.7"></a><p></p>
<h2>5.7	Anaphylactoid Reactions</h2>
<p class="First">As with NSAIDs in general, anaphylactoid reactions have occurred in patients without known prior exposure to CELEBREX. In post-marketing experience, rare cases of anaphylactic reactions and <span class='product-label-link' type='condition' conceptid='432791' conceptname='Angioedema'>angioedema</span> have been reported in patients receiving CELEBREX. CELEBREX should not be given to patients with the aspirin triad. This symptom complex typically occurs in <span class='product-label-link' type='condition' conceptid='317009' conceptname='Asthma'>asthma</span>tic patients who experience <span class='product-label-link' type='condition' conceptid='4320791' conceptname='Rhinitis'>rhinitis</span> with or without <span class='product-label-link' type='condition' conceptid='253788' conceptname='Nasal polyp'>nasal <span class='product-label-link' type='condition' conceptid='4209223' conceptname='Polyp'>polyp</span></span>s, or who exhibit severe, potentially fatal <span class='product-label-link' type='condition' conceptid='256717' conceptname='Bronchospasm'>bronchospasm</span> after taking aspirin or other NSAIDs [<span class="Italics">see <a href="#S4">Contraindications (4)</a>, <a href="#S5.7">Warnings and Precautions (5.7)</a></span>]. Emergency help should be sought in cases where an anaphylactoid reaction occurs.</p>
<p class="First">As with NSAIDs in general, anaphylactoid reactions have occurred in patients without known prior exposure to CELEBREX. In post-marketing experience, rare cases of anaphylactic reactions and angioedema have been reported in patients receiving CELEBREX. CELEBREX should not be given to patients with the <span class='product-label-link' type='medication' conceptid='1112807' conceptname='Aspirin'>aspirin</span> triad. This symptom complex typically occurs in asthmatic patients who experience rhinitis with or without nasal polyps, or who exhibit severe, potentially fatal bronchospasm after taking <span class='product-label-link' type='medication' conceptid='1112807' conceptname='Aspirin'>aspirin</span> or other NSAIDs [<span class="Italics">see <a href="#S4">Contraindications (4)</a>, <a href="#S5.7">Warnings and Precautions (5.7)</a></span>]. Emergency help should be sought in cases where an anaphylactoid reaction occurs.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.8"></a><a name="section-5.8"></a><p></p>
<h2>5.8	Skin Reactions</h2>
<p class="First">CELEBREX is a sulfonamide and can cause serious skin adverse events such as exfoliative dermatitis, <span class='product-label-link' type='condition' conceptid='141651' conceptname='Stevens-Johnson syndrome'>Stevens-Johnson syndrome</span> (SJS), and toxic epidermal necrolysis (TEN), which can be fatal. These serious events can occur without warning and in patients without prior known sulfa allergy. Patients should be informed about the signs and symptoms of serious skin manifestations and use of the drug should be discontinued at the first appearance of skin rash or any other sign of hypersensitivity.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.9"></a><a name="section-5.9"></a><p></p>
<h2>5.9	Pregnancy</h2>
<p class="First">In late pregnancy, starting at 30 weeks gestation, CELEBREX should be avoided because it may cause premature closure of the ductus arteriosus  [<span class="Italics">see <a href="#S8.1">Use in Specific Populations (8.1)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.10"></a><a name="section-5.10"></a><p></p>
<h2>5.10 Corticosteroid Treatment</h2>
<p class="First">CELEBREX cannot be expected to substitute for corticosteroids or to treat corticosteroid insufficiency.  Abrupt discontinuation of corticosteroids may lead to exacerbation of corticosteroid-responsive illness.  Patients on prolonged corticosteroid therapy should have their therapy tapered slowly if a decision is made to discontinue corticosteroids.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.11"></a><a name="section-5.11"></a><p></p>
<h2>5.11 Hematological Effects</h2>
<p class="First"><span class='product-label-link' type='condition' conceptid='439777' conceptname='Anemia'>Anemia</span> is sometimes seen in patients receiving CELEBREX. In controlled clinical trials the incidence of <span class='product-label-link' type='condition' conceptid='439777' conceptname='Anemia'>Anemia</span> was 0.6% with CELEBREX and 0.4% with placebo. Patients on long-term treatment with CELEBREX should have their hemoglobin or hematocrit checked if they exhibit any signs or symptoms of <span class='product-label-link' type='condition' conceptid='439777' conceptname='Anemia'>Anemia</span> or blood loss. CELEBREX does not generally affect platelet counts, prothrombin time (PT), or partial thromboplastin time (PTT), and does not inhibit platelet aggregation at indicated dosages [<span class="Italics">see <a href="#S12.2">Clinical Pharmacology (12.2)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.12"></a><a name="section-5.12"></a><p></p>
<h2>5.12 <span class='product-label-link' type='condition' conceptid='436093' conceptname='Disseminated intravascular coagulation'>Disseminated Intravascular Coagulation</span> (DIC) </h2>
<p class="First">CELEBREX should be used only with caution in pediatric patients with systemic onset JRA due to the risk of <span class='product-label-link' type='condition' conceptid='436093' conceptname='Disseminated intravascular coagulation'>disseminated intravascular coagulation</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.13"></a><a name="section-5.13"></a><p></p>
<h2>5.13 Preexisting <span class='product-label-link' type='condition' conceptid='317009' conceptname='Asthma'>Asthma</span></h2>
<p class="First">Patients with <span class='product-label-link' type='condition' conceptid='317009' conceptname='Asthma'>asthma</span> may have aspirin-sensitive <span class='product-label-link' type='condition' conceptid='317009' conceptname='Asthma'>asthma</span>.  The use of aspirin in patients with aspirin-sensitive <span class='product-label-link' type='condition' conceptid='317009' conceptname='Asthma'>asthma</span> has been associated with severe <span class='product-label-link' type='condition' conceptid='256717' conceptname='Bronchospasm'>bronchospasm</span>, which can be fatal.  Since cross reactivity, including <span class='product-label-link' type='condition' conceptid='256717' conceptname='Bronchospasm'>bronchospasm</span>, between aspirin and other nonsteroidal anti-inflammatory drugs has been reported in such aspirin-sensitive patients, CELEBREX should not be administered to patients with this form of aspirin sensitivity and should be used with caution in patients with preexisting <span class='product-label-link' type='condition' conceptid='317009' conceptname='Asthma'>asthma</span>.</p>
<p class="First">Patients with asthma may have <span class='product-label-link' type='medication' conceptid='1112807' conceptname='Aspirin'>aspirin</span>-sensitive asthma.  The use of <span class='product-label-link' type='medication' conceptid='1112807' conceptname='Aspirin'>aspirin</span> in patients with <span class='product-label-link' type='medication' conceptid='1112807' conceptname='Aspirin'>aspirin</span>-sensitive asthma has been associated with severe bronchospasm, which can be fatal.  Since cross reactivity, including bronchospasm, between <span class='product-label-link' type='medication' conceptid='1112807' conceptname='Aspirin'>aspirin</span> and other nonsteroidal anti-inflammatory drugs has been reported in such <span class='product-label-link' type='medication' conceptid='1112807' conceptname='Aspirin'>aspirin</span>-sensitive patients, CELEBREX should not be administered to patients with this form of <span class='product-label-link' type='medication' conceptid='1112807' conceptname='Aspirin'>aspirin</span> sensitivity and should be used with caution in patients with preexisting asthma.</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="S5.14"></a><a name="section-5.14"></a><p></p>
<h2>5.14 Laboratory Tests</h2>
<p class="First">Because serious GI tract <span class='product-label-link' type='condition' conceptid='4177703' conceptname='Ulcer'>ulcer</span>ations and <span class='product-label-link' type='condition' conceptid='437312' conceptname='Bleeding'>bleeding</span> can occur without warning symptoms, physicians should monitor for signs or symptoms of GI <span class='product-label-link' type='condition' conceptid='437312' conceptname='Bleeding'>bleeding</span>. Patients on long-term treatment with NSAIDs should have a CBC and a chemistry profile checked periodically. If abnormal liver tests or renal tests persist or worsen, CELEBREX should be discontinued.</p>
<p>In controlled clinical trials, elevated BUN occurred more frequently in patients receiving CELEBREX compared with patients on placebo. This laboratory abnormality was also seen in patients who received comparator NSAIDs in these studies. The clinical significance of this abnormality has not been established.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.15"></a><a name="section-5.15"></a><p></p>
<h2>5.15 Inflammation </h2>
<p class="First">The pharmacological activity of CELEBREX in reducing inflammation, and possibly fever, may diminish the utility of these diagnostic signs in detecting infectious <span class='product-label-link' type='condition' conceptid='433128' conceptname='Complication'>complication</span>s of presumed noninfectious, <span class='product-label-link' type='condition' conceptid='4329041' conceptname='Pain'>pain</span>ful conditions.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.16"></a><a name="section-5.16"></a><p></p>
<h2>5.16 Concomitant NSAID Use </h2>
<p class="First">The concomitant use of CELEBREX with any dose of a non-<span class='product-label-link' type='medication' conceptid='1112807' conceptname='Aspirin'>aspirin</span> NSAID should be avoided due to the potential for increased risk of adverse reactions.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="S6"></a><a name="section-6"></a><p></p>
<h1>6.	ADVERSE REACTIONS</h1>
<p class="First">Of the CELEBREX-treated patients in the pre-marketing controlled clinical trials, approximately 4,250 were patients with OA, approximately 2,100 were patients with RA, and approximately 1,050 were patients with post-surgical <span class='product-label-link' type='condition' conceptid='4329041' conceptname='Pain'>pain</span>. More than 8,500 patients received a total daily dose of CELEBREX of 200 mg (100 mg twice daily or 200 mg once daily) or more, including more than 400 treated at 800 mg (400 mg twice daily). Approximately 3,900 patients received CELEBREX at these doses for 6 months or more; approximately 2,300 of these have received it for 1 year or more and 124 of these have received it for 2 years or more.</p>
<p>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The adverse reaction information from clinical trials does, however, provide a basis for identifying the adverse events that appear to be related to drug use and for approximating rates.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.1"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Pre-marketing Controlled <span class='product-label-link' type='condition' conceptid='4291025' conceptname='Arthritis'>Arthritis</span> Trials</h2>
<p class="First">Table 1 lists all adverse events, regardless of causality, occurring in ≥2% of patients receiving CELEBREX from 12 controlled studies conducted in patients with OA or RA that included a placebo and/or a positive control group. Since these 12 trials were of different durations, and patients in the trials may not have been exposed for the same duration of time, these percentages do not capture cumulative rates of occurrence.</p>
<a name="table1"></a><table width="100%">
<caption><span>Table 1:  Adverse Events Occurring in ≥2% of CELEBREX Patients from Pre-marketing Controlled <span class='product-label-link' type='condition' conceptid='4291025' conceptname='Arthritis'>Arthritis</span> Trials</span></caption>
<col align="left" valign="top" width="25%">
<col align="center" valign="top" width="15%">
<col align="center" valign="top" width="15%">
<col align="center" valign="top" width="15%">
<col align="center" valign="top" width="15%">
<col align="center" valign="top" width="15%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center">CBX N=4146</th>
<th class="Rrule" align="center">Placebo N=1864</th>
<th class="Rrule" align="center">NAP N=1366</th>
<th class="Rrule" align="center">DCF N=387</th>
<th class="Rrule" align="center">IBU N=345</th>
</tr></thead>
<tfoot><tr class="First Last"><td align="left" colspan="6">CBX = CELEBREX 100 – 200 mg twice daily or 200 mg once daily; NAP = <span class='product-label-link' type='medication' conceptid='1115008' conceptname='Naproxen'>Naproxen</span> 500 mg twice daily; DCF = <span class='product-label-link' type='medication' conceptid='1124300' conceptname='Diclofenac'>Diclofenac</span> 75 mg twice daily; IBU = <span class='product-label-link' type='medication' conceptid='1177480' conceptname='Ibuprofen'>Ibuprofen</span> 800 mg three times daily.</td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Lrule Rrule" align="left"><span class="Bold">Gastrointestinal</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class='product-label-link' type='condition' conceptid='200219' conceptname='Abdominal pain'>Abdominal <span class='product-label-link' type='condition' conceptid='4329041' conceptname='Pain'>Pain</span></span></td>
<td class="Rrule" align="center">4.1%</td>
<td class="Rrule" align="center">2.8%</td>
<td class="Rrule" align="center">7.7%</td>
<td class="Rrule" align="center">9.0%</td>
<td class="Rrule" align="center">9.0%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class='product-label-link' type='condition' conceptid='196523' conceptname='Diarrhea'>Diarrhea</span></td>
<td class="Rrule" align="center">5.6%</td>
<td class="Rrule" align="center">3.8%</td>
<td class="Rrule" align="center">5.3%</td>
<td class="Rrule" align="center">9.3%</td>
<td class="Rrule" align="center">5.8%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  Dyspepsia</td>
<td class="Rrule" align="center">8.8%</td>
<td class="Rrule" align="center">6.2%</td>
<td class="Rrule" align="center">12.2%</td>
<td class="Rrule" align="center">10.9%</td>
<td class="Rrule" align="center">12.8%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  Flatulence</td>
<td class="Rrule" align="center">2.2%</td>
<td class="Rrule" align="center">1.0%</td>
<td class="Rrule" align="center">3.6%</td>
<td class="Rrule" align="center">4.1%</td>
<td class="Rrule" align="center">3.5%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class='product-label-link' type='condition' conceptid='31967' conceptname='Nausea'>Nausea</span></td>
<td class="Rrule" align="center">3.5%</td>
<td class="Rrule" align="center">4.2%</td>
<td class="Rrule" align="center">6.0%</td>
<td class="Rrule" align="center">3.4%</td>
<td class="Rrule" align="center">6.7%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="Bold">Body as a whole</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  Back <span class='product-label-link' type='condition' conceptid='4329041' conceptname='Pain'>Pain</span></td>
<td class="Rrule" align="center">2.8%</td>
<td class="Rrule" align="center">3.6%</td>
<td class="Rrule" align="center">2.2%</td>
<td class="Rrule" align="center">2.6%</td>
<td class="Rrule" align="center">0.9%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  Peripheral <span class='product-label-link' type='condition' conceptid='433595' conceptname='Edema'>Edema</span></td>
<td class="Rrule" align="center">2.1%</td>
<td class="Rrule" align="center">1.1%</td>
<td class="Rrule" align="center">2.1%</td>
<td class="Rrule" align="center">1.0%</td>
<td class="Rrule" align="center">3.5%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Injury-Accidental</td>
<td class="Rrule" align="center">2.9%</td>
<td class="Rrule" align="center">2.3%</td>
<td class="Rrule" align="center">3.0%</td>
<td class="Rrule" align="center">2.6%</td>
<td class="Rrule" align="center">3.2%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="Bold">Central, Peripheral Nervous system</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  Dizziness</td>
<td class="Rrule" align="center">2.0%</td>
<td class="Rrule" align="center">1.7%</td>
<td class="Rrule" align="center">2.6%</td>
<td class="Rrule" align="center">1.3%</td>
<td class="Rrule" align="center">2.3%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class='product-label-link' type='condition' conceptid='378253' conceptname='Headache'>Headache</span></td>
<td class="Rrule" align="center">15.8%</td>
<td class="Rrule" align="center">20.2%</td>
<td class="Rrule" align="center">14.5%</td>
<td class="Rrule" align="center">15.5%</td>
<td class="Rrule" align="center">15.4%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="Bold">Psychiatric</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Insomnia</td>
<td class="Rrule" align="center">2.3%</td>
<td class="Rrule" align="center">2.3%</td>
<td class="Rrule" align="center">2.9%</td>
<td class="Rrule" align="center">1.3%</td>
<td class="Rrule" align="center">1.4%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="Bold">Respiratory</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class='product-label-link' type='condition' conceptid='4226263' conceptname='Pharyngitis'>Pharyngitis</span></td>
<td class="Rrule" align="center">2.3%</td>
<td class="Rrule" align="center">1.1%</td>
<td class="Rrule" align="center">1.7%</td>
<td class="Rrule" align="center">1.6%</td>
<td class="Rrule" align="center">2.6%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class='product-label-link' type='condition' conceptid='4320791' conceptname='Rhinitis'>Rhinitis</span></td>
<td class="Rrule" align="center">2.0%</td>
<td class="Rrule" align="center">1.3%</td>
<td class="Rrule" align="center">2.4%</td>
<td class="Rrule" align="center">2.3%</td>
<td class="Rrule" align="center">0.6%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class='product-label-link' type='condition' conceptid='4283893' conceptname='Sinusitis'>Sinusitis</span></td>
<td class="Rrule" align="center">5.0%</td>
<td class="Rrule" align="center">4.3%</td>
<td class="Rrule" align="center">4.0%</td>
<td class="Rrule" align="center">5.4%</td>
<td class="Rrule" align="center">5.8%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Upper Respiratory Infection</td>
<td class="Rrule" align="center">8.1%</td>
<td class="Rrule" align="center">6.7%</td>
<td class="Rrule" align="center">9.9%</td>
<td class="Rrule" align="center">9.8%</td>
<td class="Rrule" align="center">9.9%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="Bold">Skin</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">  Rash</td>
<td class="Rrule" align="center">2.2%</td>
<td class="Rrule" align="center">2.1%</td>
<td class="Rrule" align="center">2.1%</td>
<td class="Rrule" align="center">1.3%</td>
<td class="Rrule" align="center">1.2%</td>
</tr>
</tbody>
</table>
<p>In placebo- or active-controlled clinical trials, the discontinuation rate due to adverse events was 7.1% for patients receiving CELEBREX and 6.1% for patients receiving placebo. Among the most common reasons for discontinuation due to adverse events in the CELEBREX treatment groups were dyspepsia and <span class='product-label-link' type='condition' conceptid='200219' conceptname='Abdominal pain'>abdominal <span class='product-label-link' type='condition' conceptid='4329041' conceptname='Pain'>pain</span></span> (cited as reasons for discontinuation in 0.8% and 0.7% of CELEBREX patients, respectively). Among patients receiving placebo, 0.6% discontinued due to dyspepsia and 0.6% withdrew due to <span class='product-label-link' type='condition' conceptid='200219' conceptname='Abdominal pain'>abdominal <span class='product-label-link' type='condition' conceptid='4329041' conceptname='Pain'>pain</span></span>.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.1"></a><p></p>
<p class="First"><span class="Bold">The following adverse reactions occurred in 0.1 – 1.9% of patients treated with CELEBREX (100 – 200 mg twice daily or 200 mg once daily):</span></p>
<table width="80%">
<col align="left" valign="top" width="25%">
<col align="left" valign="top" width="75%">
<tbody class="Headless">
<tr class="First Toprule">
<td align="left">
<span class="Bold Italics">Gastrointestinal</span><span class="Italics">:</span>
</td>
<td align="left"><span class='product-label-link' type='condition' conceptid='75860' conceptname='Constipation'>Constipation</span>, <span class='product-label-link' type='condition' conceptid='4141224' conceptname='Diverticulitis'>diverticulitis</span>, dysphagia, eructation, <span class='product-label-link' type='condition' conceptid='30753' conceptname='Esophagitis'>esophagitis</span>, <span class='product-label-link' type='condition' conceptid='201340' conceptname='Gastritis'>gastritis</span>, <span class='product-label-link' type='condition' conceptid='4101468' conceptname='Gastroenteritis'>gastroenteritis</span>, gastroesophageal reflux, hemorrhoids, hiatal hernia, <span class='product-label-link' type='condition' conceptid='4103703' conceptname='Melena'>melena</span>, dry mouth, <span class='product-label-link' type='condition' conceptid='138455' conceptname='Stomatitis'>stomatitis</span>, tenesmus, <span class='product-label-link' type='condition' conceptid='441408' conceptname='Vomiting'>vomiting</span></td>
</tr>
<tr>
<td align="left"><span class="Bold Italics">Cardiovascular:</span></td>
<td align="left">Aggravated hypertension, <span class='product-label-link' type='condition' conceptid='321318' conceptname='Angina pectoris'>angina pectoris</span>, coronary artery disorder, <span class='product-label-link' type='condition' conceptid='4329847' conceptname='Myocardial infarction'>myocardial infarction</span></td>
</tr>
<tr>
<td align="left">
<span class="Bold Italics">General</span><span class="Italics">:</span>
</td>
<td align="left">Allergy aggravated, allergic reaction, <span class='product-label-link' type='condition' conceptid='77670' conceptname='Chest pain'>chest <span class='product-label-link' type='condition' conceptid='4329041' conceptname='Pain'>pain</span></span>, <span class='product-label-link' type='condition' conceptid='4209224' conceptname='Cyst'>cyst</span> NOS, <span class='product-label-link' type='condition' conceptid='433595' conceptname='Edema'>edema</span> generalized, face <span class='product-label-link' type='condition' conceptid='433595' conceptname='Edema'>edema</span>, fatigue, fever, hot flushes, <span class='product-label-link' type='condition' conceptid='4266367' conceptname='Influenza'>influenza</span>-like symptoms, <span class='product-label-link' type='condition' conceptid='4329041' conceptname='Pain'>pain</span>, peripheral <span class='product-label-link' type='condition' conceptid='4329041' conceptname='Pain'>pain</span></td>
</tr>
<tr>
<td align="left"><span class="Bold Italics">Central, peripheral nervous system:</span></td>
<td align="left">Leg cramps, hypertonia, hypoesthesia, <span class='product-label-link' type='condition' conceptid='318736' conceptname='Migraine'>migraine</span>, <span class='product-label-link' type='condition' conceptid='4236484' conceptname='Paresthesia'>paresthesia</span>, vertigo</td>
</tr>
<tr>
<td align="left">
<span class="Bold Italics">Hearing and vestibular</span><span class="Italics">:</span>
</td>
<td align="left">Deafness, tinnitus</td>
</tr>
<tr>
<td align="left">
<span class="Bold Italics">Heart rate and rhythm</span><span class="Italics">:</span>
</td>
<td align="left">Palpitation, <span class='product-label-link' type='condition' conceptid='444070' conceptname='Tachycardia'>tachycardia</span></td>
</tr>
<tr>
<td align="left">
<span class="Bold Italics">Liver and biliary</span><span class="Italics">:</span>
</td>
<td align="left">Hepatic function abnormal, SGOT increased, SGPT increased</td>
</tr>
<tr>
<td align="left">
<span class="Bold Italics">Metabolic and nutritional</span><span class="Italics">:</span>
</td>
<td align="left">BUN increased, CPK increased, <span class='product-label-link' type='condition' conceptid='4029305' conceptname='Hypercholesterolemia'>hypercholesterolemia</span>, <span class='product-label-link' type='condition' conceptid='4214376' conceptname='Hyperglycemia'>hyperglycemia</span>, <span class='product-label-link' type='condition' conceptid='437833' conceptname='Hypokalemia'>hypokalemia</span>, NPN increased, creatinine increased, alkaline phosphatase increased, weight increased</td>
</tr>
<tr>
<td align="left">
<span class="Bold Italics">Musculoskeletal</span><span class="Italics">:</span>
</td>
<td align="left">Arthralgia, arthrosis, myalgia, <span class='product-label-link' type='condition' conceptid='4168183' conceptname='Synovitis'>synovitis</span>, tendinitis</td>
</tr>
<tr>
<td align="left">
<span class="Bold Italics">Platelets (<span class='product-label-link' type='condition' conceptid='437312' conceptname='Bleeding'>bleeding</span> or clotting)</span><span class="Italics">:</span>
</td>
<td align="left">Ecchymosis, <span class='product-label-link' type='condition' conceptid='318556' conceptname='Epistaxis'>epistaxis</span>, thrombocythemia</td>
</tr>
<tr>
<td align="left">
<span class="Bold Italics">Psychiatric</span><span class="Italics">:</span>
</td>
<td align="left">Anorexia, <span class='product-label-link' type='condition' conceptid='441542' conceptname='Anxiety'>anxiety</span>, appetite increased, depression, nervousness, somnolence</td>
</tr>
<tr>
<td align="left">
<span class="Bold Italics">Hemic</span><span class="Italics">: </span>
</td>
<td align="left"><span class='product-label-link' type='condition' conceptid='439777' conceptname='Anemia'>Anemia</span></td>
</tr>
<tr>
<td align="left">
<span class="Bold Italics">Respiratory</span><span class="Italics">:</span>
</td>
<td align="left"><span class='product-label-link' type='condition' conceptid='256451' conceptname='Bronchitis'>Bronchitis</span>, <span class='product-label-link' type='condition' conceptid='256717' conceptname='Bronchospasm'>bronchospasm</span>, <span class='product-label-link' type='condition' conceptid='256717' conceptname='Bronchospasm'>bronchospasm</span> aggravated, <span class='product-label-link' type='condition' conceptid='254761' conceptname='Cough'>cough</span>ing, dyspnea, <span class='product-label-link' type='condition' conceptid='24969' conceptname='Laryngitis'>laryngitis</span>, <span class='product-label-link' type='condition' conceptid='255848' conceptname='Pneumonia'>pneumonia</span></td>
</tr>
<tr>
<td align="left">
<span class="Bold Italics">Skin and appendages</span><span class="Italics">:</span>
</td>
<td align="left"><span class='product-label-link' type='condition' conceptid='133280' conceptname='Alopecia'>Alopecia</span>, dermatitis, photosensitivity reaction, pruritus, rash <span class='product-label-link' type='condition' conceptid='137193' conceptname='Erythema'>erythema</span>tous, rash maculopapular, skin disorder, skin dry, sweating increased, <span class='product-label-link' type='condition' conceptid='139900' conceptname='Urticaria'>urticaria</span></td>
</tr>
<tr>
<td align="left">
<span class="Bold Italics">Application site disorders</span><span class="Italics">:</span>
</td>
<td align="left"><span class='product-label-link' type='condition' conceptid='435613' conceptname='Cellulitis'>Cellulitis</span>, dermatitis contact</td>
</tr>
<tr class="Botrule Last">
<td align="left">
<span class="Bold Italics">Urinary</span><span class="Italics">:</span>
</td>
<td align="left">Albuminuria, <span class='product-label-link' type='condition' conceptid='195588' conceptname='<span class='product-label-link' type='condition' conceptid='4209224' conceptname='Cyst'>cyst</span>itis'><span class='product-label-link' type='condition' conceptid='4209224' conceptname='Cyst'>cyst</span>itis</span>, <span class='product-label-link' type='condition' conceptid='197684' conceptname='Dysuria'>dysuria</span>, hematuria, micturition frequency, renal calculus</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.2"></a><p></p>
<p class="First"><span class="Bold">The following serious adverse events (causality not evaluated) occurred in &lt;0.1% of patients (cases reported only in post-marketing experience are indicated <span class="Italics">in italics</span>):</span></p>
<table width="80%">
<col align="left" valign="top" width="25%">
<col align="left" valign="top" width="75%">
<tbody class="Headless">
<tr class="First Toprule">
<td align="left">
<span class="Bold Italics">Cardiovascular</span><span class="Italics">:</span>
</td>
<td align="left"><span class='product-label-link' type='condition' conceptid='135360' conceptname='Syncope'>Syncope</span>, congestive <span class='product-label-link' type='condition' conceptid='316139' conceptname='Heart failure'>heart failure</span>, <span class='product-label-link' type='condition' conceptid='437894' conceptname='Ventricular fibrillation'>ventricular <span class='product-label-link' type='condition' conceptid='4226399' conceptname='Fibrillation'>fibrillation</span></span>, <span class='product-label-link' type='condition' conceptid='440417' conceptname='Pulmonary embolism'>pulmonary <span class='product-label-link' type='condition' conceptid='4185607' conceptname='Embolism'>embolism</span></span>, <span class='product-label-link' type='condition' conceptid='381316' conceptname='Cerebrovascular accident'>cerebrovascular accident</span>, peripheral gangrene, <span class='product-label-link' type='condition' conceptid='320741' conceptname='Thrombophlebitis'>thrombophlebitis</span>, <span class="Italics"><span class='product-label-link' type='condition' conceptid='4137275' conceptname='Vasculitis'>vasculitis</span>, <span class='product-label-link' type='condition' conceptid='4133004' conceptname='Deep venous thrombosis'>deep <span class='product-label-link' type='condition' conceptid='444247' conceptname='Venous thrombosis'>venous <span class='product-label-link' type='condition' conceptid='4231363' conceptname='Thrombosis'>thrombosis</span></span></span></span>
</td>
</tr>
<tr>
<td align="left">
<span class="Bold Italics">Gastrointestinal</span><span class="Italics">:</span>
</td>
<td align="left"><span class='product-label-link' type='condition' conceptid='193518' conceptname='Intestinal obstruction'>Intestinal obstruction</span>, intestinal perforation, gastrointestinal <span class='product-label-link' type='condition' conceptid='437312' conceptname='Bleeding'>bleeding</span>, <span class='product-label-link' type='condition' conceptid='4272488' conceptname='Colitis'>colitis</span> with <span class='product-label-link' type='condition' conceptid='437312' conceptname='Bleeding'>bleeding</span>, esophageal perforation, <span class='product-label-link' type='condition' conceptid='4192640' conceptname='Pancreatitis'>pancreatitis</span>, ileus</td>
</tr>
<tr>
<td align="left">
<span class="Bold Italics">Liver and biliary</span><span class="Italics">:</span>
</td>
<td align="left">Cholelithiasis, <span class="Italics">hepatitis, <span class='product-label-link' type='condition' conceptid='137977' conceptname='Jaundice'>jaundice</span>, liver failure</span>
</td>
</tr>
<tr>
<td align="left">
<span class="Bold Italics">Hemic and lymphatic</span><span class="Italics">:</span>
</td>
<td align="left">Thrombocytopenia, <span class="Italics"><span class='product-label-link' type='condition' conceptid='440689' conceptname='Agranulocytosis'>agranulocytosis</span>,<span class='product-label-link' type='condition' conceptid='137829' conceptname='Aplastic anemia'>aplastic <span class='product-label-link' type='condition' conceptid='439777' conceptname='Anemia'>anemia</span></span>, <span class='product-label-link' type='condition' conceptid='432881' conceptname='Pancytopenia'>pancytopenia</span>, leucopenia</span>
</td>
</tr>
<tr>
<td align="left"><span class="Bold Italics">Metabolic:</span></td>
<td align="left"><span class="Italics">Hypoglycemia, <span class='product-label-link' type='condition' conceptid='4232311' conceptname='Hyponatremia'>hyponatremia</span></span></td>
</tr>
<tr>
<td align="left">
<span class="Bold Italics">Nervous</span><span class="Italics">:</span>
</td>
<td align="left"><span class='product-label-link' type='condition' conceptid='437584' conceptname='Ataxia'>Ataxia</span>, suicide,<span class="Italics"> aseptic <span class='product-label-link' type='condition' conceptid='435785' conceptname='Meningitis'>meningitis</span>, ageusia, anosmia, fatal <span class='product-label-link' type='condition' conceptid='439847' conceptname='Intracranial hemorrhage'>intracranial hemorrhage</span> [see <a href="#S7.1">Drug Interactions (7.1)</a>]</span>
</td>
</tr>
<tr>
<td align="left">
<span class="Bold Italics">Renal</span><span class="Italics">:</span>
</td>
<td align="left">Acute renal failure,<span class="Italics"> <span class='product-label-link' type='condition' conceptid='4103224' conceptname='Interstitial nephritis'>interstitial <span class='product-label-link' type='condition' conceptid='193253' conceptname='Nephritis'>nephritis</span></span></span>
</td>
</tr>
<tr>
<td align="left"><span class="Bold Italics">Skin:</span></td>
<td align="left"><span class="Italics"><span class='product-label-link' type='condition' conceptid='132702' conceptname='<span class='product-label-link' type='condition' conceptid='137193' conceptname='Erythema'>Erythema</span> multiforme'><span class='product-label-link' type='condition' conceptid='137193' conceptname='Erythema'>Erythema</span> multiforme</span>, exfoliative dermatitis, <span class='product-label-link' type='condition' conceptid='141651' conceptname='Stevens-Johnson syndrome'>Stevens-Johnson syndrome</span>, toxic epidermal necrolysis drug rash with eosinophilia and systemic symptoms (DRESS, or hypersensitivity syndrome)</span></td>
</tr>
<tr class="Botrule Last">
<td align="left">
<span class="Bold Italics">General</span><span class="Italics">:</span>
</td>
<td align="left"><span class='product-label-link' type='condition' conceptid='132797' conceptname='Sepsis'>Sepsis</span>, sudden death, <span class="Italics">anaphylactoid reaction, <span class='product-label-link' type='condition' conceptid='432791' conceptname='Angioedema'>angioedema</span></span>
</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.2"></a><a name="section-6.2"></a><p></p>
<h2>6.2 The <span class='product-label-link' type='medication' conceptid='1118084' conceptname='celecoxib'>Celecoxib</span> Long-Term Arthritis Safety Study  </h2>
<h2>6.2 The Celecoxib Long-Term <span class='product-label-link' type='condition' conceptid='4291025' conceptname='Arthritis'>Arthritis</span> Safety Study  </h2>
<p class="First"><span class="Bold">[see <span class="Italics"><a href="#S14.6">Special Studies (14.6)</a></span>]</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.2.1"></a><p></p>
<h3></h3>
<p class="First"><span class="Bold Italics">Hematological Events</span><span class="Italics">:</span> The incidence of clinically significant decreases in hemoglobin (&gt;2 g/dL) was lower in patients on CELEBREX 400 mg twice daily (0.5%) compared to patients on either <span class='product-label-link' type='medication' conceptid='1124300' conceptname='Diclofenac'>diclofenac</span> 75 mg twice daily (1.3%) or <span class='product-label-link' type='medication' conceptid='1177480' conceptname='Ibuprofen'>ibuprofen</span> 800 mg three times daily 1.9%. The lower incidence of events with CELEBREX was maintained with or without ASA use [<span class="Italics">see <a href="#S12.2">Clinical Pharmacology (12.2)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.2.2"></a><p></p>
<h3></h3>
<p class="First"><span class="Bold Italics">Withdrawals/Serious Adverse Events</span><span class="Italics">:</span> Kaplan-Meier cumulative rates at 9 months for withdrawals due to adverse events for CELEBREX, <span class='product-label-link' type='medication' conceptid='1124300' conceptname='Diclofenac'>diclofenac</span> and <span class='product-label-link' type='medication' conceptid='1177480' conceptname='Ibuprofen'>ibuprofen</span> were 24%, 29%, and 26%, respectively. Rates for serious adverse events (i.e., causing hospitalization or felt to be life-threatening or otherwise medically significant), regardless of causality, were not different across treatment groups (8%, 7%, and 8%, respectively).</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.3"></a><a name="section-6.3"></a><p></p>
<h2>6.3 Juvenile Rheumatoid <span class='product-label-link' type='condition' conceptid='4291025' conceptname='Arthritis'>Arthritis</span> Study</h2>
<p class="First">In a 12-week, double-blind, active-controlled study, 242 JRA patients 2 years to 17 years of age were treated with <span class='product-label-link' type='medication' conceptid='1118084' conceptname='celecoxib'>celecoxib</span> or <span class='product-label-link' type='medication' conceptid='1115008' conceptname='Naproxen'>naproxen</span>; 77 JRA patients were treated with <span class='product-label-link' type='medication' conceptid='1118084' conceptname='celecoxib'>celecoxib</span> 3 mg/kg BID, 82 patients were treated with <span class='product-label-link' type='medication' conceptid='1118084' conceptname='celecoxib'>celecoxib</span> 6 mg/kg BID, and 83 patients were treated with <span class='product-label-link' type='medication' conceptid='1115008' conceptname='Naproxen'>naproxen</span> 7.5 mg/kg BID. The most commonly occurring (≥5%) adverse events in <span class='product-label-link' type='medication' conceptid='1118084' conceptname='celecoxib'>celecoxib</span> treated patients were headache, fever (pyrexia), upper abdominal pain, cough, nasopharyngitis, abdominal pain, nausea, arthralgia, diarrhea and vomiting. The most commonly occurring (≥5%) adverse experiences for <span class='product-label-link' type='medication' conceptid='1115008' conceptname='Naproxen'>naproxen</span>-treated patients were headache, nausea, vomiting, fever, upper abdominal pain, diarrhea, cough, abdominal pain, and dizziness (Table 2). Compared with <span class='product-label-link' type='medication' conceptid='1115008' conceptname='Naproxen'>naproxen</span>, <span class='product-label-link' type='medication' conceptid='1118084' conceptname='celecoxib'>celecoxib</span> at doses of 3 and 6 mg/kg BID had no observable deleterious effect on growth and development during the course of the 12-week double-blind study. There was no substantial difference in the number of clinical exacerbations of uveitis or systemic features of JRA among treatment groups.</p>
<p class="First">In a 12-week, double-blind, active-controlled study, 242 JRA patients 2 years to 17 years of age were treated with celecoxib or naproxen; 77 JRA patients were treated with celecoxib 3 mg/kg BID, 82 patients were treated with celecoxib 6 mg/kg BID, and 83 patients were treated with naproxen 7.5 mg/kg BID. The most commonly occurring (≥5%) adverse events in celecoxib treated patients were <span class='product-label-link' type='condition' conceptid='378253' conceptname='Headache'>headache</span>, fever (pyrexia), upper <span class='product-label-link' type='condition' conceptid='200219' conceptname='Abdominal pain'>abdominal <span class='product-label-link' type='condition' conceptid='4329041' conceptname='Pain'>pain</span></span>, <span class='product-label-link' type='condition' conceptid='254761' conceptname='Cough'>cough</span>, <span class='product-label-link' type='condition' conceptid='4197268' conceptname='Nasopharyngitis'>nasopharyngitis</span>, <span class='product-label-link' type='condition' conceptid='200219' conceptname='Abdominal pain'>abdominal <span class='product-label-link' type='condition' conceptid='4329041' conceptname='Pain'>pain</span></span>, <span class='product-label-link' type='condition' conceptid='31967' conceptname='Nausea'>nausea</span>, arthralgia, <span class='product-label-link' type='condition' conceptid='196523' conceptname='Diarrhea'>diarrhea</span> and <span class='product-label-link' type='condition' conceptid='441408' conceptname='Vomiting'>vomiting</span>. The most commonly occurring (≥5%) adverse experiences for naproxen-treated patients were <span class='product-label-link' type='condition' conceptid='378253' conceptname='Headache'>headache</span>, <span class='product-label-link' type='condition' conceptid='31967' conceptname='Nausea'>nausea</span>, <span class='product-label-link' type='condition' conceptid='441408' conceptname='Vomiting'>vomiting</span>, fever, upper <span class='product-label-link' type='condition' conceptid='200219' conceptname='Abdominal pain'>abdominal <span class='product-label-link' type='condition' conceptid='4329041' conceptname='Pain'>pain</span></span>, <span class='product-label-link' type='condition' conceptid='196523' conceptname='Diarrhea'>diarrhea</span>, <span class='product-label-link' type='condition' conceptid='254761' conceptname='Cough'>cough</span>, <span class='product-label-link' type='condition' conceptid='200219' conceptname='Abdominal pain'>abdominal <span class='product-label-link' type='condition' conceptid='4329041' conceptname='Pain'>pain</span></span>, and dizziness (Table 2). Compared with naproxen, celecoxib at doses of 3 and 6 mg/kg BID had no observable deleterious effect on growth and development during the course of the 12-week double-blind study. There was no substantial difference in the number of clinical exacerbations of <span class='product-label-link' type='condition' conceptid='4028363' conceptname='Uveitis'>uveitis</span> or systemic features of JRA among treatment groups.</p>
<p>In a 12-week, open-label extension of the double-blind study described above, 202 JRA patients were treated with <span class='product-label-link' type='medication' conceptid='1118084' conceptname='celecoxib'>celecoxib</span> 6 mg/kg BID.  The incidence of adverse events was similar to that observed during the double-blind study; no unexpected adverse events of clinical importance emerged.</p>
<a name="table2"></a><table width="80%">
<caption><span>Table 2: Adverse Events Occurring in ≥5% of JRA Patients in Any Treatment Group, by System Organ Class (% of patients with events)</span></caption>
<col align="left" valign="bottom" width="40%">
<col align="center" valign="bottom" width="20%">
<col align="center" valign="bottom" width="20%">
<col align="center" valign="bottom" width="20%">
<thead>
<tr class="First">
<th align="left"></th>
<th class="Botrule" align="center" colspan="3">All  Doses Twice Daily</th>
</tr>
<tr class="Last">
<th align="left">System Organ Class   Preferred Term</th>
<th align="center"><span class='product-label-link' type='medication' conceptid='1118084' conceptname='celecoxib'>Celecoxib</span> 3 mg/kg N=77</th>
<th align="center"><span class='product-label-link' type='medication' conceptid='1118084' conceptname='celecoxib'>Celecoxib</span> 6 mg/kg N=82</th>
<th align="center"><span class='product-label-link' type='medication' conceptid='1115008' conceptname='Naproxen'>Naproxen</span> 7.5 mg/kg N=83</th>
</tr>
</thead>
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Abnormal laboratory tests, which include:  Prolonged activated partial thromboplastin time, Bacteriuria NOS present, Blood creatine phosphokinase increased, Blood culture positive, Blood <span class='product-label-link' type='medication' conceptid='1560524' conceptname='Glucose'>glucose</span> increased, Blood pressure increased, Blood uric acid increased, Hematocrit decreased, Hematuria present, Hemoglobin decreased, Liver function tests NOS abnormal, Proteinuria present, Transaminase NOS increased, Urine analysis abnormal NOS</dd>
<dd>Abnormal laboratory tests, which include:  Prolonged activated partial thromboplastin time, Bacteriuria NOS present, Blood creatine phosphokinase increased, Blood culture positive, Blood glucose increased, Blood pressure increased, Blood uric acid increased, Hematocrit decreased, Hematuria present, Hemoglobin decreased, Liver function tests NOS abnormal, <span class='product-label-link' type='condition' conceptid='75650' conceptname='Proteinuria'>Proteinuria</span> present, Transaminase NOS increased, Urine analysis abnormal NOS</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td align="left"><span class="Bold">Any Event</span></td>
<td align="center"><span class="Bold">64</span></td>
<td align="center"><span class="Bold">70</span></td>
<td align="center"><span class="Bold">72</span></td>
</tr>
<tr class="Botrule">
<td align="left"><span class="Bold">Eye Disorders</span></td>
<td align="center"><span class="Bold">5</span></td>
<td align="center"><span class="Bold">5</span></td>
<td align="center"><span class="Bold">5</span></td>
</tr>
<tr class="Botrule">
<td align="left"><span class="Bold">Gastrointestinal</span></td>
<td align="center"><span class="Bold">26</span></td>
<td align="center"><span class="Bold">24</span></td>
<td align="center"><span class="Bold">36</span></td>
</tr>
<tr>
<td align="left">  <span class='product-label-link' type='condition' conceptid='200219' conceptname='Abdominal pain'>Abdominal <span class='product-label-link' type='condition' conceptid='4329041' conceptname='Pain'>pain</span></span> NOS</td>
<td align="center">4</td>
<td align="center">7</td>
<td align="center">7</td>
</tr>
<tr>
<td align="left">  <span class='product-label-link' type='condition' conceptid='200219' conceptname='Abdominal pain'>Abdominal <span class='product-label-link' type='condition' conceptid='4329041' conceptname='Pain'>pain</span></span> upper</td>
<td align="center">8</td>
<td align="center">6</td>
<td align="center">10</td>
</tr>
<tr>
<td align="left">  <span class='product-label-link' type='condition' conceptid='441408' conceptname='Vomiting'>Vomiting</span> NOS</td>
<td align="center">3</td>
<td align="center">6</td>
<td align="center">11</td>
</tr>
<tr>
<td align="left">  <span class='product-label-link' type='condition' conceptid='196523' conceptname='Diarrhea'>Diarrhea</span> NOS</td>
<td align="center">5</td>
<td align="center">4</td>
<td align="center">8</td>
</tr>
<tr>
<td align="left">  <span class='product-label-link' type='condition' conceptid='31967' conceptname='Nausea'>Nausea</span></td>
<td align="center">7</td>
<td align="center">4</td>
<td align="center">11</td>
</tr>
<tr class="Botrule">
<td class="Toprule" align="left"><span class="Bold">General</span></td>
<td class="Toprule" align="center"><span class="Bold">13</span></td>
<td class="Toprule" align="center"><span class="Bold">11</span></td>
<td class="Toprule" align="center"><span class="Bold">18</span></td>
</tr>
<tr class="Botrule">
<td align="left">  Pyrexia</td>
<td align="center">8</td>
<td align="center">9</td>
<td align="center">11</td>
</tr>
<tr class="Botrule">
<td align="left"><span class="Bold">Infections </span></td>
<td align="center"><span class="Bold">25</span></td>
<td align="center"><span class="Bold">20</span></td>
<td align="center"><span class="Bold">27</span></td>
</tr>
<tr class="Botrule">
<td align="left">  <span class='product-label-link' type='condition' conceptid='4197268' conceptname='Nasopharyngitis'>Nasopharyngitis</span></td>
<td align="center">5</td>
<td align="center">6</td>
<td align="center">5</td>
</tr>
<tr class="Botrule">
<td align="left"><span class="Bold">Injury and <span class='product-label-link' type='condition' conceptid='442562' conceptname='Poisoning'>Poisoning</span> </span></td>
<td align="center"><span class="Bold">4</span></td>
<td align="center"><span class="Bold">6</span></td>
<td align="center"><span class="Bold">5</span></td>
</tr>
<tr class="Botrule">
<td align="left"><span class="Bold">Investigations<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a></span></td>
<td align="center"><span class="Bold">3</span></td>
<td align="center"><span class="Bold">11</span></td>
<td align="center"><span class="Bold">7</span></td>
</tr>
<tr class="Botrule">
<td align="left"><span class="Bold">Musculoskeletal </span></td>
<td align="center"><span class="Bold">8</span></td>
<td align="center"><span class="Bold">10</span></td>
<td align="center"><span class="Bold">17</span></td>
</tr>
<tr class="Botrule">
<td align="left">  Arthralgia</td>
<td align="center">3</td>
<td align="center">7</td>
<td align="center">4</td>
</tr>
<tr class="Botrule">
<td align="left"><span class="Bold">Nervous System</span></td>
<td align="center"><span class="Bold">17</span></td>
<td align="center"><span class="Bold">11</span></td>
<td align="center"><span class="Bold">21</span></td>
</tr>
<tr>
<td align="left">  <span class='product-label-link' type='condition' conceptid='378253' conceptname='Headache'>Headache</span>  NOS</td>
<td align="center">13</td>
<td align="center">10</td>
<td align="center">16</td>
</tr>
<tr>
<td align="left">  Dizziness  (excl vertigo) </td>
<td align="center">1</td>
<td align="center">1</td>
<td align="center">7</td>
</tr>
<tr class="Botrule">
<td class="Toprule" align="left"><span class="Bold">Respiratory</span></td>
<td class="Toprule" align="center"><span class="Bold">8</span></td>
<td class="Toprule" align="center"><span class="Bold">15</span></td>
<td class="Toprule" align="center"><span class="Bold">15</span></td>
</tr>
<tr class="Botrule">
<td align="left">  <span class='product-label-link' type='condition' conceptid='254761' conceptname='Cough'>Cough</span></td>
<td align="center">7</td>
<td align="center">7</td>
<td align="center">8</td>
</tr>
<tr class="Last">
<td align="left"><span class="Bold">Skin &amp; Subcutaneous</span></td>
<td align="center"><span class="Bold">10</span></td>
<td align="center"><span class="Bold">7</span></td>
<td align="center"><span class="Bold">18</span></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.4"></a><a name="section-6.4"></a><p></p>
<h2>6.4 Other Pre-Approval Studies</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.4.1"></a><p></p>
<h3></h3>
<p class="First"><span class="Bold Italics">Adverse Events from <span class='product-label-link' type='condition' conceptid='437082' conceptname='Ankylosing spondylitis'>Ankylosing <span class='product-label-link' type='condition' conceptid='4223530' conceptname='Spondylitis'>Spondylitis</span></span> Studies: </span>A total of 378 patients were treated with CELEBREX in placebo- and active-controlled AS studies. Doses up to 400 mg once daily were studied. The types of adverse events reported in the AS studies were similar to those reported in the OA/RAstudies.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.4.2"></a><p></p>
<h3></h3>
<p class="First"><span class="Bold Italics">Adverse Events from Analgesia and <span class='product-label-link' type='condition' conceptid='194696' conceptname='Dysmenorrhea'>Dysmenorrhea</span> Studies:</span> Approximately 1,700 patients were treated with CELEBREX in analgesia and <span class='product-label-link' type='condition' conceptid='194696' conceptname='Dysmenorrhea'>Dysmenorrhea</span> studies. All patients in post-oral surgery <span class='product-label-link' type='condition' conceptid='4329041' conceptname='Pain'>pain</span> studies received a single dose of study medication. Doses up to 600 mg/day of CELEBREX were studied in primary <span class='product-label-link' type='condition' conceptid='194696' conceptname='Dysmenorrhea'>Dysmenorrhea</span> and post-orthopedic surgery <span class='product-label-link' type='condition' conceptid='4329041' conceptname='Pain'>pain</span> studies. The types of adverse events in the analgesia and <span class='product-label-link' type='condition' conceptid='194696' conceptname='Dysmenorrhea'>Dysmenorrhea</span> studies were similar to those reported in <span class='product-label-link' type='condition' conceptid='4291025' conceptname='Arthritis'>arthritis</span> studies. The only additional adverse event reported was post-dental extraction alveolar <span class='product-label-link' type='condition' conceptid='4196380' conceptname='Osteitis'>osteitis</span> (dry socket) in the post-oral surgery <span class='product-label-link' type='condition' conceptid='4329041' conceptname='Pain'>pain</span> studies.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.5"></a><a name="section-6.5"></a><p></p>
<h2>6.5 The APC and PreSAP Trials</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.5.1"></a><p></p>
<p class="First"><span class="Bold Italics">												Adverse reactions from long-term, placebo-controlled <span class='product-label-link' type='condition' conceptid='4209223' conceptname='Polyp'>polyp</span> prevention studies</span>: Exposure to CELEBREX in the APC and PreSAP trials was 400 to 800 mg daily for up to 3 years [<span class="Italics">see <a href="#S14.6">Special Studies Adenomatous <span class='product-label-link' type='condition' conceptid='4209223' conceptname='Polyp'>polyp</span> Prevention Studies (14.6)</a></span>]. </p>
<p>Some adverse reactions occurred in higher percentages of patients than in the <span class='product-label-link' type='condition' conceptid='4291025' conceptname='Arthritis'>arthritis</span> pre-marketing trials (treatment durations up to 12 weeks; see <span class="Italics"><a href="#S6.1">Adverse events from CELEBREX pre-marketing controlled <span class='product-label-link' type='condition' conceptid='4291025' conceptname='Arthritis'>arthritis</span> trials</a></span>, above). The adverse reactions for which these differences in patients treated with CELEBREX were greater as compared to the <span class='product-label-link' type='condition' conceptid='4291025' conceptname='Arthritis'>arthritis</span> pre-marketing trials were as follows:  </p>
<table width="80%">
<col align="left" valign="middle" width="50%">
<col align="center" valign="middle" width="25%">
<col align="center" valign="bottom" width="25%">
<thead><tr class="First Last">
<th align="left"></th>
<th align="center">CELEBREX (400 to 800 mg daily) N = 2285</th>
<th align="center">Placebo N=1303</th>
</tr></thead>
<tbody>
<tr class="First">
<td align="left"><span class='product-label-link' type='condition' conceptid='196523' conceptname='Diarrhea'>Diarrhea</span></td>
<td align="center">10.5%</td>
<td align="center">7.0%</td>
</tr>
<tr>
<td align="left"><span class='product-label-link' type='condition' conceptid='318800' conceptname='Gastroesophageal reflux disease'>Gastroesophageal reflux disease</span></td>
<td align="center">4.7%</td>
<td align="center">3.1%</td>
</tr>
<tr>
<td align="left"><span class='product-label-link' type='condition' conceptid='31967' conceptname='Nausea'>Nausea</span></td>
<td align="center">6.8%</td>
<td align="center">5.3%</td>
</tr>
<tr>
<td align="left"><span class='product-label-link' type='condition' conceptid='441408' conceptname='Vomiting'>Vomiting</span></td>
<td align="center">3.2%</td>
<td align="center">2.1%</td>
</tr>
<tr>
<td align="left">Dyspnea</td>
<td align="center">2.8%</td>
<td align="center">1.6%</td>
</tr>
<tr class="Last">
<td align="left">Hypertension</td>
<td align="center">12.5%</td>
<td align="center">9.8%</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.5.2"></a><p></p>
<p class="First">The following additional adverse reactions occurred in ≥0.1% and &lt;1% of patients taking CELEBREX, at an incidence greater than placebo in the long-term <span class='product-label-link' type='condition' conceptid='4209223' conceptname='Polyp'>polyp</span> prevention studies and were either not reported during the controlled <span class='product-label-link' type='condition' conceptid='4291025' conceptname='Arthritis'>arthritis</span> pre-marketing trials or occurred with greater frequency in the long-term, placebo-controlled <span class='product-label-link' type='condition' conceptid='4209223' conceptname='Polyp'>polyp</span> prevention studies:</p>
<table width="80%">
<col align="left" valign="top" width="25%">
<col align="left" valign="top" width="75%">
<tbody class="Headless">
<tr class="First Toprule">
<td align="left"><span class="Bold Italics">Nervous system disorders:</span></td>
<td align="left"><span class='product-label-link' type='condition' conceptid='443454' conceptname='Cerebral infarction'>Cerebral infarction</span></td>
</tr>
<tr>
<td align="left">
<span class="Bold Italics">Eye disorders</span><span class="Italics">:</span>
</td>
<td align="left">Vitreous floaters, conjunctival hemorrhage</td>
</tr>
<tr>
<td align="left">
<span class="Bold Italics">Ear and labyrinth</span><span class="Italics">:</span>
</td>
<td align="left"><span class='product-label-link' type='condition' conceptid='74052' conceptname='Labyrinthitis'>Labyrinthitis</span></td>
</tr>
<tr>
<td align="left">
<span class="Bold Italics">Cardiac disorders</span><span class="Italics">:</span>
</td>
<td align="left">Angina unstable, aortic valve incompetence, coronary artery atherosclerosis, sinus <span class='product-label-link' type='condition' conceptid='4169095' conceptname='Bradycardia'>bradycardia</span>, <span class='product-label-link' type='condition' conceptid='4145489' conceptname='Ventricular hypertrophy'>ventricular hypertrophy</span></td>
</tr>
<tr>
<td align="left">
<span class="Bold Italics"><span class='product-label-link' type='condition' conceptid='443784' conceptname='Vascular disorder'>Vascular disorder</span>s</span><span class="Italics">:</span>
</td>
<td align="left">Deep vein <span class='product-label-link' type='condition' conceptid='4231363' conceptname='Thrombosis'>thrombosis</span></td>
</tr>
<tr>
<td align="left">
<span class="Bold Italics">Reproductive system and breast disorders</span><span class="Italics">:</span>
</td>
<td align="left">Ovarian <span class='product-label-link' type='condition' conceptid='4209224' conceptname='Cyst'>cyst</span></td>
</tr>
<tr>
<td align="left">
<span class="Bold Italics">Investigations</span><span class="Italics">:</span>
</td>
<td align="left">Blood potassium increased, blood sodium increased, blood <span class='product-label-link' type='medication' conceptid='1636780' conceptname='Testosterone'>testosterone</span> decreased</td>
</tr>
<tr class="Botrule Last">
<td align="left"><span class="Bold Italics">Injury, <span class='product-label-link' type='condition' conceptid='442562' conceptname='Poisoning'>poisoning</span> and procedural <span class='product-label-link' type='condition' conceptid='433128' conceptname='Complication'>complication</span>s:</span></td>
<td align="left"><span class='product-label-link' type='condition' conceptid='4249170' conceptname='Epicondylitis'>Epicondylitis</span>, tendon rupture</td>
</tr>
</tbody>
</table>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="S7"></a><a name="section-7"></a><p></p>
<h1>7.	DRUG INTERACTIONS</h1>
<p class="First"><span class="Bold">General:  </span><span class='product-label-link' type='medication' conceptid='1118084' conceptname='celecoxib'>Celecoxib</span> metabolism is predominantly mediated via cytochrome P450 (CYP) 2C9 in the liver.  Co-administration of <span class='product-label-link' type='medication' conceptid='1118084' conceptname='celecoxib'>Celecoxib</span> with drugs that are known to inhibit CYP2C9 should be done with caution. Significant interactions may occur when <span class='product-label-link' type='medication' conceptid='1118084' conceptname='celecoxib'>Celecoxib</span> is administered together with drugs that inhibit CYP2C9.</p>
<p><span class="Italics">In vitro</span> studies indicate that <span class='product-label-link' type='medication' conceptid='1118084' conceptname='celecoxib'>celecoxib</span>, although not a substrate, is an inhibitor of CYP2D6.  Therefore, there is a potential for an <span class="Italics">in vivo</span> drug interaction with drugs that are metabolized by CYP2D6.  </p>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.1"></a><a name="section-7.1"></a><p></p>
<h2>7.1	<span class='product-label-link' type='medication' conceptid='1310149' conceptname='Warfarin'>Warfarin</span></h2>
<p class="First">Anticoagulant activity should be monitored, particularly in the first few days, after initiating or changing CELEBREX therapy in patients receiving <span class='product-label-link' type='medication' conceptid='1310149' conceptname='Warfarin'>warfarin</span> or similar agents, since these patients are at an increased risk of bleeding complications. The effect of <span class='product-label-link' type='medication' conceptid='1118084' conceptname='celecoxib'>celecoxib</span> on the anticoagulant effect of <span class='product-label-link' type='medication' conceptid='1310149' conceptname='Warfarin'>warfarin</span> was studied in a group of healthy subjects receiving daily 2–5 mg doses of <span class='product-label-link' type='medication' conceptid='1310149' conceptname='Warfarin'>warfarin</span>. In these subjects, <span class='product-label-link' type='medication' conceptid='1118084' conceptname='celecoxib'>celecoxib</span> did not alter the anticoagulant effect of <span class='product-label-link' type='medication' conceptid='1310149' conceptname='Warfarin'>warfarin</span> as determined by prothrombin time. However, in post-marketing experience, serious bleeding events, some of which were fatal, have been reported, predominantly in the elderly, in association with increases in prothrombin time in patients receiving CELEBREX concurrently with <span class='product-label-link' type='medication' conceptid='1310149' conceptname='Warfarin'>warfarin</span>.</p>
<p class="First">Anticoagulant activity should be monitored, particularly in the first few days, after initiating or changing CELEBREX therapy in patients receiving warfarin or similar agents, since these patients are at an increased risk of <span class='product-label-link' type='condition' conceptid='437312' conceptname='Bleeding'>bleeding</span> <span class='product-label-link' type='condition' conceptid='433128' conceptname='Complication'>complication</span>s. The effect of celecoxib on the anticoagulant effect of warfarin was studied in a group of healthy subjects receiving daily 2–5 mg doses of warfarin. In these subjects, celecoxib did not alter the anticoagulant effect of warfarin as determined by prothrombin time. However, in post-marketing experience, serious <span class='product-label-link' type='condition' conceptid='437312' conceptname='Bleeding'>bleeding</span> events, some of which were fatal, have been reported, predominantly in the elderly, in association with increases in prothrombin time in patients receiving CELEBREX concurrently with warfarin.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.2"></a><a name="section-7.2"></a><p></p>
<h2>7.2	Lithium</h2>
<p class="First">In a study conducted in healthy subjects, mean steady-state lithium plasma levels increased approximately 17% in subjects receiving lithium 450 mg twice daily with CELEBREX 200 mg twice daily as compared to subjects receiving lithium alone. Patients on lithium treatment should be closely monitored when CELEBREX is introduced or withdrawn.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.3"></a><a name="section-7.3"></a><p></p>
<h2>7.3	<span class='product-label-link' type='medication' conceptid='1112807' conceptname='Aspirin'>Aspirin</span></h2>
<p class="First">CELEBREX can be used with low-dose <span class='product-label-link' type='medication' conceptid='1112807' conceptname='Aspirin'>aspirin</span>. However, concomitant administration of <span class='product-label-link' type='medication' conceptid='1112807' conceptname='Aspirin'>aspirin</span> with CELEBREX increases the rate of GI ulceration or other complications, compared to use of CELEBREX alone [<span class="Italics">see <a href="#S5.1">Warnings and Precautions (5.1</a>, <a href="#S5.4">5.4)</a> and <a href="#S14.6">Clinical Studies (14.6)</a></span>]. <span class="Bold">Because of its lack of platelet effects, CELEBREX is not a substitute for <span class='product-label-link' type='medication' conceptid='1112807' conceptname='Aspirin'>aspirin</span> for cardiovascular prophylaxis</span><span class="Bold"> [<span class="Italics">see <a href="#S12.2">Clinical Pharmacology (12.2)</a></span>].</span></p>
<p class="First">CELEBREX can be used with low-dose aspirin. However, concomitant administration of aspirin with CELEBREX increases the rate of GI <span class='product-label-link' type='condition' conceptid='4177703' conceptname='Ulcer'>ulcer</span>ation or other <span class='product-label-link' type='condition' conceptid='433128' conceptname='Complication'>complication</span>s, compared to use of CELEBREX alone [<span class="Italics">see <a href="#S5.1">Warnings and Precautions (5.1</a>, <a href="#S5.4">5.4)</a> and <a href="#S14.6">Clinical Studies (14.6)</a></span>]. <span class="Bold">Because of its lack of platelet effects, CELEBREX is not a substitute for aspirin for cardiovascular prophylaxis</span><span class="Bold"> [<span class="Italics">see <a href="#S12.2">Clinical Pharmacology (12.2)</a></span>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.4"></a><a name="section-7.4"></a><p></p>
<h2>7.4	ACE-inhibitors and Angiotensin II Antagonists</h2>
<p class="First">Reports suggest that NSAIDs may diminish the antihypertensive effect of Angiotensin Converting Enzyme (ACE) inhibitors and angiotensin II antagonists. This interaction should be given consideration in patients taking CELEBREX concomitantly with ACE-inhibitors and angiotensin II antagonists [<span class="Italics">see <a href="#S12.2">Clinical Pharmacology (12.2</a></span>].</p>
<p>In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, co-administration of NSAIDs, including selective COX-2 inhibitors, with ACE inhibitors, may result in deterioration of renal function, including possible acute renal failure. Discontinuation of NSAID therapy is usually followed by recovery to the pretreatment state.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.5"></a><a name="section-7.5"></a><p></p>
<h2>7.5	<span class='product-label-link' type='medication' conceptid='1754994' conceptname='Fluconazole'>Fluconazole</span></h2>
<p class="First">Concomitant administration of <span class='product-label-link' type='medication' conceptid='1754994' conceptname='Fluconazole'>fluconazole</span> at 200 mg once daily resulted in a two-fold increase in <span class='product-label-link' type='medication' conceptid='1118084' conceptname='celecoxib'>celecoxib</span> plasma concentration. This increase is due to the inhibition of <span class='product-label-link' type='medication' conceptid='1118084' conceptname='celecoxib'>celecoxib</span> metabolism via P450 2C9 by <span class='product-label-link' type='medication' conceptid='1754994' conceptname='Fluconazole'>fluconazole</span> [<span class="Italics">see <a href="#S12.3">Clinical Pharmacology (12.3)</a></span>]. CELEBREX should be introduced at the lowest recommended dose in patients receiving <span class='product-label-link' type='medication' conceptid='1754994' conceptname='Fluconazole'>fluconazole</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.6"></a><a name="section-7.6"></a><p></p>
<h2>7.6	<span class='product-label-link' type='medication' conceptid='956874' conceptname='Furosemide'>Furosemide</span></h2>
<p class="First">Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of <span class='product-label-link' type='medication' conceptid='956874' conceptname='Furosemide'>furosemide</span> and thiazides in some patients. This response has been attributed to inhibition of renal prostaglandin synthesis.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.7"></a><a name="section-7.7"></a><p></p>
<h2>7.7 <span class='product-label-link' type='medication' conceptid='1305058' conceptname='Methotrexate'>Methotrexate</span></h2>
<p class="First">In an interaction study of rheumatoid <span class='product-label-link' type='condition' conceptid='4291025' conceptname='Arthritis'>arthritis</span> patients taking methotrexate, CELEBREX did not have an effect on the pharmacokinetics of methotrexate [<span class="Italics">see <a href="#S12.3">Clinical Pharmacology (12.3)</a></span>].</p>
<p class="First">In an interaction study of rheumatoid arthritis patients taking <span class='product-label-link' type='medication' conceptid='1305058' conceptname='Methotrexate'>methotrexate</span>, CELEBREX did not have an effect on the pharmacokinetics of <span class='product-label-link' type='medication' conceptid='1305058' conceptname='Methotrexate'>methotrexate</span> [<span class="Italics">see <a href="#S12.3">Clinical Pharmacology (12.3)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.8"></a><a name="section-7.8"></a><p></p>
<h2>7.8 Concomitant NSAID Use </h2>
<p class="First">The concomitant use of CELEBREX with any dose of a non-<span class='product-label-link' type='medication' conceptid='1112807' conceptname='Aspirin'>aspirin</span> NSAID should be avoided due to the potential for increased risk of adverse reactions.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="S8"></a><a name="section-8"></a><p></p>
<h1>8.	USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="S8.1"></a><a name="section-8.1"></a><p></p>
<h2>8.1	Pregnancy</h2>
<p class="First">Pregnancy Category C. Pregnancy category D from 30 weeks of gestation onward.</p>
<div class="Section" data-sectionCode="34077-8">
<a name="section-8.1.1"></a><p></p>
<p class="First"><span class="Bold Italics">Teratogenic effects</span><span class="Italics">:</span> <span class='product-label-link' type='medication' conceptid='1118084' conceptname='celecoxib'>Celecoxib</span> at oral doses ≥150 mg/kg/day (approximately 2-fold human exposure at 200 mg twice daily as measured by AUC<span class="Sub">0–24</span>), caused an increased incidence of ventricular septal defects, a rare event, and fetal alterations, such as ribs fused, sternebrae fused and sternebrae misshapen when rabbits were treated throughout organogenesis. A dose-dependent increase in diaphragmatic hernias was observed when rats were given <span class='product-label-link' type='medication' conceptid='1118084' conceptname='celecoxib'>Celecoxib</span> at oral doses ≥30 mg/kg/day (approximately 6-fold human exposure based on the AUC<span class="Sub">0–24</span> at 200 mg twice daily) throughout organogenesis. There are no studies in pregnant women. CELEBREX should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
<p class="First"><span class="Bold Italics">Teratogenic effects</span><span class="Italics">:</span> Celecoxib at oral doses ≥150 mg/kg/day (approximately 2-fold human exposure at 200 mg twice daily as measured by AUC<span class="Sub">0–24</span>), caused an increased incidence of <span class='product-label-link' type='condition' conceptid='434462' conceptname='Ventricular septal defect'>ventricular septal defect</span>s, a rare event, and fetal alterations, such as ribs fused, sternebrae fused and sternebrae misshapen when rabbits were treated throughout organogenesis. A dose-dependent increase in <span class='product-label-link' type='condition' conceptid='201061' conceptname='Diaphragmatic hernia'>diaphragmatic hernia</span>s was observed when rats were given celecoxib at oral doses ≥30 mg/kg/day (approximately 6-fold human exposure based on the AUC<span class="Sub">0–24</span> at 200 mg twice daily) throughout organogenesis. There are no studies in pregnant women. CELEBREX should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
</div>
<div class="Section" data-sectionCode="34078-6">
<a name="section-8.1.2"></a><p></p>
<p class="First"><span class="Bold Italics">Nonteratogenic effects:</span>  <span class='product-label-link' type='medication' conceptid='1118084' conceptname='celecoxib'>Celecoxib</span> produced pre-implantation and post-implantation losses and reduced embryo/fetal survival in rats at oral dosages ≥50 mg/kg/day (approximately 6-fold human exposure based on the AUC<span class="Sub">0–24</span> at 200 mg twice daily). These changes are expected with inhibition of prostaglandin synthesis and are not the result of permanent alteration of female reproductive function, nor are they expected at clinical exposures. No studies have been conducted to evaluate the effect of <span class='product-label-link' type='medication' conceptid='1118084' conceptname='celecoxib'>Celecoxib</span> on the closure of the ductus arteriosus in humans. Therefore, use of CELEBREX during the third trimester of pregnancy should be avoided.</p>
</div>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="S8.2"></a><a name="section-8.2"></a><p></p>
<h2>8.2	Labor and Delivery</h2>
<p class="First"><span class='product-label-link' type='medication' conceptid='1118084' conceptname='celecoxib'>Celecoxib</span> produced no evidence of delayed labor or parturition at oral doses up to 100 mg/kg in rats (approximately 7-fold human exposure as measured by the AUC<span class="Sub">0–24</span> at 200 mg BID). The effects of CELEBREX on labor and delivery in pregnant women are unknown. </p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="S8.3"></a><a name="section-8.3"></a><p></p>
<h2>8.3	Nursing Mothers</h2>
<p class="First">Limited data from 3 published reports that included a total of 12 breastfeeding women showed low levels of CELEBREX in breast milk. The calculated average daily infant dose was 10–40 mcg/kg/day, less than 1% of the weight-based therapeutic dose for a two-year old-child. A report of two breastfed infants 17 and 22 months of age did not show any adverse events.  Caution should be exercised when CELEBREX is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="S8.4"></a><a name="section-8.4"></a><p></p>
<h2>8.4	Pediatric Use</h2>
<p class="First">CELEBREX is approved for relief of the signs and symptoms of Juvenile Rheumatoid <span class='product-label-link' type='condition' conceptid='4291025' conceptname='Arthritis'>Arthritis</span> in patients 2 years and older. Safety and efficacy have not been studied beyond six months in children. The long-term cardiovascular toxicity in children exposed to CELEBREX has not been evaluated and it is unknown if long-term risks may be similar to that seen in adults exposed to CELEBREX or other COX-2 selective and non-selective NSAIDs [<span class="Italics">(see <a href="#Box">Boxed Warning</a>, <a href="#S5.12">Warnings and Precautions (5.12)</a>, and <a href="#S14.3">Clinical Studies (14.3)</a></span>].</p>
<p>The use of <span class='product-label-link' type='medication' conceptid='1118084' conceptname='celecoxib'>celecoxib</span> in patients 2 years to 17 years of age with pauciarticular, polyarticular course JRA or in patients with systemic onset JRA was studied in a 12-week, double-blind, active controlled, pharmacokinetic, safety and efficacy study, with a 12-week open-label extension. <span class='product-label-link' type='medication' conceptid='1118084' conceptname='celecoxib'>celecoxib</span> has not been studied in patients under the age of 2 years, in patients with body weight less than 10 kg (22 lbs), and in patients with active systemic features. Patients with systemic onset JRA (without active systemic features) appear to be at risk for the development of abnormal coagulation laboratory tests. In some patients with systemic onset JRA, both <span class='product-label-link' type='medication' conceptid='1118084' conceptname='celecoxib'>celecoxib</span> and <span class='product-label-link' type='medication' conceptid='1115008' conceptname='Naproxen'>naproxen</span> were associated with mild prolongation of activated partial thromboplastin time (APTT) but not prothrombin time (PT). NSAIDs including <span class='product-label-link' type='medication' conceptid='1118084' conceptname='celecoxib'>celecoxib</span> should be used only with caution in patients with systemic onset JRA, due to the risk of disseminated intravascular coagulation. Patients with systemic onset JRA should be monitored for the development of abnormal coagulation tests [see <span class="Italics"><a href="#S2.3">Dosage and Administration (2.3)</a>, <a href="#S5.12">Warnings and Precautions (5.12)</a>, <a href="#S6.3">Adverse Reactions (6.3)</a>, <a href="#S13.2">Animal Toxicology (13.2)</a>, <a href="#S14.3">Clinical Studies (14.3)</a></span>].</p>
<p>The use of celecoxib in patients 2 years to 17 years of age with pauciarticular, polyarticular course JRA or in patients with systemic onset JRA was studied in a 12-week, double-blind, active controlled, pharmacokinetic, safety and efficacy study, with a 12-week open-label extension. Celecoxib has not been studied in patients under the age of 2 years, in patients with body weight less than 10 kg (22 lbs), and in patients with active systemic features. Patients with systemic onset JRA (without active systemic features) appear to be at risk for the development of abnormal coagulation laboratory tests. In some patients with systemic onset JRA, both celecoxib and naproxen were associated with mild prolongation of activated partial thromboplastin time (APTT) but not prothrombin time (PT). NSAIDs including celecoxib should be used only with caution in patients with systemic onset JRA, due to the risk of <span class='product-label-link' type='condition' conceptid='436093' conceptname='Disseminated intravascular coagulation'>disseminated intravascular coagulation</span>. Patients with systemic onset JRA should be monitored for the development of abnormal coagulation tests [see <span class="Italics"><a href="#S2.3">Dosage and Administration (2.3)</a>, <a href="#S5.12">Warnings and Precautions (5.12)</a>, <a href="#S6.3">Adverse Reactions (6.3)</a>, <a href="#S13.2">Animal Toxicology (13.2)</a>, <a href="#S14.3">Clinical Studies (14.3)</a></span>].</p>
<p>Alternative therapies for treatment of JRA should be considered in pediatric patients identified to be CYP2C9 poor metabolizers [see <span class="Italics"><a href="#S8.8">Poor Metabolizers of CYP2C9 substrates (8.8)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="S8.5"></a><a name="section-8.5"></a><p></p>
<h2>8.5	Geriatric Use</h2>
<p class="First">Of the total number of patients who received CELEBREX in pre-approval clinical trials, more than 3,300 were 65–74 years of age, while approximately 1,300 additional patients were 75 years and over. No substantial differences in effectiveness were observed between these subjects and younger subjects. In clinical studies comparing renal function as measured by the GFR, BUN and creatinine, and platelet function as measured by <span class='product-label-link' type='condition' conceptid='437312' conceptname='Bleeding'>bleeding</span> time and platelet aggregation, the results were not different between elderly and young volunteers. However, as with other NSAIDs, including those that selectively inhibit COX-2, there have been more spontaneous post-marketing reports of fatal GI events and acute renal failure in the elderly than in younger patients [<span class="Italics">see <a href="#S5.4">Warnings and Precautions (5.4</a><a href="#S5.6">, 5.6</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S8.6"></a><a name="section-8.6"></a><p></p>
<h2>8.6 Hepatic Insufficiency</h2>
<p class="First">The daily recommended dose of CELEBREX capsules in patients with moderate hepatic impairment (Child-Pugh Class B) should be reduced by 50%. The use of CELEBREX in patients with severe hepatic impairment is not recommended [<span class="Italics">see <a href="#S2.6">Dosage and Administration (2.6)</a> and <a href="#S12.3">Clinical Pharmacology (12.3)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S8.7"></a><a name="section-8.7"></a><p></p>
<h2>8.7 Renal Insufficiency</h2>
<p class="First">CELEBREX is not recommended in patients with severe renal insufficiency [<span class="Italics">see <a href="#S5.6">Warnings and Precautions (5.6)</a> and <a href="#S12.3">Clinical Pharmacology (12.3)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S8.8"></a><a name="section-8.8"></a><p></p>
<h2>8.8 Poor Metabolizers of CYP2C9 Substrates</h2>
<p class="First">Patients who are known or suspected to be poor CYP2C9 metabolizers based on genotype or previous history/experience with other CYP2C9 substrates (such as <span class='product-label-link' type='medication' conceptid='1310149' conceptname='Warfarin'>warfarin</span>, <span class='product-label-link' type='medication' conceptid='740910' conceptname='Phenytoin'>phenytoin</span>) should be administered <span class='product-label-link' type='medication' conceptid='1118084' conceptname='celecoxib'>celecoxib</span> with caution. Consider starting treatment at half the lowest recommended dose in poor metabolizers (i.e., CYP2C9*3/*3).  Alternative management should be considered in JRA patients identified to be CYP2C9 poor metabolizers.  [<span class="Italics">see <a href="#S2.6">Dosage and Administration (2.6)</a> and <a href="#S12.5">Clinical Pharmacology (12.5)</a></span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="S10"></a><a name="section-9"></a><p></p>
<h1>10.	OVERDOSAGE</h1>
<p class="First">No overdoses of CELEBREX were reported during clinical trials. Doses up to 2400 mg/day for up to 10 days in 12 patients did not result in serious toxicity. Symptoms following acute NSAID overdoses are usually limited to lethargy, drowsiness, <span class='product-label-link' type='condition' conceptid='31967' conceptname='Nausea'>nausea</span>, <span class='product-label-link' type='condition' conceptid='441408' conceptname='Vomiting'>vomiting</span>, and epigastric <span class='product-label-link' type='condition' conceptid='4329041' conceptname='Pain'>pain</span>, which are generally reversible with supportive care. Gastrointestinal <span class='product-label-link' type='condition' conceptid='437312' conceptname='Bleeding'>bleeding</span> can occur. Hypertension, acute renal failure, respiratory depression and <span class='product-label-link' type='condition' conceptid='380834' conceptname='Coma'>coma</span> may occur, but are rare. Anaphylactoid reactions have been reported with therapeutic ingestion of NSAIDs, and may occur following an overdose.</p>
<p>Patients should be managed by symptomatic and supportive care following an NSAID overdose. There are no specific antidotes. No information is available regarding the removal of <span class='product-label-link' type='medication' conceptid='1118084' conceptname='celecoxib'>celecoxib</span> by hemodialysis, but based on its high degree of plasma protein binding (&gt;97%) dialysis is unlikely to be useful in overdose. Emesis and/or activated charcoal (60 to 100 g in adults, 1 to 2 g/kg in children) and/or osmotic cathartic may be indicated in patients seen within 4 hours of ingestion with symptoms or following a large overdose. Forced diuresis, alkalinization of urine, hemodialysis, or hemoperfusion may not be useful due to high protein binding.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="S11"></a><a name="section-10"></a><p></p>
<h1>11.	DESCRIPTION</h1>
<p class="First">CELEBREX (<span class='product-label-link' type='medication' conceptid='1118084' conceptname='celecoxib'>celecoxib</span>) is chemically designated as 4-[5-(4-methylphenyl)- 3-(trifluoromethyl)-1H-pyrazol-1-yl] benzenesulfonamide and is a diaryl-substituted pyrazole. The empirical formula is C<span class="Sub">17</span>H<span class="Sub">14</span>F<span class="Sub">3</span>N<span class="Sub">3</span>O<span class="Sub">2</span>S, and the molecular weight is 381.38; the chemical structure is as follows:</p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8d52185d-421f-4e34-8db7-f7676db2a226&amp;name=celebrex-01.jpg"></div>
<p>CELEBREX oral capsules contain either 50 mg, 100 mg, 200 mg or 400 mg of <span class='product-label-link' type='medication' conceptid='1118084' conceptname='celecoxib'>celecoxib</span>, together with inactive ingredients including: croscarmellose sodium, edible inks, gelatin, lactose monohydrate, magnesium stearate, povidone and sodium lauryl sulfate.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="S12"></a><a name="section-11"></a><p></p>
<h1>12.	CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="S12.1"></a><a name="section-11.1"></a><p></p>
<h2>12.1	Mechanism of Action</h2>
<p class="First">CELEBREX is a nonsteroidal anti-inflammatory drug that exhibits anti-inflammatory, analgesic, and antipyretic activities in animal models. The mechanism of action of CELEBREX is believed to be due to inhibition of prostaglandin synthesis, primarily via inhibition of cyclooxygenase-2 (COX-2), and at therapeutic concentrations in humans, CELEBREX does not inhibit the cyclooxygenase-1 (COX-1) isoenzyme. In animal colon tumor models, CELEBREX reduced the incidence and multiplicity of tumors.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="S12.2"></a><a name="section-11.2"></a><p></p>
<h2>12.2	Pharmacodynamics</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.1"></a><p></p>
<p class="First"><span class="Bold Italics">Platelets</span><span class="Italics">:</span> In clinical trials using normal volunteers, CELEBREX at single doses up to 800 mg and multiple doses of 600 mg twice daily for up to 7 days duration (higher than recommended therapeutic doses) had no effect on reduction of platelet aggregation or increase in <span class='product-label-link' type='condition' conceptid='437312' conceptname='Bleeding'>bleeding</span> time. Because of its lack of platelet effects, CELEBREX is not a substitute for aspirin for cardiovascular prophylaxis. It is not known if there are any effects of CELEBREX on platelets that may contribute to the increased risk of serious cardiovascular thrombotic adverse events associated with the use of CELEBREX.</p>
<p class="First"><span class="Bold Italics">Platelets</span><span class="Italics">:</span> In clinical trials using normal volunteers, CELEBREX at single doses up to 800 mg and multiple doses of 600 mg twice daily for up to 7 days duration (higher than recommended therapeutic doses) had no effect on reduction of platelet aggregation or increase in bleeding time. Because of its lack of platelet effects, CELEBREX is not a substitute for <span class='product-label-link' type='medication' conceptid='1112807' conceptname='Aspirin'>aspirin</span> for cardiovascular prophylaxis. It is not known if there are any effects of CELEBREX on platelets that may contribute to the increased risk of serious cardiovascular thrombotic adverse events associated with the use of CELEBREX.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.2"></a><p></p>
<p class="First"><span class="Bold Italics">Fluid Retention</span><span class="Italics">:</span> Inhibition of PGE2 synthesis may lead to sodium and water retention through increased reabsorption in the renal medullary thick ascending loop of Henle and perhaps other segments of the distal nephron. In the collecting ducts, PGE2 appears to inhibit water reabsorption by counteracting the action of antidiuretic hormone.</p>
</div>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="S12.3"></a><a name="section-11.3"></a><p></p>
<h2>12.3	Pharmacokinetics</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.1"></a><p></p>
<p class="First"><span class="Bold Italics">Absorption</span><span class="Italics">: </span>Peak plasma levels of <span class='product-label-link' type='medication' conceptid='1118084' conceptname='celecoxib'>celecoxib</span> occur approximately 3 hrs after an oral dose. Under fasting conditions, both peak plasma levels (C<span class="Sub">max</span>) and area under the curve (AUC) are roughly dose-proportional up to 200 mg BID; at higher doses there are less than proportional increases in C<span class="Sub">max</span> and AUC <span class="Italics">[see <a href="#Food">Food Effects</a>]</span>. Absolute bioavailability studies have not been conducted. With multiple dosing, steady-state conditions are reached on or before Day 5. The pharmacokinetic parameters of <span class='product-label-link' type='medication' conceptid='1118084' conceptname='celecoxib'>celecoxib</span> in a group of healthy subjects are shown in Table 3.</p>
<a name="table3"></a><table width="80%">
<caption><span>Table 3 Summary of Single Dose (200 mg) Disposition Kinetics of <span class='product-label-link' type='medication' conceptid='1118084' conceptname='celecoxib'>Celecoxib</span> in Healthy Subjects<a name="footnote-reference-2" href="#footnote-2" class="Sup">*</a></span></caption>
<col align="center" valign="middle" width="20%">
<col align="center" valign="middle" width="20%">
<col align="center" valign="middle" width="20%">
<col align="center" valign="middle" width="20%">
<col align="center" valign="middle" width="20%">
<thead>
<tr class="Botrule First"><th class="Lrule Rrule" align="center" colspan="5">Mean (%CV) PK Parameter Values</th></tr>
<tr class="Last">
<th class="Lrule Rrule" align="center">C<span class="Sub">max</span>, ng/mL</th>
<th class="Rrule" align="center">T<span class="Sub">max</span>, hr</th>
<th class="Rrule" align="center">Effective t<span class="Sub">1/2</span>, hr</th>
<th class="Rrule" align="center">V<span class="Sub">ss</span>/F, L</th>
<th class="Rrule" align="center">CL/F, L/hr</th>
</tr>
</thead>
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-2" href="#footnote-reference-2">*</a></dt>
<dd>Subjects under fasting conditions (n=36, 19–52 yrs.)</dd>
</dl></td></tr></tfoot>
<tbody><tr class="First Last">
<td class="Lrule Rrule" align="center">705 (38)</td>
<td class="Rrule" align="center">2.8 (37)</td>
<td class="Rrule" align="center">11.2 (31)</td>
<td class="Rrule" align="center">429 (34)</td>
<td class="Rrule" align="center">27.7 (28)</td>
</tr></tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Food"></a><a name="section-11.3.2"></a><p></p>
<p class="First"><span class="Bold Italics">Food Effects</span><span class="Italics">:</span> When CELEBREX capsules were taken with a high fat meal, peak plasma levels were delayed for about 1 to 2 hours with an increase in total absorption (AUC) of 10% to 20%. Under fasting conditions, at doses above 200 mg, there is less than a proportional increase in C<span class="Sub">max </span>and AUC, which is thought to be due to the low solubility of the drug in aqueous media. </p>
<p>Coadministration of CELEBREX with an aluminum- and magnesium-containing antacids resulted in a reduction in plasma <span class='product-label-link' type='medication' conceptid='1118084' conceptname='celecoxib'>celecoxib</span> concentrations with a decrease of 37% in C<span class="Sub">max</span> and 10% in AUC. CELEBREX, at doses up to 200 mg twice daily, can be administered without regard to timing of meals. Higher doses (400 mg twice daily) should be administered with food to improve absorption. </p>
<p>In healthy adult volunteers, the overall systemic exposure (AUC) of <span class='product-label-link' type='medication' conceptid='1118084' conceptname='celecoxib'>celecoxib</span> was equivalent when <span class='product-label-link' type='medication' conceptid='1118084' conceptname='celecoxib'>celecoxib</span> was administered as intact capsule or capsule contents sprinkled on applesauce. There were no significant alterations in Cmax, Tmax or t<span class="Sub">1/2</span> after administration of capsule contents on applesauce [<span class="Italics">see <a href="#S2">Dosage and Administration (2)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.3"></a><p></p>
<p class="First"><span class="Bold Italics">Distribution</span><span class="Italics">: </span>In healthy subjects, <span class='product-label-link' type='medication' conceptid='1118084' conceptname='celecoxib'>celecoxib</span> is highly protein bound (~97%) within the clinical dose range. <span class="Italics">In vitro</span> studies indicate that <span class='product-label-link' type='medication' conceptid='1118084' conceptname='celecoxib'>celecoxib</span> binds primarily to albumin and, to a lesser extent, α<span class="Sub">1</span>-acid glycoprotein. The apparent volume of distribution at steady state (V<span class="Sub">ss</span>/F) is approximately 400 L, suggesting extensive distribution into the tissues. <span class='product-label-link' type='medication' conceptid='1118084' conceptname='celecoxib'>celecoxib</span> is not preferentially bound to red blood cells.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.4"></a><p></p>
<p class="First"><span class="Bold Italics">Metabolism</span><span class="Italics">:</span> <span class='product-label-link' type='medication' conceptid='1118084' conceptname='celecoxib'>Celecoxib</span> metabolism is primarily mediated via CYP2C9.  Three metabolites, a primary alcohol, the corresponding carboxylic acid and its glucuronide conjugate, have been identified in human plasma.  These metabolites are inactive as COX-1 or COX-2 inhibitors.   </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.5"></a><p></p>
<p class="First"><span class="Bold Italics">Excretion</span><span class="Italics">: </span><span class='product-label-link' type='medication' conceptid='1118084' conceptname='celecoxib'>Celecoxib</span> is eliminated predominantly by hepatic metabolism with little (&lt;3%) unchanged drug recovered in the urine and feces. Following a single oral dose of radiolabeled drug, approximately 57% of the dose was excreted in the feces and 27% was excreted into the urine. The primary metabolite in both urine and feces was the carboxylic acid metabolite (73% of dose) with low amounts of the glucuronide also appearing in the urine. It appears that the low solubility of the drug prolongs the absorption process making terminal half-life (t<span class="Sub">1/2</span>) determinations more variable. The effective half-life is approximately 11 hours under fasted conditions. The apparent plasma clearance (CL/F) is about 500 mL/min.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.6"></a><p></p>
<p class="First"><span class="Bold Italics">Geriatric</span>: At steady state, elderly subjects (over 65 years old) had a 40% higher C<span class="Sub">max</span> and a 50% higher AUC compared to the young subjects. In elderly females, <span class='product-label-link' type='medication' conceptid='1118084' conceptname='celecoxib'>celecoxib</span> C<span class="Sub">max</span> and AUC are higher than those for elderly males, but these increases are predominantly due to lower body weight in elderly females. Dose adjustment in the elderly is not generally necessary. However, for patients of less than 50 kg in body weight, initiate therapy at the lowest recommended dose [<span class="Italics">see <a href="#S2.6">Dosage and Administration (2.6)</a> and <a href="#S8.5">Use in Specific Populations (8.5)</a></span>]. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.7"></a><p></p>
<p class="First"><span class="Bold Italics">Pediatric</span>: The steady state pharmacokinetics of <span class='product-label-link' type='medication' conceptid='1118084' conceptname='celecoxib'>celecoxib</span> administered as an investigational oral suspension was evaluated in 152 JRA patients 2 years to 17 years of age weighing ≥10 kg with pauciarticular or polyarticular course JRA and in patients with systemic onset JRA. Population pharmacokinetic analysis indicated that the oral clearance (unadjusted for body weight) of <span class='product-label-link' type='medication' conceptid='1118084' conceptname='celecoxib'>celecoxib</span> increases less than proportionally to increasing weight, with 10 kg and 25 kg patients predicted to have 40% and 24% lower clearance, respectively, compared with a 70 kg adult RA patient. </p>
<p>Twice-daily administration of 50 mg capsules to JRA patients weighing ≥12 to ≤25 kg and 100 mg capsules to JRA patients weighing &gt;25 kg should achieve plasma concentrations similar to those observed in a clinical trial that demonstrated the non-inferiority of <span class='product-label-link' type='medication' conceptid='1118084' conceptname='celecoxib'>celecoxib</span> to <span class='product-label-link' type='medication' conceptid='1115008' conceptname='Naproxen'>naproxen</span> 7.5 mg/kg twice daily (<span class="Italics">see <a href="#S2.3">Dosage and Administration (2.3)</a>. </span><span class='product-label-link' type='medication' conceptid='1118084' conceptname='celecoxib'>celecoxib</span> has not been studied in JRA patients under the age of 2 years, in patients with body weight less than 10 kg (22 lbs), or beyond 24 weeks.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.8"></a><p></p>
<p class="First"><span class="Bold Italics">Race</span><span class="Italics">: </span>Meta-analysis of pharmacokinetic studies has suggested an approximately 40% higher AUC of <span class='product-label-link' type='medication' conceptid='1118084' conceptname='celecoxib'>celecoxib</span> in Blacks compared to Caucasians. The cause and clinical significance of this finding is unknown.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.9"></a><p></p>
<p class="First"><span class="Bold Italics">Hepatic Insufficiency</span><span class="Italics">: </span>A pharmacokinetic study in subjects with mild (Child-Pugh Class A) and moderate (Child-Pugh Class B) hepatic impairment has shown that steady-state <span class='product-label-link' type='medication' conceptid='1118084' conceptname='celecoxib'>celecoxib</span> AUC is increased about 40% and 180%, respectively, above that seen in healthy control subjects. Therefore, the daily recommended dose of CELEBREX capsules should be reduced by approximately 50% in patients with moderate (Child-Pugh Class B) hepatic impairment. Patients with severe hepatic impairment (Child-Pugh Class C) have not been studied. The use of CELEBREX in patients with severe hepatic impairment is not recommended [<span class="Italics">see <a href="#S2.6">Dosage and Administration (2.6)</a> and <a href="#S8.6">Use in Specific Populations (8.6)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.10"></a><p></p>
<p class="First"><span class="Bold Italics">Renal Insufficiency</span><span class="Italics">: </span>In a cross-study comparison, <span class='product-label-link' type='medication' conceptid='1118084' conceptname='celecoxib'>celecoxib</span> AUC was approximately 40% lower in patients with chronic renal insufficiency (GFR 35–60 mL/min) than that seen in subjects with normal renal function. No significant relationship was found between GFR and <span class='product-label-link' type='medication' conceptid='1118084' conceptname='celecoxib'>celecoxib</span> clearance. Patients with severe renal insufficiency have not been studied. Similar to other NSAIDs, CELEBREX is not recommended in patients with severe renal insufficiency [<span class="Italics">see <a href="#S5.6">Warnings and Precautions (5.6)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.11"></a><p></p>
<h3></h3>
<p class="First"><span class="Bold Italics">Drug interactions: </span></p>
<p><span class="Italics">In vitro studies </span>indicate that <span class='product-label-link' type='medication' conceptid='1118084' conceptname='celecoxib'>celecoxib</span> is not an inhibitor of cytochrome P450 2C9, 2C19 or 3A4.</p>
<p><span class="Italics">In vivo studies have shown the following: </span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.11.1"></a><p></p>
<h4></h4>
<p class="First"><span class="Bold">Lithium:  </span>In a study conducted in healthy subjects, mean steady-state lithium plasma levels increased approximately 17% in subjects receiving lithium 450 mg twice daily with CELEBREX 200 mg twice daily as compared to subjects receiving lithium alone [<span class="Italics">see <a href="#S7.2">Drug Interactions (7.2)</a></span>]. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.11.2"></a><p></p>
<h4></h4>
<p class="First"><span class="Bold"><span class='product-label-link' type='medication' conceptid='1754994' conceptname='Fluconazole'>Fluconazole</span>:  </span>Concomitant administration of <span class='product-label-link' type='medication' conceptid='1754994' conceptname='Fluconazole'>Fluconazole</span> at 200 mg once daily resulted in a two-fold increase in <span class='product-label-link' type='medication' conceptid='1118084' conceptname='celecoxib'>celecoxib</span> plasma concentration.  This increase is due to the inhibition of <span class='product-label-link' type='medication' conceptid='1118084' conceptname='celecoxib'>celecoxib</span> metabolism via P450 2C9 by <span class='product-label-link' type='medication' conceptid='1754994' conceptname='Fluconazole'>Fluconazole</span> [<span class="Italics">see <a href="#S7.5">Drug Interactions (7.5)</a></span>].  </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.11.3"></a><p></p>
<h4></h4>
<p class="First"><span class="Bold">Other Drugs:  </span>The effects of <span class='product-label-link' type='medication' conceptid='1118084' conceptname='celecoxib'>celecoxib</span> on the pharmacokinetics and/or pharmacodynamics of <span class='product-label-link' type='medication' conceptid='1559684' conceptname='Glyburide'>glyburide</span>, <span class='product-label-link' type='medication' conceptid='985708' conceptname='Ketoconazole'>ketoconazole</span>, <span class='product-label-link' type='medication' conceptid='1305058' conceptname='Methotrexate'>methotrexate</span> [<span class="Italics">see <a href="#S7.7">Drug Interactions (7.7)</a></span>], <span class='product-label-link' type='medication' conceptid='740910' conceptname='Phenytoin'>phenytoin</span>, and <span class='product-label-link' type='medication' conceptid='1502855' conceptname='Tolbutamide'>tolbutamide</span> have been studied <span class="Italics">in vivo</span> and clinically important interactions have not been found.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S12.5"></a><a name="section-11.4"></a><p></p>
<h2>12.5 Pharmacogenomics</h2>
<p class="First">CYP2C9 activity is reduced in individuals with genetic polymorphisms that lead to reduced enzyme activity, such as those homozygous for the CYP2C9*2 and CYP2C9*3 polymorphisms.  Limited data from 4 published reports that included a total of 8 subjects with the homozygous CYP2C9*3/*3 genotype showed <span class='product-label-link' type='medication' conceptid='1118084' conceptname='celecoxib'>celecoxib</span> systemic levels that were 3- to 7-fold higher in these subjects compared to subjects with CYP2C9*1/*1 or *I/*3 genotypes. The pharmacokinetics of <span class='product-label-link' type='medication' conceptid='1118084' conceptname='celecoxib'>celecoxib</span> have not been evaluated in subjects with other CYP2C9 polymorphisms, such as *2, *5, *6, *9 and *11.  It is estimated that the frequency of the homozygous *3/*3 genotype is 0.3% to 1.0% in various ethnic groups. [<span class="Italics">see <a href="#S2.6">Dosage and Administration (2.6)</a>, <a href="#S8.8">Use in Specific Populations (8.8)</a></span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="S13"></a><a name="section-12"></a><p></p>
<h1>13. NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="S13.1"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First"><span class='product-label-link' type='medication' conceptid='1118084' conceptname='celecoxib'>Celecoxib</span> was not carcinogenic in rats given oral doses up to 200 mg/kg for males and 10 mg/kg for females (approximately 2-to 4-fold  the human exposure as measured by the AUC<span class="Sub">0–24</span> at 200 mg twice daily) or in mice given oral doses up to 25 mg/kg for males and 50 mg/kg for females (approximately equal to human exposure as measured by the AUC<span class="Sub">0–24</span> at 200 mg twice daily) for two years.</p>
<p><span class='product-label-link' type='medication' conceptid='1118084' conceptname='celecoxib'>Celecoxib</span> was not mutagenic in an Ames test and a mutation assay in Chinese hamster ovary (CHO) cells, nor clastogenic in a chromosome aberration assay in CHO cells and an <span class="Italics">in vivo</span> micronucleus test in rat bone marrow. </p>
<p><span class='product-label-link' type='medication' conceptid='1118084' conceptname='celecoxib'>Celecoxib</span> did not impair male and female fertility in rats at oral doses up to 600 mg/kg/day (approximately 11-fold human exposure at 200 mg twice daily based on the AUC<span class="Sub">0–24</span>).</p>
</div>
<div class="Section" data-sectionCode="34091-9">
<a name="S13.2"></a><a name="section-12.2"></a><p></p>
<h2>13.2 Animal Toxicology</h2>
<p class="First">An increase in the incidence of background findings of spermatocele with or without secondary changes such as epididymal hypospermia as well as minimal to slight dilation of the seminiferous tubules was seen in the juvenile rat. These reproductive findings while apparently treatment-related did not increase in incidence or severity with dose and may indicate an exacerbation of a spontaneous condition. Similar reproductive findings were not observed in studies of juvenile or adult dogs or in adult rats treated with <span class='product-label-link' type='medication' conceptid='1118084' conceptname='celecoxib'>celecoxib</span>. The clinical significance of this observation is unknown.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="S14"></a><a name="section-13"></a><p></p>
<h1>14.	CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.1"></a><a name="section-13.1"></a><p></p>
<h2>14.1	<span class='product-label-link' type='condition' conceptid='80180' conceptname='Osteoarthritis'>Osteoarthritis</span></h2>
<p class="First">CELEBREX has demonstrated significant reduction in <span class='product-label-link' type='condition' conceptid='77074' conceptname='Joint pain'>joint <span class='product-label-link' type='condition' conceptid='4329041' conceptname='Pain'>pain</span></span> compared to placebo. CELEBREX was evaluated for treatment of the signs and the symptoms of OA of the knee and hip in placebo- and active-controlled clinical trials of up to 12 weeks duration. In patients with OA, treatment with CELEBREX 100 mg twice daily or 200 mg once daily resulted in improvement in WOMAC (Western Ontario and McMaster Universities) <span class='product-label-link' type='condition' conceptid='80180' conceptname='Osteoarthritis'>osteoarthritis</span> index, a composite of <span class='product-label-link' type='condition' conceptid='4329041' conceptname='Pain'>pain</span>, stiffness, and functional measures in OA. In three 12-week studies of <span class='product-label-link' type='condition' conceptid='4329041' conceptname='Pain'>pain</span> accompanying OA flare, CELEBREX doses of 100 mg twice daily and 200 mg twice daily provided significant reduction of <span class='product-label-link' type='condition' conceptid='4329041' conceptname='Pain'>pain</span> within 24–48 hours of initiation of dosing. At doses of 100 mg twice daily or 200 mg twice daily the effectiveness of CELEBREX was shown to be similar to that of naproxen 500 mg twice daily. Doses of 200 mg twice daily provided no additional benefit above that seen with 100 mg twice daily. A total daily dose of 200 mg has been shown to be equally effective whether administered as 100 mg twice daily or 200 mg once daily.</p>
<p class="First">CELEBREX has demonstrated significant reduction in joint pain compared to placebo. CELEBREX was evaluated for treatment of the signs and the symptoms of OA of the knee and hip in placebo- and active-controlled clinical trials of up to 12 weeks duration. In patients with OA, treatment with CELEBREX 100 mg twice daily or 200 mg once daily resulted in improvement in WOMAC (Western Ontario and McMaster Universities) osteoarthritis index, a composite of pain, stiffness, and functional measures in OA. In three 12-week studies of pain accompanying OA flare, CELEBREX doses of 100 mg twice daily and 200 mg twice daily provided significant reduction of pain within 24–48 hours of initiation of dosing. At doses of 100 mg twice daily or 200 mg twice daily the effectiveness of CELEBREX was shown to be similar to that of <span class='product-label-link' type='medication' conceptid='1115008' conceptname='Naproxen'>naproxen</span> 500 mg twice daily. Doses of 200 mg twice daily provided no additional benefit above that seen with 100 mg twice daily. A total daily dose of 200 mg has been shown to be equally effective whether administered as 100 mg twice daily or 200 mg once daily.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.2"></a><a name="section-13.2"></a><p></p>
<h2>14.2	Rheumatoid <span class='product-label-link' type='condition' conceptid='4291025' conceptname='Arthritis'>Arthritis</span></h2>
<p class="First">CELEBREX has demonstrated significant reduction in joint tenderness/<span class='product-label-link' type='condition' conceptid='4329041' conceptname='Pain'>pain</span> and joint <span class='product-label-link' type='condition' conceptid='4275722' conceptname='Swelling'>swelling</span> compared to placebo. CELEBREX was evaluated for treatment of the signs and symptoms of RA in placebo- and active-controlled clinical trials of up to 24 weeks in duration. CELEBREX was shown to be superior to placebo in these studies, using the ACR20 Responder Index, a composite of clinical, laboratory, and functional measures in RA. CELEBREX doses of 100 mg twice daily and 200 mg twice daily were similar in effectiveness and both were comparable to naproxen 500 mg twice daily.</p>
<p class="First">CELEBREX has demonstrated significant reduction in joint tenderness/pain and joint swelling compared to placebo. CELEBREX was evaluated for treatment of the signs and symptoms of RA in placebo- and active-controlled clinical trials of up to 24 weeks in duration. CELEBREX was shown to be superior to placebo in these studies, using the ACR20 Responder Index, a composite of clinical, laboratory, and functional measures in RA. CELEBREX doses of 100 mg twice daily and 200 mg twice daily were similar in effectiveness and both were comparable to <span class='product-label-link' type='medication' conceptid='1115008' conceptname='Naproxen'>naproxen</span> 500 mg twice daily.</p>
<p>Although CELEBREX 100 mg twice daily and 200 mg twice daily provided similar overall effectiveness, some patients derived additional benefit from the 200 mg twice daily dose. Doses of 400 mg twice daily provided no additional benefit above that seen with 100–200 mg twice daily.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.3"></a><a name="section-13.3"></a><p></p>
<h2>14.3	Juvenile Rheumatoid <span class='product-label-link' type='condition' conceptid='4291025' conceptname='Arthritis'>Arthritis</span></h2>
<p class="First">In a 12-week, randomized, double-blind active-controlled, parallel-group, multicenter, non-inferiority study, patients from 2 years to 17 years of age with pauciarticular, polyarticular course JRA or systemic onset JRA (with currently inactive systemic features), received one of the following treatments: <span class='product-label-link' type='medication' conceptid='1118084' conceptname='celecoxib'>celecoxib</span> 3 mg/kg (to a maximum of 150 mg) twice daily; <span class='product-label-link' type='medication' conceptid='1118084' conceptname='celecoxib'>celecoxib</span> 6 mg/kg (to a maximum of 300 mg) twice daily; or <span class='product-label-link' type='medication' conceptid='1115008' conceptname='Naproxen'>naproxen</span> 7.5 mg/kg (to a maximum of 500 mg) twice daily. The response rates were based upon the JRA Definition of Improvement greater than or equal to 30% (JRA DOI 30) criterion, which is a composite of clinical, laboratory, and functional measures of JRA. The JRA DOI 30 response rates at week 12 were 69%, 80% and 67% in the <span class='product-label-link' type='medication' conceptid='1118084' conceptname='celecoxib'>celecoxib</span> 3 mg/kg BID, <span class='product-label-link' type='medication' conceptid='1118084' conceptname='celecoxib'>celecoxib</span> 6 mg/kg BID, and <span class='product-label-link' type='medication' conceptid='1115008' conceptname='Naproxen'>naproxen</span> 7.5 mg/kg BID treatment groups, respectively. </p>
<p>The efficacy and safety of CELEBREX for JRA have not been studied beyond six months. The long-term cardiovascular toxicity in children exposed to CELEBREX has not been evaluated and it is unknown if the long-term risk may be similar to that seen in adults exposed to CELEBREX or other COX-2 selective and non-selective NSAIDs [(<span class="Italics">see <a href="#Box">Boxed Warning</a>, <a href="#S5.12">Warnings and Precautions (5.12)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.4"></a><a name="section-13.4"></a><p></p>
<h2>14.4	<span class='product-label-link' type='condition' conceptid='437082' conceptname='Ankylosing spondylitis'>Ankylosing <span class='product-label-link' type='condition' conceptid='4223530' conceptname='Spondylitis'>Spondylitis</span></span></h2>
<p class="First">CELEBREX was evaluated in AS patients in two placebo- and active-controlled clinical trials of 6 and 12 weeks duration. CELEBREX at doses of 100 mg twice daily, 200 mg once daily and 400 mg once daily was shown to be statistically superior to placebo in these studies for all three co-primary efficacy measures assessing global <span class='product-label-link' type='condition' conceptid='4329041' conceptname='Pain'>pain</span> intensity (Visual Analogue Scale), global disease activity (Visual Analogue Scale) and functional impairment (Bath <span class='product-label-link' type='condition' conceptid='437082' conceptname='Ankylosing spondylitis'>Ankylosing <span class='product-label-link' type='condition' conceptid='4223530' conceptname='Spondylitis'>Spondylitis</span></span> Functional Index). In the 12-week study, there was no difference in the extent of improvement between the 200 mg and 400 mg CELEBREX doses in a comparison of mean change from baseline, but there was a greater percentage of patients who responded to CELEBREX 400 mg, 53%, than to CELEBREX 200 mg, 44%, using the Assessment in <span class='product-label-link' type='condition' conceptid='437082' conceptname='Ankylosing spondylitis'>Ankylosing <span class='product-label-link' type='condition' conceptid='4223530' conceptname='Spondylitis'>Spondylitis</span></span> response criteria (ASAS 20). The ASAS 20 defines a responder as improvement from baseline of at least 20% and an absolute improvement of at least 10 mm, on a 0 to 100 mm scale, in at least three of the four following domains:  patient global <span class='product-label-link' type='condition' conceptid='4329041' conceptname='Pain'>pain</span>, Bath <span class='product-label-link' type='condition' conceptid='437082' conceptname='Ankylosing spondylitis'>Ankylosing <span class='product-label-link' type='condition' conceptid='4223530' conceptname='Spondylitis'>Spondylitis</span></span> Functional Index, and inflammation. The responder analysis also demonstrated no change in the responder rates beyond 6 weeks.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.5"></a><a name="section-13.5"></a><p></p>
<h2>14.5	Analgesia, including Primary <span class='product-label-link' type='condition' conceptid='194696' conceptname='Dysmenorrhea'>Dysmenorrhea</span></h2>
<p class="First">In acute analgesic models of post-oral surgery <span class='product-label-link' type='condition' conceptid='4329041' conceptname='Pain'>pain</span>, post-orthopedic surgical <span class='product-label-link' type='condition' conceptid='4329041' conceptname='Pain'>pain</span>, and primary <span class='product-label-link' type='condition' conceptid='194696' conceptname='Dysmenorrhea'>dysmenorrhea</span>, CELEBREX relieved <span class='product-label-link' type='condition' conceptid='4329041' conceptname='Pain'>pain</span> that was rated by patients as moderate to severe. Single doses [<span class="Italics">see <a href="#S2.5">Dosage and Administration (2.5)</a></span>] of CELEBREX provided <span class='product-label-link' type='condition' conceptid='4329041' conceptname='Pain'>pain</span> relief within 60 minutes.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.6"></a><a name="section-13.6"></a><p></p>
<h2>14.6	Special Studies</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.6.1"></a><p></p>
<p class="First"><span class="Bold Italics">Adenomatous <span class='product-label-link' type='condition' conceptid='4209223' conceptname='Polyp'>Polyp</span> Prevention Studies</span><span class="Italics">:</span></p>
<p>Cardiovascular safety was evaluated in two randomized, double-blind, placebo-controlled, three year studies involving patients with Sporadic Adenomatous <span class='product-label-link' type='condition' conceptid='4209223' conceptname='Polyp'>Polyp</span>s treated with CELEBREX: the APC trial (Adenoma Prevention with Celecoxib) and the PreSAP trial (Prevention of Spontaneous Adenomatous <span class='product-label-link' type='condition' conceptid='4209223' conceptname='Polyp'>Polyp</span>s). In the APC trial, there was a dose-related increase in the composite endpoint (adjudicated) of cardiovascular death, <span class='product-label-link' type='condition' conceptid='4329847' conceptname='Myocardial infarction'>myocardial infarction</span>, or stroke with celecoxib compared to placebo over 3 years of treatment. The PreSAP trial did not demonstrate a statistically significant increased risk for the same composite endpoint (adjudicated):</p>
<p>Cardiovascular safety was evaluated in two randomized, double-blind, placebo-controlled, three year studies involving patients with Sporadic Adenomatous Polyps treated with CELEBREX: the APC trial (Adenoma Prevention with <span class='product-label-link' type='medication' conceptid='1118084' conceptname='celecoxib'>Celecoxib</span>) and the PreSAP trial (Prevention of Spontaneous Adenomatous Polyps). In the APC trial, there was a dose-related increase in the composite endpoint (adjudicated) of cardiovascular death, myocardial infarction, or stroke with <span class='product-label-link' type='medication' conceptid='1118084' conceptname='celecoxib'>Celecoxib</span> compared to placebo over 3 years of treatment. The PreSAP trial did not demonstrate a statistically significant increased risk for the same composite endpoint (adjudicated):</p>
<ul>
<li>In the APC trial, the hazard ratios compared to placebo for a composite endpoint (adjudicated) of cardiovascular death, <span class='product-label-link' type='condition' conceptid='4329847' conceptname='Myocardial infarction'>myocardial infarction</span>, or stroke were 3.4 (95% CI 1.4 – 8.5) with celecoxib 400 mg twice daily and 2.8 (95% CI 1.1 – 7.2) with celecoxib 200 mg twice daily. Cumulative rates for this composite endpoint over 3 years were 3.0% (20/671 subjects) and 2.5% (17/685 subjects), respectively, compared to 0.9% (6/679 subjects) with placebo treatment. The increases in both celecoxib dose groups versus placebo-treated patients were mainly due to an increased incidence of <span class='product-label-link' type='condition' conceptid='4329847' conceptname='Myocardial infarction'>myocardial infarction</span>.</li>
<li>In the APC trial, the hazard ratios compared to placebo for a composite endpoint (adjudicated) of cardiovascular death, myocardial infarction, or stroke were 3.4 (95% CI 1.4 – 8.5) with <span class='product-label-link' type='medication' conceptid='1118084' conceptname='celecoxib'>celecoxib</span> 400 mg twice daily and 2.8 (95% CI 1.1 – 7.2) with <span class='product-label-link' type='medication' conceptid='1118084' conceptname='celecoxib'>celecoxib</span> 200 mg twice daily. Cumulative rates for this composite endpoint over 3 years were 3.0% (20/671 subjects) and 2.5% (17/685 subjects), respectively, compared to 0.9% (6/679 subjects) with placebo treatment. The increases in both <span class='product-label-link' type='medication' conceptid='1118084' conceptname='celecoxib'>celecoxib</span> dose groups versus placebo-treated patients were mainly due to an increased incidence of myocardial infarction.</li>
<li>In the PreSAP trial, the hazard ratio for this same composite endpoint (adjudicated) was 1.2 (95% CI 0.6 – 2.4) with <span class='product-label-link' type='medication' conceptid='1118084' conceptname='celecoxib'>celecoxib</span> 400 mg once daily compared to placebo. Cumulative rates for this composite endpoint over 3 years were 2.3% (21/933 subjects) and 1.9% (12/628 subjects), respectively.</li>
</ul>
<p>Clinical trials of other COX-2 selective and non-selective NSAIDs of up to three-years duration have shown an increased risk of serious cardiovascular thrombotic events, <span class='product-label-link' type='condition' conceptid='4329847' conceptname='Myocardial infarction'>myocardial infarction</span>, and stroke, which can be fatal.  As a result, all NSAIDs are considered potentially associated with this risk.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.6.2"></a><p></p>
<p class="First"><span class="Bold Italics"><span class='product-label-link' type='medication' conceptid='1118084' conceptname='celecoxib'>Celecoxib</span> Long-Term Arthritis Safety Study (CLASS):</span></p>
<p class="First"><span class="Bold Italics">Celecoxib Long-Term <span class='product-label-link' type='condition' conceptid='4291025' conceptname='Arthritis'>Arthritis</span> Safety Study (CLASS):</span></p>
<p>This was a prospective, long-term, safety outcome study conducted post-marketing in approximately 5,800 OA patients and 2,200 RA patients. Patients received CELEBREX 400 mg twice daily (4-fold and 2-fold the recommended OA and RA doses, respectively), <span class='product-label-link' type='medication' conceptid='1177480' conceptname='Ibuprofen'>ibuprofen</span> 800 mg three times daily or <span class='product-label-link' type='medication' conceptid='1124300' conceptname='Diclofenac'>diclofenac</span> 75 mg twice daily (common therapeutic doses). Median exposures for CELEBREX (n = 3,987) and <span class='product-label-link' type='medication' conceptid='1124300' conceptname='Diclofenac'>diclofenac</span> (n = 1,996) were 9 months while <span class='product-label-link' type='medication' conceptid='1177480' conceptname='Ibuprofen'>ibuprofen</span> (n = 1,985) was 6 months. The primary endpoint of this outcome study was the incidence of complicated ulcers (gastrointestinal bleeding, perforation or obstruction). Patients were allowed to take concomitant low-dose (≤ 325 mg/day) <span class='product-label-link' type='medication' conceptid='1112807' conceptname='Aspirin'>aspirin</span> (ASA) for cardiovascular prophylaxis (ASA subgroups: CELEBREX, n = 882; <span class='product-label-link' type='medication' conceptid='1124300' conceptname='Diclofenac'>diclofenac</span>, n = 445; <span class='product-label-link' type='medication' conceptid='1177480' conceptname='Ibuprofen'>ibuprofen</span>, n = 412). Differences in the incidence of complicated ulcers between CELEBREX and the combined group of <span class='product-label-link' type='medication' conceptid='1177480' conceptname='Ibuprofen'>ibuprofen</span> and <span class='product-label-link' type='medication' conceptid='1124300' conceptname='Diclofenac'>diclofenac</span> were not statistically significant. </p>
<p>This was a prospective, long-term, safety outcome study conducted post-marketing in approximately 5,800 OA patients and 2,200 RA patients. Patients received CELEBREX 400 mg twice daily (4-fold and 2-fold the recommended OA and RA doses, respectively), ibuprofen 800 mg three times daily or diclofenac 75 mg twice daily (common therapeutic doses). Median exposures for CELEBREX (n = 3,987) and diclofenac (n = 1,996) were 9 months while ibuprofen (n = 1,985) was 6 months. The primary endpoint of this outcome study was the incidence of complicated <span class='product-label-link' type='condition' conceptid='4177703' conceptname='Ulcer'>ulcer</span>s (gastrointestinal <span class='product-label-link' type='condition' conceptid='437312' conceptname='Bleeding'>bleeding</span>, perforation or obstruction). Patients were allowed to take concomitant low-dose (≤ 325 mg/day) aspirin (ASA) for cardiovascular prophylaxis (ASA subgroups: CELEBREX, n = 882; diclofenac, n = 445; ibuprofen, n = 412). Differences in the incidence of complicated <span class='product-label-link' type='condition' conceptid='4177703' conceptname='Ulcer'>ulcer</span>s between CELEBREX and the combined group of ibuprofen and diclofenac were not statistically significant. </p>
<p>Patients on CELEBREX and concomitant low-dose ASA (N=882) experienced 4-fold higher rates of complicated <span class='product-label-link' type='condition' conceptid='4177703' conceptname='Ulcer'>ulcer</span>s compared to those not on ASA (N=3105). The Kaplan-Meier rate for complicated <span class='product-label-link' type='condition' conceptid='4177703' conceptname='Ulcer'>ulcer</span>s at 9 months was 1.12% versus 0.32% for those on low-dose ASA and those not on ASA, respectively [<span class="Italics">see <a href="#S5.4">Warnings and Precautions (5.4)</a></span>].</p>
<p>The estimated cumulative rates at 9 months of complicated and symptomatic <span class='product-label-link' type='condition' conceptid='4177703' conceptname='Ulcer'>ulcer</span>s for patients treated with CELEBREX 400 mg twice daily are described in Table 4. Table 4 also displays results for patients less than or greater than 65 years of age. The difference in rates between CELEBREX alone and CELEBREX with ASA groups may be due to the higher risk for GI events in ASA users.</p>
<a name="table4"></a><table width="80%">
<caption><span>Table 4:  Complicated and Symptomatic <span class='product-label-link' type='condition' conceptid='4177703' conceptname='Ulcer'>Ulcer</span> Rates in Patients Taking CELEBREX 400 mg Twice Daily (Kaplan-Meier Rates at 9 months [%]) Based on Risk Factors</span></caption>
<col align="left" valign="middle" width="80%">
<col align="left" valign="middle" width="20%">
<tbody class="Headless">
<tr class="First Toprule">
<td align="left"><span class="Bold">All Patients</span></td>
<td align="left"></td>
</tr>
<tr>
<td align="left">  CELEBREX alone (n=3105)</td>
<td align="left">0.78</td>
</tr>
<tr>
<td align="left">  CELEBREX with ASA (n=882)</td>
<td align="left">2.19</td>
</tr>
<tr>
<td align="left"><span class="Bold">Patients &lt;65 Years</span></td>
<td align="left"></td>
</tr>
<tr>
<td align="left">  CELEBREX alone (n=2025)</td>
<td align="left">0.47</td>
</tr>
<tr>
<td align="left">  CELEBREX with ASA (n=403)</td>
<td align="left">1.26</td>
</tr>
<tr>
<td align="left"><span class="Bold">Patients ≥65 Years</span></td>
<td align="left"></td>
</tr>
<tr>
<td align="left">  CELEBREX alone (n=1080)</td>
<td align="left">1.40</td>
</tr>
<tr class="Botrule Last">
<td align="left">  CELEBREX with ASA (n=479)</td>
<td align="left">3.06</td>
</tr>
</tbody>
</table>
<p>In a small number of patients with a history of <span class='product-label-link' type='condition' conceptid='4177703' conceptname='Ulcer'>ulcer</span> disease, the complicated and symptomatic <span class='product-label-link' type='condition' conceptid='4177703' conceptname='Ulcer'>ulcer</span> rates in patients taking CELEBREX alone or CELEBREX with ASA were, respectively, 2.56% (n=243) and 6.85% (n=91) at 48 weeks. These results are to be expected in patients with a prior history of <span class='product-label-link' type='condition' conceptid='4177703' conceptname='Ulcer'>ulcer</span> disease [<span class="Italics">see <a href="#S5.4">Warnings and Precautions (5.4)</a> and <a href="#S6.1">Adverse Reactions (6.1)</a></span>].</p>
<p>Cardiovascular safety outcomes were also evaluated in the CLASS trial. Kaplan-Meier cumulative rates for investigator-reported serious cardiovascular thromboembolic adverse events (including MI, <span class='product-label-link' type='condition' conceptid='440417' conceptname='Pulmonary embolism'>pulmonary <span class='product-label-link' type='condition' conceptid='4185607' conceptname='Embolism'>embolism</span></span>, <span class='product-label-link' type='condition' conceptid='4133004' conceptname='Deep venous thrombosis'>deep <span class='product-label-link' type='condition' conceptid='444247' conceptname='Venous thrombosis'>venous <span class='product-label-link' type='condition' conceptid='4231363' conceptname='Thrombosis'>thrombosis</span></span></span>, unstable angina, transient ischemic attacks, and ischemic <span class='product-label-link' type='condition' conceptid='381316' conceptname='Cerebrovascular accident'>cerebrovascular accident</span>s) demonstrated no differences between the CELEBREX, diclofenac, or ibuprofen treatment groups. The cumulative rates in all patients at nine months for CELEBREX, diclofenac, and ibuprofen were 1.2%, 1.4%, and 1.1%, respectively. The cumulative rates in non-ASA users at nine months in each of the three treatment groups were less than 1%. The cumulative rates for <span class='product-label-link' type='condition' conceptid='4329847' conceptname='Myocardial infarction'>myocardial infarction</span> in non-ASA users at nine months in each of the three treatment groups were less than 0.2%. There was no placebo group in the CLASS trial, which limits the ability to determine whether the three drugs tested had no increased risk of CV events or if they all increased the risk to a similar degree.</p>
<p>Cardiovascular safety outcomes were also evaluated in the CLASS trial. Kaplan-Meier cumulative rates for investigator-reported serious cardiovascular thromboembolic adverse events (including MI, pulmonary embolism, deep venous thrombosis, unstable angina, transient ischemic attacks, and ischemic cerebrovascular accidents) demonstrated no differences between the CELEBREX, <span class='product-label-link' type='medication' conceptid='1124300' conceptname='Diclofenac'>diclofenac</span>, or <span class='product-label-link' type='medication' conceptid='1177480' conceptname='Ibuprofen'>ibuprofen</span> treatment groups. The cumulative rates in all patients at nine months for CELEBREX, <span class='product-label-link' type='medication' conceptid='1124300' conceptname='Diclofenac'>diclofenac</span>, and <span class='product-label-link' type='medication' conceptid='1177480' conceptname='Ibuprofen'>ibuprofen</span> were 1.2%, 1.4%, and 1.1%, respectively. The cumulative rates in non-ASA users at nine months in each of the three treatment groups were less than 1%. The cumulative rates for myocardial infarction in non-ASA users at nine months in each of the three treatment groups were less than 0.2%. There was no placebo group in the CLASS trial, which limits the ability to determine whether the three drugs tested had no increased risk of CV events or if they all increased the risk to a similar degree.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.6.3"></a><p></p>
<p class="First"><span class="Bold Italics">Endoscopic Studies</span><span class="Italics">: </span> The correlation between findings of short-term endoscopic studies with CELEBREX and the relative incidence of clinically significant serious upper GI events with long-term use has not been established.  Serious clinically significant upper GI <span class='product-label-link' type='condition' conceptid='437312' conceptname='Bleeding'>bleeding</span> has been observed in patients receiving CELEBREX in controlled and open-labeled trials [<span class="Italics">see <a href="#S5.4">Warnings and Precautions (5.4)</a> and <a href="#S14.6">Clinical Studies (14.6)</a></span>] </p>
<p>A randomized, double-blind study in 430 RA patients was conducted in which an endoscopic examination was performed at 6 months.  The incidence of endoscopic <span class='product-label-link' type='condition' conceptid='4177703' conceptname='Ulcer'>ulcer</span>s in patients taking CELEBREX 200 mg twice daily was 4% vs. 15% for patients taking diclofenac SR 75 mg twice daily.  However, CELEBREX was not statistically different than diclofenac for clinically relevant GI outcomes in the CLASS trial [<span class="Italics">see <a href="#S14.6">Clinical Studies (14.6)</a></span>].</p>
<p>A randomized, double-blind study in 430 RA patients was conducted in which an endoscopic examination was performed at 6 months.  The incidence of endoscopic ulcers in patients taking CELEBREX 200 mg twice daily was 4% vs. 15% for patients taking <span class='product-label-link' type='medication' conceptid='1124300' conceptname='Diclofenac'>diclofenac</span> SR 75 mg twice daily.  However, CELEBREX was not statistically different than <span class='product-label-link' type='medication' conceptid='1124300' conceptname='Diclofenac'>diclofenac</span> for clinically relevant GI outcomes in the CLASS trial [<span class="Italics">see <a href="#S14.6">Clinical Studies (14.6)</a></span>].</p>
<p>The incidence of endoscopic <span class='product-label-link' type='condition' conceptid='4177703' conceptname='Ulcer'>ulcer</span>s was studied in two 12-week, placebo-controlled studies in 2157 OA and RA patients in whom baseline endoscopies revealed no <span class='product-label-link' type='condition' conceptid='4177703' conceptname='Ulcer'>ulcer</span>s. There was no dose relationship for the incidence of gastroduodenal <span class='product-label-link' type='condition' conceptid='4177703' conceptname='Ulcer'>ulcer</span>s and the dose of CELEBREX (50 mg to 400 mg twice daily).  The incidence for naproxen 500 mg twice daily was 16.2 and 17.6% in the two studies, for placebo was 2.0 and 2.3%, and for all doses of CELEBREX the incidence ranged between 2.7%–5.9%.  There have been no large, clinical outcome studies to compare clinically relevant GI outcomes with CELEBREX and naproxen.</p>
<p>The incidence of endoscopic ulcers was studied in two 12-week, placebo-controlled studies in 2157 OA and RA patients in whom baseline endoscopies revealed no ulcers. There was no dose relationship for the incidence of gastroduodenal ulcers and the dose of CELEBREX (50 mg to 400 mg twice daily).  The incidence for <span class='product-label-link' type='medication' conceptid='1115008' conceptname='Naproxen'>naproxen</span> 500 mg twice daily was 16.2 and 17.6% in the two studies, for placebo was 2.0 and 2.3%, and for all doses of CELEBREX the incidence ranged between 2.7%–5.9%.  There have been no large, clinical outcome studies to compare clinically relevant GI outcomes with CELEBREX and <span class='product-label-link' type='medication' conceptid='1115008' conceptname='Naproxen'>naproxen</span>.</p>
<p>In the endoscopic studies, approximately 11% of patients were taking <span class='product-label-link' type='medication' conceptid='1112807' conceptname='Aspirin'>aspirin</span> (≤ 325 mg/day).  In the CELEBREX groups, the endoscopic ulcer rate appeared to be higher in <span class='product-label-link' type='medication' conceptid='1112807' conceptname='Aspirin'>aspirin</span> users than in non-users.  However, the increased rate of ulcers in these <span class='product-label-link' type='medication' conceptid='1112807' conceptname='Aspirin'>aspirin</span> users was less than the endoscopic ulcer rates observed in the active comparator groups, with or without <span class='product-label-link' type='medication' conceptid='1112807' conceptname='Aspirin'>aspirin</span>.</p>
<p>In the endoscopic studies, approximately 11% of patients were taking aspirin (≤ 325 mg/day).  In the CELEBREX groups, the endoscopic <span class='product-label-link' type='condition' conceptid='4177703' conceptname='Ulcer'>ulcer</span> rate appeared to be higher in aspirin users than in non-users.  However, the increased rate of <span class='product-label-link' type='condition' conceptid='4177703' conceptname='Ulcer'>ulcer</span>s in these aspirin users was less than the endoscopic <span class='product-label-link' type='condition' conceptid='4177703' conceptname='Ulcer'>ulcer</span> rates observed in the active comparator groups, with or without aspirin.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="S16"></a><a name="section-14"></a><p></p>
<h1>16.	HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">CELEBREX 50 mg capsules are white, with reverse printed white on red band of body and cap with markings of 7767 on the cap and 50 on the body, supplied as:</p>
<p><span class="Bold Underline">NDC Number</span>                 <span class="Bold Underline">Size</span></p>
<p>0025-1515-01                 bottle of 60 </p>
<p>CELEBREX 100 mg capsules are white, with reverse printed white on blue band of body and cap with markings of 7767 on the cap and 100 on the body, supplied as:</p>
<p><span class="Bold Underline">NDC Number</span>                 <span class="Bold Underline">Size</span></p>
<p>0025-1520-31                 bottle of 100</p>
<p>0025-1520-51                 bottle of 500</p>
<p>0025-1520-34                 carton of 100 unit dose</p>
<p>CELEBREX 200 mg capsules are white, with reverse printed white on gold band with markings of 7767 on the cap and 200 on the body, supplied as:</p>
<p><span class="Bold Underline">NDC Number</span>                 <span class="Bold Underline">Size</span></p>
<p>0025-1525-31                 bottle of 100</p>
<p>0025-1525-51                 bottle of 500</p>
<p>0025-1525-34                 carton of 100 unit dose</p>
<p>CELEBREX 400 mg capsules are white, with reverse printed white on green band with markings of 7767 on the cap and 400 on the body, supplied as:</p>
<p><span class="Bold Underline">NDC Number</span>                 <span class="Bold Underline">Size</span></p>
<p>0025-1530-02                 bottle of 60</p>
<p>0025-1530-01                 carton of 100 unit dose</p>
<div class="Section" data-sectionCode="44425-7">
<a name="section-14.1"></a><p></p>
<p class="First"><span class="Bold Italics">Storage</span><span class="Italics">: </span>Store at 25°C (77°F); excursions permitted to 15–30°C (59–86°F) [see USP Controlled Room Temperature]</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="S17"></a><a name="section-15"></a><p></p>
<h1>17. PATIENT COUNSELING INFORMATION</h1>
<p class="First">Patients should be informed of the following information before initiating therapy with CELEBREX and periodically during the course of ongoing therapy. </p>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.1"></a><a name="section-15.1"></a><p></p>
<h2>17.1	Medication Guide</h2>
<p class="First">Patients should be informed of the availability of a Medication Guide for NSAIDs that accompanies each prescription dispensed, and should be instructed to read the Medication Guide prior to using CELEBREX.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.2"></a><a name="section-15.2"></a><p></p>
<h2>17.2	Cardiovascular Effects</h2>
<p class="First">Patients should be informed that CELEBREX may cause serious CV side effects such as MI or stroke, which may result in hospitalization and even death.  Patients should be informed of the signs and symptoms of <span class='product-label-link' type='condition' conceptid='77670' conceptname='Chest pain'>chest <span class='product-label-link' type='condition' conceptid='4329041' conceptname='Pain'>pain</span></span>, shortness of breath, weakness, slurring of speech, and to seek immediate medical advice if they observe any of these signs or symptoms. [<span class="Italics">see <a href="#S5.1">Warnings and Precautions (5.1)</a></span>].</p>
<p>Patients should be informed that CELEBREX can lead to the onset of new hypertension or worsening of preexisting hypertension, and that CELEBREX may impair the response of some antihypertensive agents.  Patients should be instructed on the proper follow up for monitoring of blood pressure.  [<span class="Italics">see <a href="#S5.2">Warnings and Precautions (5.2)</a> and <a href="#S7.4">Drug Interactions (7.4)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.3"></a><a name="section-15.3"></a><p></p>
<h2>17.3	Gastrointestinal Effects</h2>
<p class="First">Patients should be informed that CELEBREX can cause gastrointestinal discomfort and more serious side effects, such as <span class='product-label-link' type='condition' conceptid='4177703' conceptname='Ulcer'>ulcer</span>s and <span class='product-label-link' type='condition' conceptid='437312' conceptname='Bleeding'>bleeding</span>, which may result in hospitalization and even death.  Patients should be informed of the signs and symptoms of <span class='product-label-link' type='condition' conceptid='4177703' conceptname='Ulcer'>ulcer</span>ations and <span class='product-label-link' type='condition' conceptid='437312' conceptname='Bleeding'>bleeding</span>, and to seek immediate medical advice if they observe any signs or symptoms that are indicative of these disorders, including epigastric <span class='product-label-link' type='condition' conceptid='4329041' conceptname='Pain'>pain</span>, dyspepsia, <span class='product-label-link' type='condition' conceptid='4103703' conceptname='Melena'>melena</span>, and <span class='product-label-link' type='condition' conceptid='26727' conceptname='Hematemesis'>hematemesis</span>. [<span class="Italics">see <a href="#S5.2">Warnings and Precautions (5.4)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.4"></a><a name="section-15.4"></a><p></p>
<h2>17.4	Hepatic Effects</h2>
<p class="First">Patients should be informed of the warning signs and symptoms of hepatotoxicity (e.g., <span class='product-label-link' type='condition' conceptid='31967' conceptname='Nausea'>nausea</span>, fatigue, lethargy, pruritus, <span class='product-label-link' type='condition' conceptid='137977' conceptname='Jaundice'>jaundice</span>, right upper quadrant tenderness, and "flu-like" symptoms).  Patients should be instructed that they should stop therapy and seek immediate medical therapy if these signs and symptoms occur [<span class="Italics">see <a href="#S5.5">Warnings and Precautions (5.5)</a>, <a href="#S8.6">Use in Specific Populations (8.6)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.5"></a><a name="section-15.5"></a><p></p>
<h2>17.5	Adverse Skin Reactions</h2>
<p class="First">Patients should be informed that CELEBREX is a sulfonamide and can cause serious skin side effects such as exfoliative dermatitis, SJS, and TEN, which may result in hospitalizations and even death.  Although serious skin reactions may occur without warning, patients should be informed of the signs and symptoms of skin rash and <span class='product-label-link' type='condition' conceptid='443720' conceptname='Blister'>blister</span>s, fever, or other signs of hypersensitivity such as itching, and seek immediate medical advice when observing any indicative signs or symptoms.</p>
<p>Patients should be advised to stop CELEBREX immediately if they develop any type of rash and contact their physician as soon as possible.  </p>
<p>Patients with prior history of sulfa allergy should not take CELEBREX [<span class="Italics">see <a href="#S5.8">Warnings and Precautions (5.8)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.6"></a><a name="section-15.6"></a><p></p>
<h2>17.6	Weight Gain and <span class='product-label-link' type='condition' conceptid='433595' conceptname='Edema'>Edema</span></h2>
<p class="First">Long-term administration of NSAIDs including CELEBREX has resulted in renal injury. Patients at greatest risk are those taking diuretics, ACE-inhibitors, angiotensin II antagonists, or with renal or liver dysfunction, <span class='product-label-link' type='condition' conceptid='316139' conceptname='Heart failure'>heart failure</span>, and the elderly [<span class="Italics">see <a href="#S5.3">Warnings and Precautions (5.3</a><a href="#S5.6">, 5.6)</a>, <a href="#S8">Use in Specific Populations (8)</a></span>].</p>
<p>Patients should be instructed to promptly report to their physicians signs or symptoms of unexplained weight gain or <span class='product-label-link' type='condition' conceptid='433595' conceptname='Edema'>edema</span> following treatment with CELEBREX [<span class="Italics">see <a href="#S5.3">Warnings and Precautions (5.3)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.7"></a><a name="section-15.7"></a><p></p>
<h2>17.7	Anaphylactoid Reactions</h2>
<p class="First">Patients should be informed of the signs and symptoms of an anaphylactoid reaction (e.g., <span class='product-label-link' type='condition' conceptid='4041664' conceptname='Difficulty breathing'>difficulty breathing</span>, <span class='product-label-link' type='condition' conceptid='4275722' conceptname='Swelling'>swelling</span> of the face or throat).  Patients should be instructed to seek immediate emergency assistance if they develop any of these signs and symptoms [<span class="Italics">see <a href="#S5.7">Warnings and Precautions (5.7)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.8"></a><a name="section-15.8"></a><p></p>
<h2>17.8	Effects During Pregnancy</h2>
<p class="First">Patients should be informed that in late pregnancy CELEBREX should be avoided because it may cause premature closure of the ductus arteriosus [<span class="Italics">see <a href="#S5.9">Warnings and Precautions (5.9)</a>, <a href="#S8.1">Use in Specific Populations (8.1)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.9"></a><a name="section-15.9"></a><p></p>
<h2>17.9	Preexisting <span class='product-label-link' type='condition' conceptid='317009' conceptname='Asthma'>Asthma</span></h2>
<p class="First">Patients should be instructed to tell their physicians if they have a history of <span class='product-label-link' type='condition' conceptid='317009' conceptname='Asthma'>asthma</span> or aspirin-sensitive <span class='product-label-link' type='condition' conceptid='317009' conceptname='Asthma'>asthma</span> because the use of NSAIDs in patients with aspirin-sensitive <span class='product-label-link' type='condition' conceptid='317009' conceptname='Asthma'>asthma</span> has been associated with severe <span class='product-label-link' type='condition' conceptid='256717' conceptname='Bronchospasm'>bronchospasm</span>, which can be fatal.  Patients with this form of aspirin sensitivity should be instructed not to take Celebrex.  Patients with preexisting <span class='product-label-link' type='condition' conceptid='317009' conceptname='Asthma'>asthma</span> should be instructed to seek immediate medical attention if their <span class='product-label-link' type='condition' conceptid='317009' conceptname='Asthma'>asthma</span> worsens after taking Celebrex  [<span class="Italics">see <a href="#S5.13">Warnings and Precautions (5.13)</a></span>].</p>
<p class="First">Patients should be instructed to tell their physicians if they have a history of asthma or <span class='product-label-link' type='medication' conceptid='1112807' conceptname='Aspirin'>aspirin</span>-sensitive asthma because the use of NSAIDs in patients with <span class='product-label-link' type='medication' conceptid='1112807' conceptname='Aspirin'>aspirin</span>-sensitive asthma has been associated with severe bronchospasm, which can be fatal.  Patients with this form of <span class='product-label-link' type='medication' conceptid='1112807' conceptname='Aspirin'>aspirin</span> sensitivity should be instructed not to take Celebrex.  Patients with preexisting asthma should be instructed to seek immediate medical attention if their asthma worsens after taking Celebrex  [<span class="Italics">see <a href="#S5.13">Warnings and Precautions (5.13)</a></span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16"></a><p></p>
<h1></h1>
<p class="First"><img alt="logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8d52185d-421f-4e34-8db7-f7676db2a226&amp;name=celebrex-02.jpg"></p>
<p>LAB-0036-16.0</p>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="S17.11"></a><a name="section-17"></a><p></p>
<p class="First"><span class="Bold Underline">Medication Guide for  Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)</span></p>
<p><span class="Underline">(See the end of this Medication Guide for a list of prescription NSAID medicines.)</span></p>
<table width="100%">
<col align="center" valign="middle" width="100%">
<tbody class="Headless"><tr class="First Last"><td align="center"></td></tr></tbody>
</table>
<p><span class="Bold">What is the most important information I should know about medicines called Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)?</span></p>
<p><span class="Bold">NSAID medicines may increase the chance of a heart attack or stroke that can lead to death.</span></p>
<p>This chance increases:</p>
<ul><li>with longer use of NSAID medicines<ul class="Disc"><li>in people who have <span class='product-label-link' type='condition' conceptid='321588' conceptname='Heart disease'>heart disease</span></li></ul>
</li></ul>
<p><span class="Bold">NSAID medicines should never be used right before or after a heart surgery called a "coronary artery bypass graft (CABG)."</span></p>
<p><span class="Bold">NSAID medicines can cause <span class='product-label-link' type='condition' conceptid='4177703' conceptname='Ulcer'>ulcer</span>s and <span class='product-label-link' type='condition' conceptid='437312' conceptname='Bleeding'>bleeding</span> in the stomach and intestines at any time during treatment. <span class='product-label-link' type='condition' conceptid='4177703' conceptname='Ulcer'>ulcer</span>s and <span class='product-label-link' type='condition' conceptid='437312' conceptname='Bleeding'>bleeding</span>:</span></p>
<ul>
<li>can happen without warning symptoms</li>
<li>may cause death</li>
</ul>
<p><span class="Bold">The chance of a person getting an <span class='product-label-link' type='condition' conceptid='4177703' conceptname='Ulcer'>ulcer</span> or <span class='product-label-link' type='condition' conceptid='437312' conceptname='Bleeding'>bleeding</span> increases with:</span></p>
<ul>
<li>taking medicines called "corticosteroids" and "anticoagulants"</li>
<li>longer use</li>
<li>smoking</li>
<li>drinking alcohol</li>
<li>older age</li>
<li>having poor health</li>
</ul>
<p><span class="Bold">NSAID medicines should only be used:</span></p>
<ul>
<li>exactly as prescribed</li>
<li>at the lowest dose possible for your treatment</li>
<li>for the shortest time needed</li>
</ul>
<table width="100%">
<col align="center" valign="middle" width="100%">
<tbody class="Headless"><tr class="First Last"><td align="center"></td></tr></tbody>
</table>
<p><span class="Bold">What are Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)?</span></p>
<p>NSAID medicines are used to treat <span class='product-label-link' type='condition' conceptid='4329041' conceptname='Pain'>pain</span> and redness, <span class='product-label-link' type='condition' conceptid='4275722' conceptname='Swelling'>swelling</span>, and heat (inflammation) from medical conditions such as:</p>
<ul>
<li>different types of <span class='product-label-link' type='condition' conceptid='4291025' conceptname='Arthritis'>arthritis</span></li>
<li>menstrual cramps and other types of short-term <span class='product-label-link' type='condition' conceptid='4329041' conceptname='Pain'>pain</span> </li>
</ul>
<p><span class="Bold">Who should not take a Non-Steroidal Anti-Inflammatory Drug (NSAID)?</span></p>
<p><span class="Bold">Do not take an NSAID medicine:</span></p>
<ul>
<li>if you had an <span class='product-label-link' type='condition' conceptid='317009' conceptname='Asthma'>asthma</span> attack, hives, or other allergic reaction with aspirin or any other NSAID medicine</li>
<li>if you had an asthma attack, hives, or other allergic reaction with <span class='product-label-link' type='medication' conceptid='1112807' conceptname='Aspirin'>aspirin</span> or any other NSAID medicine</li>
<li>for <span class='product-label-link' type='condition' conceptid='4329041' conceptname='Pain'>pain</span> right before or after heart bypass surgery </li>
</ul>
<p><span class="Bold">Tell your healthcare provider:</span></p>
<ul>
<li>about all of your medical conditions.</li>
<li>about all of the medicines you take. NSAIDs and some other medicines can interact with each other and cause serious side effects. <span class="Bold">Keep a list of your medicines to show to your healthcare provider and pharmacist.</span>
</li>
<li>if you are pregnant. <span class="Bold">NSAID medicines should not be used by pregnant women late in their pregnancy.</span>
</li>
<li>if you are breastfeeding. <span class="Bold">Talk to your doctor.</span>
</li>
</ul>
<p><span class="Bold">What are the possible side effects of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)?</span></p>
<table width="80%">
<col align="left" valign="top" width="50%">
<col align="left" valign="top" width="50%">
<tbody class="Headless">
<tr class="First">
<td class="Lrule" align="left"><span class="Bold">Serious side effects include:</span></td>
<td class="Lrule Rrule" align="left"><span class="Bold">Other side effects include:</span></td>
</tr>
<tr class="Last">
<td class="Lrule" align="left"><ul>
<li>heart attack</li>
<li>stroke</li>
<li>high blood pressure</li>
<li><span class='product-label-link' type='condition' conceptid='316139' conceptname='Heart failure'>heart failure</span> from body <span class='product-label-link' type='condition' conceptid='4275722' conceptname='Swelling'>swelling</span> (fluid retention)</li>
<li>kidney problems including kidney failure</li>
<li><span class='product-label-link' type='condition' conceptid='437312' conceptname='Bleeding'>bleeding</span> and <span class='product-label-link' type='condition' conceptid='4177703' conceptname='Ulcer'>ulcer</span>s in the stomach and intestine </li>
<li>low red blood cells (<span class='product-label-link' type='condition' conceptid='439777' conceptname='Anemia'>anemia</span>)</li>
<li>life-threatening skin reactions</li>
<li>life-threatening allergic reactions</li>
<li>liver problems including liver failure</li>
<li><span class='product-label-link' type='condition' conceptid='317009' conceptname='Asthma'>asthma</span> attacks in people who have <span class='product-label-link' type='condition' conceptid='317009' conceptname='Asthma'>asthma</span></li>
</ul></td>
<td class="Lrule Rrule" align="left"><ul>
<li>stomach <span class='product-label-link' type='condition' conceptid='4329041' conceptname='Pain'>pain</span></li>
<li><span class='product-label-link' type='condition' conceptid='75860' conceptname='Constipation'>constipation</span></li>
<li><span class='product-label-link' type='condition' conceptid='196523' conceptname='Diarrhea'>diarrhea</span></li>
<li>gas</li>
<li>heartburn</li>
<li><span class='product-label-link' type='condition' conceptid='31967' conceptname='Nausea'>nausea</span></li>
<li><span class='product-label-link' type='condition' conceptid='441408' conceptname='Vomiting'>vomiting</span></li>
<li>dizziness</li>
</ul></td>
</tr>
</tbody>
</table>
<p><span class="Bold">Get emergency help right away if you have any of the following symptoms:</span></p>
<table width="80%">
<col align="left" valign="top" width="50%">
<col align="left" valign="top" width="50%">
<tbody class="Headless"><tr class="Botrule First Last Toprule">
<td align="left"><ul>
<li>shortness of breath or trouble breathing</li>
<li><span class='product-label-link' type='condition' conceptid='77670' conceptname='Chest pain'>chest <span class='product-label-link' type='condition' conceptid='4329041' conceptname='Pain'>pain</span></span></li>
<li>weakness in one part or side of your body</li>
</ul></td>
<td align="left"><ul>
<li>slurred speech</li>
<li><span class='product-label-link' type='condition' conceptid='4275722' conceptname='Swelling'>swelling</span> of the face or throat</li>
</ul></td>
</tr></tbody>
</table>
<p><span class="Bold">Stop your NSAID medicine and call your healthcare provider right away if you have any of the following symptoms:</span></p>
<table width="80%">
<col align="left" valign="top" width="50%">
<col align="left" valign="top" width="50%">
<tbody class="Headless"><tr class="Botrule First Last Toprule">
<td align="left"><ul>
<li><span class='product-label-link' type='condition' conceptid='31967' conceptname='Nausea'>nausea</span></li>
<li>more tired or weaker than usual</li>
<li>itching</li>
<li>your skin or eyes look yellow</li>
<li>stomach <span class='product-label-link' type='condition' conceptid='4329041' conceptname='Pain'>pain</span></li>
<li>flu-like symptoms</li>
</ul></td>
<td align="left"><ul>
<li>vomit blood</li>
<li>there is blood in your bowel movement or it is black and sticky like tar</li>
<li>skin rash or <span class='product-label-link' type='condition' conceptid='443720' conceptname='Blister'>blister</span>s with fever</li>
<li>unusual weight gain</li>
<li><span class='product-label-link' type='condition' conceptid='4275722' conceptname='Swelling'>swelling</span> of the arms and legs, hands and feet</li>
</ul></td>
</tr></tbody>
</table>
<p>These are not all the side effects with NSAID medicines. Talk to your healthcare provider or pharmacist for more information about NSAID medicines.</p>
<p><span class="Bold">Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</span></p>
<p><span class="Bold">Other information about Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)</span></p>
<ul>
<li><span class='product-label-link' type='medication' conceptid='1112807' conceptname='Aspirin'>Aspirin</span> is an NSAID medicine but it does not increase the chance of a heart attack. <span class='product-label-link' type='medication' conceptid='1112807' conceptname='Aspirin'>Aspirin</span> can cause bleeding in the brain, stomach, and intestines. <span class='product-label-link' type='medication' conceptid='1112807' conceptname='Aspirin'>Aspirin</span> can also cause ulcers in the stomach and intestines.</li>
<li>Aspirin is an NSAID medicine but it does not increase the chance of a heart attack. Aspirin can cause <span class='product-label-link' type='condition' conceptid='437312' conceptname='Bleeding'>bleeding</span> in the brain, stomach, and intestines. Aspirin can also cause <span class='product-label-link' type='condition' conceptid='4177703' conceptname='Ulcer'>ulcer</span>s in the stomach and intestines.</li>
<li>Some of these NSAID medicines are sold in lower doses without a prescription (over –the –counter). Talk to your healthcare provider before using over –the –counter NSAIDs for more than 10 days. </li>
</ul>
<table width="100%">
<caption><span>NSAID medicines that need a prescription</span></caption>
<col align="left" valign="top" width="40%">
<col align="left" valign="top" width="60%">
<thead><tr class="First Last">
<th class="Lrule" align="left">Generic Name</th>
<th class="Lrule Rrule" align="left">Tradename</th>
</tr></thead>
<tfoot><tr><td colspan="2" align="left"><dl class="Footnote">
<dt><a name="footnote-3" href="#footnote-reference-3">*</a></dt>
<dd>Vicoprofen contains the same dose of <span class='product-label-link' type='medication' conceptid='1177480' conceptname='Ibuprofen'>ibuprofen</span> as over-the-counter (OTC) NSAIDs, and is usually used for less than 10 days to treat pain.  The OTC NSAID label warns that long term continuous use may increase the risk of heart attack or stroke.</dd>
<dd>Vicoprofen contains the same dose of ibuprofen as over-the-counter (OTC) NSAIDs, and is usually used for less than 10 days to treat <span class='product-label-link' type='condition' conceptid='4329041' conceptname='Pain'>pain</span>.  The OTC NSAID label warns that long term continuous use may increase the risk of heart attack or stroke.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Botrule Lrule" align="left"><span class='product-label-link' type='medication' conceptid='1118084' conceptname='celecoxib'>Celecoxib</span></td>
<td class="Botrule Lrule Rrule" align="left">Celebrex</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left"><span class='product-label-link' type='medication' conceptid='1124300' conceptname='Diclofenac'>Diclofenac</span></td>
<td class="Botrule Lrule Rrule" align="left">Cataflam, Voltaren, Arthrotec (combined with <span class='product-label-link' type='medication' conceptid='1150871' conceptname='Misoprostol'>misoprostol</span>)</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left"><span class='product-label-link' type='medication' conceptid='1126128' conceptname='Diflunisal'>Diflunisal</span></td>
<td class="Botrule Lrule Rrule" align="left">Dolobid</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left"><span class='product-label-link' type='medication' conceptid='1195492' conceptname='Etodolac'>Etodolac</span></td>
<td class="Botrule Lrule Rrule" align="left">Lodine, Lodine XL</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left">Fenoprofen</td>
<td class="Botrule Lrule Rrule" align="left">Nalfon, Nalfon 200</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left"><span class='product-label-link' type='medication' conceptid='1156378' conceptname='Flurbiprofen'>Flurbiprofen</span></td>
<td class="Botrule Lrule Rrule" align="left">Ansaid</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left"><span class='product-label-link' type='medication' conceptid='1177480' conceptname='Ibuprofen'>Ibuprofen</span></td>
<td class="Botrule Lrule Rrule" align="left">Motrin, Tab-Profen, Vicoprofen<a name="footnote-reference-3" href="#footnote-3" class="Sup">*</a> (combined with <span class='product-label-link' type='medication' conceptid='1174888' conceptname='Hydrocodone'>hydrocodone</span>), Combunox (combined with <span class='product-label-link' type='medication' conceptid='1124957' conceptname='Oxycodone'>oxycodone</span>)</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left"><span class='product-label-link' type='medication' conceptid='1178663' conceptname='Indomethacin'>Indomethacin</span></td>
<td class="Botrule Lrule Rrule" align="left">Indocin, Indocin SR, Indo-Lemmon, Indomethagan</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left"><span class='product-label-link' type='medication' conceptid='1185922' conceptname='Ketoprofen'>Ketoprofen</span></td>
<td class="Botrule Lrule Rrule" align="left">Oruvail</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left"><span class='product-label-link' type='medication' conceptid='1136980' conceptname='Ketorolac'>Ketorolac</span></td>
<td class="Botrule Lrule Rrule" align="left">Toradol</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left">Mefenamic Acid</td>
<td class="Botrule Lrule Rrule" align="left">Ponstel</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left"><span class='product-label-link' type='medication' conceptid='1150345' conceptname='meloxicam'>Meloxicam</span></td>
<td class="Botrule Lrule Rrule" align="left">Mobic</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left"><span class='product-label-link' type='medication' conceptid='1113648' conceptname='nabumetone'>Nabumetone</span></td>
<td class="Botrule Lrule Rrule" align="left">Relafen</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left"><span class='product-label-link' type='medication' conceptid='1115008' conceptname='Naproxen'>Naproxen</span></td>
<td class="Botrule Lrule Rrule" align="left">Naprosyn, Anaprox, Anaprox DS, EC-Naproxyn, Naprelan, Naprapac (copackaged with <span class='product-label-link' type='medication' conceptid='929887' conceptname='lansoprazole'>lansoprazole</span>)</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left"><span class='product-label-link' type='medication' conceptid='1118045' conceptname='oxaprozin'>Oxaprozin</span></td>
<td class="Botrule Lrule Rrule" align="left">Daypro</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left"><span class='product-label-link' type='medication' conceptid='1146810' conceptname='Piroxicam'>Piroxicam</span></td>
<td class="Botrule Lrule Rrule" align="left">Feldene</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left"><span class='product-label-link' type='medication' conceptid='1236607' conceptname='Sulindac'>Sulindac</span></td>
<td class="Botrule Lrule Rrule" align="left">Clinoril</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" align="left">Tolmetin</td>
<td class="Botrule Lrule Rrule" align="left">Tolectin, Tolectin DS, Tolectin 600</td>
</tr>
</tbody>
</table>
<p><span class="Italics">This Medication Guide has been approved by the U.S. Food and Drug Administration.</span></p>
<p>LAB-0609-1.0</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-18"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 50 mg Bottle Label</span></p>
<p><span class="Bold Italics">ALWAYS DISPENSE WITH MEDICATION GUIDE</span></p>
<p><span class="Bold Italics">Pfizer</span></p>
<p>NDC 0025-1515-01</p>
<p><span class="Bold">Celebrex</span><span class="Sup">®</span> <span class='product-label-link' type='medication' conceptid='1118084' conceptname='celecoxib'>celecoxib</span> capsules</p>
<p><span class="Bold">50 mg</span></p>
<p>60 Capsules <span class="Bold">Rx only</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 50 mg Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8d52185d-421f-4e34-8db7-f7676db2a226&amp;name=celebrex-03.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-19"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 100 mg Bottle Label</span></p>
<p><span class="Bold Italics">ALWAYS DISPENSE WITH MEDICATION GUIDE</span></p>
<p><span class="Bold Italics">Pfizer</span></p>
<p>NDC 0025-1520-31</p>
<p><span class="Bold">Celebrex</span><span class="Sup">®</span> <span class='product-label-link' type='medication' conceptid='1118084' conceptname='celecoxib'>celecoxib</span> capsules</p>
<p><span class="Bold">100 mg</span></p>
<p>100 Capsules <span class="Bold">Rx only</span></p>
<div class="Figure"><img alt="Principal Display Panel - 100 mg Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8d52185d-421f-4e34-8db7-f7676db2a226&amp;name=celebrex-04.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-20"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 100 mg <span class='product-label-link' type='condition' conceptid='443720' conceptname='Blister'>Blister</span> Pack</span></p>
<p><span class="Bold">Celebrex<span class="Sup">®</span></span> <span class='product-label-link' type='medication' conceptid='1118084' conceptname='celecoxib'>celecoxib</span> capsules</p>
<p><span class="Bold">100 mg</span></p>
<p><span class="Italics">Distributed by </span><span class="Bold">G.D. Searle LLC </span>Div of Pfizer Inc, NY, NY 10017 MADE IN SINGAPORE</p>
<div class="Figure"><img alt="Principal Display Panel - 100 mg <span class='product-label-link' type='condition' conceptid='443720' conceptname='Blister'>Blister</span> Pack" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8d52185d-421f-4e34-8db7-f7676db2a226&amp;name=celebrex-05.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-21"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 100 mg 10-<span class='product-label-link' type='condition' conceptid='443720' conceptname='Blister'>Blister</span> Pack Carton</span></p>
<p><span class="Bold Italics">ALWAYS DISPENSE WITH MEDICATION GUIDE</span></p>
<p><span class="Bold Italics">Pfizer</span></p>
<p>NDC 0025-1520-34 <span class="Bold">Rx only</span></p>
<p><span class="Bold">Celebrex<span class="Sup">®</span></span> <span class='product-label-link' type='medication' conceptid='1118084' conceptname='celecoxib'>celecoxib</span> capsules</p>
<p><span class="Bold">100 mg</span></p>
<p>For in-institution use only</p>
<p>100 Capsules UNIT DOSE</p>
<div class="Figure"><img alt="Principal Display Panel - 100 mg 10-<span class='product-label-link' type='condition' conceptid='443720' conceptname='Blister'>Blister</span> Pack Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8d52185d-421f-4e34-8db7-f7676db2a226&amp;name=celebrex-06.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-22"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 200 mg Bottle Label</span></p>
<p><span class="Bold Italics">ALWAYS DISPENSE WITH MEDICATION GUIDE</span></p>
<p><span class="Bold Italics">Pfizer</span></p>
<p>NDC 0025-1525-31</p>
<p><span class="Bold">Celebrex</span><span class="Sup">®</span> <span class='product-label-link' type='medication' conceptid='1118084' conceptname='celecoxib'>celecoxib</span> capsules</p>
<p><span class="Bold">200 mg</span></p>
<p>100 Capsules <span class="Bold">Rx only</span></p>
<div class="Figure"><img alt="Principal Display Panel - 200 mg Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8d52185d-421f-4e34-8db7-f7676db2a226&amp;name=celebrex-07.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-23"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 200 mg <span class='product-label-link' type='condition' conceptid='443720' conceptname='Blister'>Blister</span> Pack</span></p>
<p><span class="Bold">Celebrex<span class="Sup">®</span></span> <span class='product-label-link' type='medication' conceptid='1118084' conceptname='celecoxib'>celecoxib</span> capsules</p>
<p><span class="Bold">200 mg</span></p>
<p><span class="Italics">Distributed by </span><span class="Bold">G.D. Searle LLC </span>Div of Pfizer Inc, NY, NY 10017 MADE IN SINGAPORE</p>
<div class="Figure"><img alt="Principal Display Panel - 200 mg <span class='product-label-link' type='condition' conceptid='443720' conceptname='Blister'>Blister</span> Pack" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8d52185d-421f-4e34-8db7-f7676db2a226&amp;name=celebrex-08.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-24"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 200 mg 10-<span class='product-label-link' type='condition' conceptid='443720' conceptname='Blister'>Blister</span> Pack Carton</span></p>
<p><span class="Bold Italics">ALWAYS DISPENSE WITH MEDICATION GUIDE</span></p>
<p><span class="Bold Italics">Pfizer</span></p>
<p>NDC 0025-1525-34 <span class="Bold">Rx only</span></p>
<p><span class="Bold">Celebrex<span class="Sup">®</span></span> <span class='product-label-link' type='medication' conceptid='1118084' conceptname='celecoxib'>celecoxib</span> capsules</p>
<p><span class="Bold">200 mg</span></p>
<p>For in-institution use only</p>
<p>100 Capsules UNIT DOSE</p>
<div class="Figure"><img alt="Principal Display Panel - 200 mg 10-<span class='product-label-link' type='condition' conceptid='443720' conceptname='Blister'>Blister</span> Pack Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8d52185d-421f-4e34-8db7-f7676db2a226&amp;name=celebrex-09.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-25"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 400 mg Bottle Label</span></p>
<p><span class="Bold Italics">ALWAYS DISPENSE WITH MEDICATION GUIDE</span></p>
<p><span class="Bold Italics">Pfizer</span></p>
<p>NDC 0025-1530-02</p>
<p><span class="Bold">Celebrex</span><span class="Sup">®</span> <span class='product-label-link' type='medication' conceptid='1118084' conceptname='celecoxib'>celecoxib</span> capsules</p>
<p><span class="Bold">400 mg</span></p>
<p>60 Capsules <span class="Bold">Rx only</span></p>
<div class="Figure"><img alt="Principal Display Panel - 400 mg Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8d52185d-421f-4e34-8db7-f7676db2a226&amp;name=celebrex-10.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-26"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 400 mg <span class='product-label-link' type='condition' conceptid='443720' conceptname='Blister'>Blister</span> Pack</span></p>
<p><span class="Bold">Celebrex<span class="Sup">®</span></span> <span class='product-label-link' type='medication' conceptid='1118084' conceptname='celecoxib'>celecoxib</span> capsules</p>
<p><span class="Bold">400 mg</span></p>
<p><span class="Italics">Distributed by </span><span class="Bold">G.D. Searle LLC </span>Div of Pfizer Inc, NY, NY 10017 MADE IN SINGAPORE</p>
<div class="Figure"><img alt="Principal Display Panel - 400 mg <span class='product-label-link' type='condition' conceptid='443720' conceptname='Blister'>Blister</span> Pack" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8d52185d-421f-4e34-8db7-f7676db2a226&amp;name=celebrex-11.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-27"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 400 mg 10-<span class='product-label-link' type='condition' conceptid='443720' conceptname='Blister'>Blister</span> Pack Carton</span></p>
<p><span class="Bold Italics">ALWAYS DISPENSE WITH MEDICATION GUIDE</span></p>
<p><span class="Bold Italics">Pfizer</span></p>
<p>NDC 0025-1530-01 <span class="Bold">Rx only</span></p>
<p><span class="Bold">Celebrex<span class="Sup">®</span></span> <span class='product-label-link' type='medication' conceptid='1118084' conceptname='celecoxib'>celecoxib</span> capsules</p>
<p><span class="Bold">400 mg</span></p>
<p>For in-institution use only</p>
<p>100 Capsules UNIT DOSE</p>
<div class="Figure"><img alt="Principal Display Panel - 400 mg 10-<span class='product-label-link' type='condition' conceptid='443720' conceptname='Blister'>Blister</span> Pack Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8d52185d-421f-4e34-8db7-f7676db2a226&amp;name=celebrex-12.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CELEBREX 		
					</strong> <span class="contentTableReg"><span class='product-label-link' type='medication' conceptid='1118084' conceptname='celecoxib'>celecoxib</span> capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0025-1515</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong><span class='product-label-link' type='medication' conceptid='1118084' conceptname='celecoxib'>CELECOXIB</span></strong> (<span class='product-label-link' type='medication' conceptid='1118084' conceptname='celecoxib'>CELECOXIB</span>) </td>
<td class="formItem"><span class='product-label-link' type='medication' conceptid='1118084' conceptname='celecoxib'>CELECOXIB</span></td>
<td class="formItem">50 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>GELATIN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POVIDONES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM LAURYL SULFATE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">18mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">7767;50</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0025-1515-01</td>
<td class="formItem">60  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020998</td>
<td class="formItem">10/02/1998</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CELEBREX 		
					</strong> <span class="contentTableReg"><span class='product-label-link' type='medication' conceptid='1118084' conceptname='celecoxib'>celecoxib</span> capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0025-1520</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong><span class='product-label-link' type='medication' conceptid='1118084' conceptname='celecoxib'>CELECOXIB</span></strong> (<span class='product-label-link' type='medication' conceptid='1118084' conceptname='celecoxib'>CELECOXIB</span>) </td>
<td class="formItem"><span class='product-label-link' type='medication' conceptid='1118084' conceptname='celecoxib'>CELECOXIB</span></td>
<td class="formItem">100 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>GELATIN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POVIDONES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM LAURYL SULFATE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">18mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">7767;100</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0025-1520-31</td>
<td class="formItem">100  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0025-1520-51</td>
<td class="formItem">500  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:0025-1520-34</td>
<td class="formItem">100  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 <span class='product-label-link' type='condition' conceptid='443720' conceptname='Blister'>BLISTER</span> PACK; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020998</td>
<td class="formItem">10/02/1998</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CELEBREX 		
					</strong> <span class="contentTableReg"><span class='product-label-link' type='medication' conceptid='1118084' conceptname='celecoxib'>celecoxib</span> capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0025-1525</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong><span class='product-label-link' type='medication' conceptid='1118084' conceptname='celecoxib'>CELECOXIB</span></strong> (<span class='product-label-link' type='medication' conceptid='1118084' conceptname='celecoxib'>CELECOXIB</span>) </td>
<td class="formItem"><span class='product-label-link' type='medication' conceptid='1118084' conceptname='celecoxib'>CELECOXIB</span></td>
<td class="formItem">200 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>GELATIN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POVIDONES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM LAURYL SULFATE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">18mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">7767;200</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0025-1525-31</td>
<td class="formItem">100  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0025-1525-51</td>
<td class="formItem">500  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:0025-1525-34</td>
<td class="formItem">100  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 <span class='product-label-link' type='condition' conceptid='443720' conceptname='Blister'>BLISTER</span> PACK; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020998</td>
<td class="formItem">10/02/1998</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CELEBREX 		
					</strong> <span class="contentTableReg"><span class='product-label-link' type='medication' conceptid='1118084' conceptname='celecoxib'>celecoxib</span> capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0025-1530</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong><span class='product-label-link' type='medication' conceptid='1118084' conceptname='celecoxib'>CELECOXIB</span></strong> (<span class='product-label-link' type='medication' conceptid='1118084' conceptname='celecoxib'>CELECOXIB</span>) </td>
<td class="formItem"><span class='product-label-link' type='medication' conceptid='1118084' conceptname='celecoxib'>CELECOXIB</span></td>
<td class="formItem">400 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>GELATIN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POVIDONES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM LAURYL SULFATE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">22mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">7767;400</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0025-1530-02</td>
<td class="formItem">60  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0025-1530-01</td>
<td class="formItem">100  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 <span class='product-label-link' type='condition' conceptid='443720' conceptname='Blister'>BLISTER</span> PACK; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020998</td>
<td class="formItem">10/02/1998</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>G.D. Searle LLC Division of Pfizer Inc
							(829077085)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Pfizer Asia Pacific PTE LTD</td>
<td class="formItem"></td>
<td class="formItem">894677996</td>
<td class="formItem">API MANUFACTURE(0025-1530, 0025-1525, 0025-1520, 0025-1515)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Pfizer Pharmaceuticals LLC</td>
<td class="formItem"></td>
<td class="formItem">829084552</td>
<td class="formItem">MANUFACTURE(0025-1530, 0025-1525, 0025-1520, 0025-1515), PACK(0025-1530, 0025-1525, 0025-1520, 0025-1515)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Pfizer Pharmaceuticals LLC</td>
<td class="formItem"></td>
<td class="formItem">829084545</td>
<td class="formItem">API MANUFACTURE(0025-1530, 0025-1525, 0025-1520, 0025-1515)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NEOLPHARMA, INC.</td>
<td class="formItem"></td>
<td class="formItem">078709787</td>
<td class="formItem">ANALYSIS(0025-1530, 0025-1525, 0025-1520, 0025-1515), MANUFACTURE(0025-1530, 0025-1525, 0025-1520, 0025-1515), PACK(0025-1530, 0025-1525, 0025-1520, 0025-1515)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 6/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>7b90168b-ed0e-4833-a2cb-1c2e1ec75f6a</div>
<div>Set id: 8d52185d-421f-4e34-8db7-f7676db2a226</div>
<div>Version: 16</div>
<div>Effective Time: 20150616</div>
</div>
</div> <div class="DistributorName">G.D. Searle LLC Division of Pfizer Inc</div></p>
</body></html>
